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ABSTRACT 
 The improvement and utility of crosslinkers are important topics of molecular imprinting.  
Crosslinker significance is evident when molecularly imprinted polymer (MIP) composition 
related to performance as separation media is examined.  Crosslinkers account for the bulk of 
MIP formulations made through traditional imprinting (80-90%) and is even greater when the 
One Monomer Molecularly Imprinted Polymer (OMNiMIP) approach is utilized (100%.)  It is 
not surprising that alteration of the bulk component will result in different separation 
performances.  Crosslinkers studied in this work were designed, synthesized, and evaluated 
toward improvement in OMNiMIP selectivity.  In particular, functionality and number of 
polymerizable groups, addition of electron withdrawing groups or stereocenters, and 
maximization of amide content of OMNiMIP crosslinkers were explored using L-BOC-Tyrosine 
as a standard template.  The separation factors (α’) obtained from chromatographic studies of 
these OMNiMIPs were compared to results from 2-(methacryloylamino)ethyl-2-methylacrylate 
(NOBE), the most successful OMNiMIP crosslinking monomer thus far.  Although several of 
these new OMNiMIPs displayed enantiomeric selectivity toward BOC-Tyr, an increased α’ was 
not observed. 
 Racemic and Scalemic imprinting as well as absolute configuration (AC) determination 
were also studied throughout this work to improve MIP utility in academia and industry.  Chiral 
OMNiMIP crosslinkers (S)-2-methacrylamidopropyl methacrylate (L-NALA) and N,O-bis-
methacryloyl L-serine (NOS) were imprinted with racemic BOC-Tyr and both exhibited partial 
enantiomeric separation by chromatography.  L-NALA was further explored through imprinting 
scalemic templates, and studies also showed enantiomeric separation.  Additionally, L-NALA 
and NOBE were studied in AC determination.  Here, a mnemonic was developed to illustrate 
xiv 
 
template recognition.  Limitations on binding factors were also set to determine data reliability in 
regards to determination of absolute configuration.   
 A chimeric antioxidant composed of vitamin E and carnosine (VECAR) was designed 
and synthesized to improve drug delivery.  VECAR was fabricated based on the lipophilicity and 
hydrophilicity of its individual components and is expected to have increased permeability in 
hydrophilic media while maintaining recognition by key proteins in biological pathways.    This 
new compound displayed similar antioxidant activity as vitamin E in vitro and is anticipated to 
reach more versatile regions of cells, leading to the elimination or reduction of diseases caused 
by oxidative damage. 
 
 1 
 
CHAPTER 1: MOLECULAR IMPRINTING INTRODUCTION 
1.1 Introduction to Molecular Imprinting 
Molecular imprinting is a field that started in the 1930’s and is increasingly gaining more 
popularity in the literature.
1
  This field is becoming distinctly more important as molecularly 
imprinted polymers, tailored to encompass selective recognition cavities based on size, shape, 
and functionality, are being developed and utilized in new and exciting ways.
2
  Ramström and 
Mosbach described various methods where MIPs have been used in an attempt to increase 
reaction rates by imprinting a template that was either a substrate, transition state, or product 
analogue to promote catalysis.
3
  Haupt’s review shows the involvement of MIPs in 
immunoassays and sensors.
4
  Also, a large number of papers have been published that use the 
recognition properties of these unique “smart” polymers as chromatographic stationary phases 
for enantiomeric separations.
5,6
  
 MIPs are not just popular for their vast application potential, they are also important 
because of the unique characteristics that separate them from biological molecules and other 
solid phase materials.  Unlike other systems, these smart polymers can withstand extremely high 
temperatures and large pH ranges.
7,8,9
  The reusability, long storage times, inexpensive 
fabrication, and straightforward and simple syntheses are also characteristics of MIPs that 
account for their attraction.
1,10,11,12
   
 There are two bonding techniques used to synthesize MIPs: covalent and non-covalent.
2
  
The covalent bonding approach involves a chemical reaction to bind the monomer(s) and 
template, and another bond breaking reaction to release the template.  Although this approach 
does generate selective MIPs, it still requires a chemical reaction to selectively bind to it again.  
 2 
 
For example, Wulff and co-workers used phenyl-α-D-mannopyranoside as the template and 
covalently bound 4-vinylphenylboronic acid by an esterification reaction to form the imprinted 
cavity.
13
   
A second bonding approach for the formation of MIPs is non-covalent imprinting.  Here, 
one advantage is that there is no need to perform a chemical reaction to add or remove the 
imprinted template from the binding site; instead non-covalent imprinting utilizes principles of 
Van der Waals forces, hydrogen bonding, and dipole-dipole interactions.  These interactions 
between the monomer(s) and template(s) in solution cause the binding site cavities to form with 
specific shape and functionality once polymerized, leading to the recognition abilities of the 
MIPs.14 
Whether the covalent or non-covalent imprinting approach is used for imprinting, the 
selectivity of the MIP needs to be tested in order to determine if it is efficient at imprinting a 
selected target.  One method to evaluate MIPs is through studying the polymer’s ability to 
selectively bind a target.  High Performance Liquid Chromatography (HPLC) is one analytical 
instrument that can be used to examine the selectivity of imprinted polymers.  Analytes (as a 
mixture or an isolated molecule) can be injected onto an HPLC column packed with MIP as the 
stationary phase.  The time that it takes the analyte(s) to travel through the column depends on 
the affinity of the analyte(s) to the imprinted column; stronger binding affinities lead to longer 
retention times.  Once a retention time is observed, a normalization factor called the capacity 
factor (k’), which is independent of column size or amount of stationary phase can be calculated.  
The capacity factor is determined by subtracting the void volume (tV), which accounts for the 
volume of solvent needed to pass through the column, from the retention time (tR) of the analyte 
divided by the void volume (Eq. 1.1). 
 3 
 
                                                                     k’ 
(t   - t )
t 
                                                        Eq. 1.1 
 The capacity factor can be determined for the imprinted analyte as well as non-imprinted 
analyte(s).  Once the k’ factors for each analyte are calculated, the selectivity of the MIP can be 
analyzed by determining the separation factor (α or α’), which is calculated by dividing the k1’ of 
the most retained by the k2’ of the least retained analyte (α denotes the separation factor for 
analytes injected on the HPLC at the same time and α’ refers to the separation factor calculated 
for analytes injected individually on the HPLC column, Eq. 1.2).  Larger separation factors 
signify greater performance of analyte separation achieved by the MIP.
2
 
                                                                   α    α′  
 1’ 
 2’  
                                                     Eq. 1.2 
 
1.2 The Traditional Imprinting Approach 
The crosslinker, template, functional monomer, initiator, temperature, and solvent (also 
referred to as porogen) are all important components used in traditional non-covalent imprinting.  
It is imperative to take into consideration the design of all components involved in synthesizing 
the imprinted polymer to ensure high selectivity.  Modifying all components to increase non-
covalent interactions and form a rigid imprinted cavity to obtain a large α’ is the goal of 
researchers pursuing MIP design. 
Comprising 80-90% of the imprinted polymer formed by traditional non-covalent 
imprinting, the chemical crosslinker is one of the most vital pieces of the MIP formulation.
5
  
There are several common crosslinkers shown throughout the literature and a few examples are 
represented in Figure 1.1.
5,15,16,17,18,19
  Each crosslinker shown has been designed to form a highly 
crosslinked network polymer whose rigid morphology allows for cavities with strong binding 
 4 
 
and re-binding capabilities of the desired analyte.  The chemical crosslinker may also possess 
features that increase non-covalent interactions.  For example, the crosslinker 2-
(methacryloylamino) ethyl-2-methylacrylate (NOBE, 1) is able to form hydrogen bonding 
interactions with templates that contain complementary donor/acceptor abilities. 
Figure 1.1: Examples of common crosslinkers. 
The ability to successfully participate in non-covalent interactions; such as, hydrogen 
bonding and electrostatic interactions, is an 
important feature that the template should also 
encompass.  Template size is another key 
feature that should be taken into account.  The 
molecular weight of the template can range in 
size from amino acids and drugs, to larger 
molecules such as proteins; however, as size 
increases, imprinting becomes more challenging.
20,21
  BOC-Tyrosine (Figure 1.2, 7) is one 
 
 
            
        7                                         8 
 
Figure 1.2: BOC-Tyrosine (7) and 
methacrylic acid (8). 
 
 
 5 
 
template that has been successfully used when studying imprinted polymers due to its modest 
size and  hydrogen bonding capabilities with the functional monomer.  A template size that is too 
large could cause the template to become permanently encapsulated in the imprinted cavity.  
Another problem associated with large templates is that their size also inhibits their ability to 
diffuse into the imprinted cavity upon rebinding.
22
  The functional monomer chosen should 
complement the template’s non-covalent interactions and provide a strong basis for binding.  
Methacrylic acid (Figure 1.2, 8) is a common functional monomer in the literature because of its 
hydrogen bond donor/acceptor relationship with templates.
23,24
  Once a functional monomer is 
selected, it is crucial to optimize its concentration in the MIP formulation.  The ratio of 
functional monomer to template, as well as to the crosslinker, needs to be optimized to generate 
the best selectivity. 
The initiator and its concentration in the polymer formulation are also important in 
imprinting.  Piletsky et al. demonstrated that lower concentrations of initiator, approximately 1-
2% formed better imprinted polymers than imprinted polymers made with up to 5% initiator.
25
  
They also demonstrated that with less than 1% initiator, a rigid polymer, which is needed to form 
structurally sound cavities, was not formed.  The porogen used for MIP syntheses should 
dissolve all contents of the formulation without interfering with the non-covalent interactions 
that occur in the pre-polymer complex.  The temperature during polymerization is another factor 
to take into consideration for MIP syntheses.  Results in the literature show that lower 
temperatures allow for imprinted polymers to form with better selectivity due to better pre-
polymer complex formation of the functional monomer and template in solution.
26,27,28,29
   
Once a formulation is derived, molecularly imprinted polymers are traditionally 
synthesized by first dissolving a functional monomer in solution with a template to allow a pre-
 6 
 
 
polymer complex to form (Figure 1.3 and Figure 1.4.)
30
  Next, a crosslinker is added to the 
Figure 1.3: Diagram of traditional imprinting. 
monomer and template solution.  After the crosslinker addition, an initiator such as AIBN is 
added and the photo polymerization is carried out in a cooled reactor.  Once the MIP is made, the 
template is removed by refluxing solvent through the polymer over several hours using a Soxhlet 
 
Figure 1.4: Imprinting illustration in the laboratory*.   
*Synthesized crosslinker combined with template and initiator dissolved in porogen (a.)  
Polymerize to solid MIP (b.)
 
 Remove MIP (c.)
  
Put MIP in Soxhlet to remove template (d.)
  
After template removal, grind MIP to the desired particle size (e.)
  
Wash and grind until enough 
material is acquired to pack the HPLC column (f.)
 
Perform
 
HPLC analysis (g.)  Reprinted with 
permission from Organic Letters 2014 16 (5), 1402-1405.  Copyright 2014 American Chemical 
Society. 
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extractor.  The MIP can then be ground and sieved to obtain an optimized particle size for use in 
chromatographic evaluation to determine its template selectivity and separation ability.
2
   
 
1.3 The OMNiMIP Imprinting Approach 
A new and exciting discovery by the Spivak research group came from studies 
developing two non-covalent traditional imprinting systems to select for either L-BOC-Tyr or a 
single enantiomer of bi-naphthol.  Here, 2-(methacryloylamino) ethyl-2-methylacrylate (NOBE, 
1) was the crosslinker and methacrylic acid was the functional monomer used in the imprinting 
process.  Throughout the study, the ratio of functional monomer to crosslinker was examined.  
During these experiments, it was discovered that when NOBE was used 100% in solution 
without any functional monomer, there was a significantly better imprinting performance for 
both template systems.  These surprising results led to the newly developed non-covalent 
imprinting approach called the One Monomer Molecularly Imprinted Polymer (OMNiMIP) 
method invented by the Spivak research group.
2,31
   
The OMNiMIP technique uses a single functional crosslinking monomer in solution with 
the template to form the imprinted polymer (Figure 1.5.)  This new and exciting approach   
Figure 1.5: Illustration of OMNiMIP technique. 
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simplifies the conditions to form MIPs making these systems even more efficient.  No longer is 
the type and amount of functional monomer, the ratios of functional monomer to crosslinker, or 
the ratio of template to functional monomer, considerations that need to be studied for making 
imprinted polymers.
31
   
 
1.4 The Improvement of Crosslinkers for Molecular Imprinting 
Improving the ability of a MIP to separate analytes is an ongoing task of imprinters.  The 
optimization of the crosslinker design in traditional and OMNiMIP imprinting is often 
studied.
32,33,34
  In particular, the structure of NOBE has 
been altered, and selectivity based on these alterations 
has been explored.  More specifically, Figure 1.6 
depicts spacer modifications possible for NOBE.  The 
spacer was modified by adding non-polar and polar 
groups between the amide and ester to explore the 
selectivity resulting from these changes to the 
crosslinking monomer for OMNiMIP imprinting.
35
  
Non-polar groups such as methyl, isopropyl, and isobutyl have been added to the amido alpha 
position (Figure 1.6); however, these additions did not improve imprinting.  In fact, the larger 
groups created steric interactions that disrupted the ability of the template to hydrogen bond to 
the crosslinking monomer.  Also, the polymers were “soft”, indicating a low degree of 
polymerization.  A trend showed that with fewer non-covalent interactions between the monomer 
and template, the imprinted polymers displayed less selectivity when analyzed as a 
chromatographic stationary phase to separate enantiomers.
33
   
 
 
 
 
 
Figure 1.6: Non-polar and polar 
spacer modification designs. 
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Figure 1.7: Non-polar spacer modifications to 
NOBE. 
In a subsequent study, polar groups 
containing acid, alcohol, amine, and amide 
functionality were attached to the alpha 
amido position of NOBE.  In this study, only 
the compound containing the acid addition, 
N,O-bis-methacryloyl L-serine (NOS), was 
soluble in the polymerization porogen and 
polymerized into an OMNiMIP.  While NOS 
was capable of separating enantiomers of 
BOC-Tyr, it did not perform better than 
NOBE.
35
  The continued alteration of the chemical structure of NOBE in an attempt to make a 
better crosslinker for imprinting is a primary focus of this work. 
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CHAPTER 2: NEW CROSSLINKERS FOR MOLECULAR IMPRINTING 
2.1 Introduction, Design and Synthesis of New Crosslinkers 
A. Crosslinkers with Alteration of Polymerizable Groups 
The polymerization rate of a monomer is largely dependent on the type of polymerizable 
group it has; for example vinyl groups polymerize slower than methacrylates.  There are two 
main contributing factors that determine the radical polymerization rates of monomers: the 
ability of a monomer to form a radical and the stability of the radical formed.
1
   An article by 
Chan et al. examines these factors and discusses the radical polymerization rates of several types 
of polymerizable groups, such as methacrylates, acrylates, methacrylamides, and acrylamides.
2
  
The experiments carried out demonstrate that methacrylates polymerize faster than acrylates.  
This phenomenon could be attributed to the stable free radical that is formed from the tertiary 
methacrylate group as opposed to a secondary radical, which is less stable.  The article also 
addressed the fact that methacrylates are more reactive to radical polymerizations than 
methacrylamide groups.  This observation is explained by the amide group’s greater participation 
in resonance versus the ester group, which makes the amide substituent not free to stabilize the 
radical as much, thus lowering the rate of radical polymerization. 
A publication by Sibrian-Vasquez et al. explored nonsymmetrical polymerizable groups, 
which included examining crosslinkers with a methacrylate and 
methacrylamide combination (e.g. NOBE, 1).
3,4,5,6
  Here, the authors 
showed that the nonsymmetrical crosslinker NOBE performed well in 
molecularly imprinted polymer systems.  In another paper, 2-Methyl-
N-(3-methyl-2-oxobut-3-enyl)acrylamide (Figure 2.1, NAG, 12), a 
crosslinker composed of a methacrylamide and vinyl ketone group was synthesized and utilized 
 
 
Figure 2.1:  NAG. 
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in traditional imprinting.
5
  This monomer showed better performance than NOBE when used in 
traditional imprinting, and the authors suggested it increased selectivity in MIPs due to the length 
reduction of NAG versus NOBE, which allowed it to form a more close-fitting binding site, 
combined with its rigidity. 
The alteration of polymerizable groups that was previously studied for traditional 
imprinting can also be applied to the One Monomer Molecularly Imprinted Polymer (OMNiMIP) 
technique, which was described in Chapter 1.  Tailoring new crosslinkers for improved 
selectivity of OMNiMIPs is important as this approach can uptake a larger amount of template in 
the pre-polymer complex (and consequently the binding site) leading to more binding sites and 
better selectivity when compared to traditional imprinting.  Designing and synthesizing 
monomers for the OMNiMIP technique that could enhance selectivity further by altering the 
polymerizable groups was one of the goals of this project.  Derivatives of NOBE that examine 
the roles of methacrylate, acrylate, or acrylamide groups in molecular imprinting were 
investigated.  These monomers were polymerized by photo-initiated radical polymerization and 
were subsequently tested as OMNiMIP chromatographic stationary phases for selective binding 
of a single enantiomer.  Although NAG has shown to form more selective MIPs than NOBE 
during traditional imprinting, it has not been utilized as the crosslinker for OMNiMIP imprinting.  
NOBE has been previously used and has been shown to form highly selective OMNiMIPs; thus, 
NOBE was enlisted as the control.
4
  As mentioned in Chapter 1, the design of NOBE 
incorporates a methacrylate and methacrylamide group.  This combination of the methacrylate 
and methacrylamide groups in NOBE is important to achieve solubility of the monomer in the 
pre-polymer porogen (i.e. solvent) and to provide hydrogen bonding interactions between the 
monomer and print molecule.  During the photo-initiated radical polymerization using NOBE, it 
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is anticipated that the methacrylate component will polymerize first, followed by the 
methacrylamide component.  It is expected that both monomeric units polymerize quickly 
because both form stable tertiary radicals (radical stability is as follows tertiary > secondary > 
primary > methyl); however, it is probable that the methacrylate radical forms before the 
methacrylamide radical because the amide portion is more likely to participate in resonance and 
stabilize the radical less.  
Improvements on the original OMNiMIP polymerizable groups began with the synthesis 
of the monomer 2-acrylamidoethyl acrylate, 13 (Figure 2.2).  The design features of 13 include 
Figure 2.2: 2-acrylamidoethyl acrylate (13) and 2-acrylamidoethyl methacrylate, (14). 
an acrylate and an acrylamide group differing from NOBE (1) only at the polymerizable ends to 
isolate the effects of changing the type of polymerizable groups.  Here, the acrylate component is 
anticipated to polymerize before than the acrylamide group.  This is attributed to the resonance 
participation of the acrylamide group slowing down the polymerization process, whereas the 
acrylate has a smaller competing resonance effect.  Overall, it is expected that 2-acrylamidoethyl 
acrylate will polymerize moderately slower than NOBE because both sides of this molecule will 
form secondary radicals, opposed to the more stable tertiary radicals that NOBE generates. 
2-acrylamidoethyl methacrylate, 14 was another compound designed and synthesized to 
study the effects of polymerization rates of OMNiMIPs (Figure 2.2.)  The design of 14 also kept 
the NOBE (1) structure intact, keeping the same number of ester and amide groups for solubility 
and hydrogen bonding, and differed only by the polymerizable groups so that selectivity based 
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on changes of these groups could be studied.  It is anticipated that 2-acrylamidoethyl 
methacrylate will have a similar polymerization pattern to 2-acrylamidoethyl acrylate with 
regard to which side of the compound polymerizes first.  Here, the methacrylate will polymerize 
much faster than the acrylamide group.  This is attributed to both the greater radical stability of 
the methacrylate portion as well as the competing effect of the amide group participating in 
resonance.  The outcome of this phenomena means that relatively long stretches of linear 
polymers/oligomers will form initially as the methacrylate polymerizes, leaving the acrylamido 
group pendant.  The slower polymerizing acrylamido group will start to form the crosslinks 
afterward, including both covalent and intermolecular hydrogen bonding of the amide groups. 
The small alterations in the design features mentioned in regards to the crosslinkers 2-
acrylamidoethyl acrylate (13) and 2-acrylamidoethyl methacrylate (14) are worthy to explore 
because the order in which polymerization of groups takes place could affect their ability to form 
more selective polymers as described previously when selectivity was improved in traditional 
imprinting using NAG.
5
  In the case of NAG, longer chains of linear polymer were formed first 
and crosslinking by the methacrylamide groups occurred subsequently, ultimately resulting in a 
superior imprinted polymer.  The crosslinker NAG is described in further detail in section D and 
its ability to form a better selective OMNiMIP based on the cooperative effects of its 
polymerizable groups and the hydrogen bonding donor/acceptor proximity is discussed.  Similar 
to the vinyl ketone forming before the methacrylamide in NAG, it is expected that 14 may 
improve OMNiMIPs because the methacrylate groups will likely form first, generating a linear 
polymer, followed by the acrylamide groups forming the crosslinked network analogous to the 
polymerization of NAG.  Since molecule 14 incorporates an acrylamide instead of a 
methacrylamide group, a smaller impact of steric interference from the lack of an alpha methyl 
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group may be observed to some extent and may also lead to better selectivity of the MIP formed.  
It is expected that 14 will form a better imprinted polymer than crosslinker 13 because the design 
of crosslinker 13 reduces the rate of formation of both polymerizable groups compared to the 
groups in the NOBE structure and therefore will not form to the same extent a linear polymer 
first followed by the crosslinked network.  The design of both 13 and 14 to some degree 
decreases the sterics of the crosslinkers, which may impact their solubility and hydrogen bonding 
capabilities and furthermore lead to the formation of OMNiMIPs with improved selectivity.  
Both 13 and 14 are expected to have improved solubility in the pre-polymer complex, which 
could lower phase separation during polymerization and lead to the formation of more selective 
binding sites.  Another improvement towards selectivity that can transpire from reducing steric 
hindrance in both 13 and 14 is the increased ability of the crosslinker to wrap closely around the 
template; therefore forming a stronger hydrogen bond network between binding site and 
template. 
The synthesis of NOBE (1), 2-acrylamidoethyl acrylate (13), and 2-acrylamidoethyl 
methacrylate (14) were all carried out using typical DCC/DMAP coupling procedures.  The 
percent yields of the NOBE synthesis ranged from approximately 80% - 98%, with most 
reactions yielding above 90%.  Percent yields of 13 and 14 were 43% and 53%, respectively.  
Although these percent yields were not as high as NOBE, they were not further optimized as the 
focus of these monomers was their use as crosslinkers for molecular imprinting.   
 
B. Three-armed Crosslinkers 
The crosslinking and number of selective sites on an OMNiMIP monomer influences its 
ability to form an imprinted polymer with high shape selectivity.  One article showed that MIPs 
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prepared with crosslinkers containing three crosslinking appendages, such as pentaerythritol 
triacrylate, 15 and trimethyllolpropane trimethacrylate (TRIM, 16) performed better than 
ethylene glycol dimethylacrylate (EGDMA, 3), which contains only two polymerizable 
appendages (Figure 2.3.)
7
  Here, the authors showed that the trifunctional crosslinkers in the 
molecularly imprinted polymer formulation for traditional imprinting resulted in MIPs exhibiting 
larger template load capacities and better chromatographic resolution.      
Figure 2.3: Structures of three and two armed crosslinkers. 
 The improvement in load capacity and resolution of the three armed crosslinkers was 
attributed to increased rigidity of the recognition site.
8
  An increase in the number of 
polymerizable groups may improve recognition of the template to the binding cavities by 
allowing a more rigid framework to form, which preserves the shape of the imprinted sites.  
While the change in the number of polymerizable groups on the crosslinker has been investigated 
for traditional imprinting, there has been no literature published to date using these crosslinking 
monomers for OMNiMIP imprinting.  In this chapter, the synthesis of a new achiral 1, 3-
dimethacrylamidopropan-2-yl methacrylate (17) and a chiral (S)-2,3-dimethacrylamidopropyl 
methacrylate (18) trifunctional crosslinker was completed and applied to OMNiMIP formation.   
Crosslinker 17 contains three polymerizable groups, two being methacrylamide linkages 
and one methacrylate (Figure 2.4.)  Not only is the increased number of polymerizable groups 
expected to form more rigid binding cavities than crosslinkers with two polymerizable groups, 
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the increased number of amide groups in comparison to NOBE is also expected to increase 
hydrogen bonding and lead to a more selective OMNiMIP.  Three methacrylamide groups as 
opposed to two would provide an additional area for hydrogen bonding to occur.  However, 
solubility of the crosslinker in the pre-polymerization porogen is expected to be poor because the 
molecule N,N'-(ethane-1,2-diyl)bis(2-methylacrylamide) (2), which contains two 
methacrylamide groups and zero methacrylate groups, is only soluble in polar porogens such as 
methanol, which would interfere with the hydrogen bonding interactions need to form the 
imprinted polymer.
5
   
The design of the three-armed 18 also includes two methacrylamide groups and one 
methacrylate polymerizable group, and is also expected to increase rigidity due to the amount of 
polymerizable groups and magnify hydrogen bonding because of the extra methacrylamide 
group (compared to NOBE.)  The difference between crosslinkers 17 and 18 is that molecule 18 
is chiral (Figure 2.4) because it was synthesized from an amino acid derivative containing a 
stereocenter.  The addition of a chiral center to this molecule may allow this crosslinker to 
complex to one enantiomer of the template stronger than the other enantiomer; therefore, each 
enantiomer should be imprinted individually and the selectivity of the resulting OMNiMIPs 
should be compared to determine which enantiomer lead to the polymer with better selectivity so 
that the better OMNiMIP can be compared to NOBE.  Furthermore, the addition of a chiral 
center in 18 could also have an impact in imprinting racemic mixtures, a technique described in 
Chapter 3.   
The syntheses of the two new trifunctional monomers, achiral 1,3-
dimethacrylamidopropan-2-yl methacrylate (17) and chiral (S)-2,3-dimethacrylamidopropyl 
methacrylate (18),  was completed.  Crosslinker 17 was synthesized using DCC/DMAP to couple 
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MAA to the amino alcohol in 65% yield.  Several approaches were attempted to synthesize 
molecule 18.  The first method comprised three steps, starting from malonic acid-mono ethyl 
ester.  Amination of the malonic acid-mono ethyl ester followed by a LAH reduction, and finally 
a DCC/DMAP coupling reaction were completed.  These steps afforded products that were 
difficult to separate on large scale; therefore, a new approach was deemed necessary.  Starting 
from the salt (S)-2,3-bis((tert-butoxycarbonyl)amino)propanoic acid · dicyclohexylamine, 18 was 
successfully synthesized in three steps.  After removal of the salt by extractions, a mixed 
anhydride was first formed by the addition of isobutyl chloroformate and NMM then reduction 
using sodium borohydride afforded the alcohol in 68% yield.  Next, the BOC groups were 
removed using ethereal hydrogen chloride in quantitative yields.  Lastly, DCC/DMAP was used 
to couple MAA to the three appendages to form molecule 18 with a 30% yield.  The solubility of 
the three-armed crosslinkers and their ability to perform as OMNiMIP chromatographic 
stationary phases to imprint a single enantiomer was next analyzed and compared to the currently 
best performing OMNiMIP crosslinker, NOBE (vide infra.) 
 
Figure 2.4:  Three-armed crosslinkers for OMNiMIP imprinting. 
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C. Crosslinkers with Electron-withdrawing Groups 
Another opportunity to improve the selectivity of non-covalently imprinted polymers is 
to strengthen the interactions of the template and monomer.  One approach to strengthen these 
interactions is to increase the 
hydrogen bonding of template to the 
functional monomer.
9
  With this logic 
in mind, a new crosslinking monomer 
was designed to improve OMNiMIP 
imprinting by increasing the strength 
of the hydrogen bonding interactions 
between the monomer and template.  
Here, the addition of an electron 
withdrawing group (EWG) to the 
NOBE structure will make the amide 
functionality more acidic and therefore strengthen its participation in hydrogen bonding.  The 
first crosslinker design incorporated CF3 groups (illustrated in Figure 2.5) into the structure of 
NOBE, with its proposed synthesis starting from commercially available 2-
(trifluoromethyl)acrylic acid.  The synthesis of the trifluorinated crosslinker 2-(2-
(trifluoromethyl)acrylamido)ethyl 2-(trifluoromethyl)acrylate has some literature precedent.  In 
one article 2-(trifluoromethyl)acryloyl chloride was synthesized from 2-(trifluoromethyl)acrylic 
acid and was added to a primary alcohol to form an ester linkage.
10
   The success of this reaction 
led to the hypothesis that addition of 2-(trifluoromethyl)acryloyl chloride to ethanolamine 
(shown in the future work) could also be achieved; however, no significant amount of this 
 
Figure 2.5: A general design placing electron-
withdrawing groups on the ends of the structure of 
NOBE (a) and 2-(2-bromoacrylamido) ethyl 2-
bromoacrylate, BrOBE (19, b). 
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material was synthesized.  One explanation could be that the system was not completely free of 
water and hydrolysis occurred prior to formation of both the ester and amide.  
Although the addition of CF3 groups was an optimal design because of its size match in 
relation to the CH3 groups that are found in NOBE, without significant amounts of material, this 
molecule was not tested as an OMNiMIP.  While larger in atom size than carbon, bromine was 
chosen as the electron withdrawing group to be added to the structure of NOBE.  Even though 
chlorine is smaller than bromine and would be a better design choice because it would create 
smaller steric interactions, the bromine starting material was more affordable at the time. The 
new crosslinker design puts Br on each end of the NOBE base structure, 2-(2-bromoacrylamido) 
ethyl 2-bromoacrylate (BrOBE, 19.)  This crosslinker design is predicted to promote stronger 
hydrogen bonding because the bromines will withdraw electron density, making the molecule 
more acidic.  As electron density is shifted away from the amide, and the proton attached to the 
nitrogen of the amide becomes more acidic, the bond is weakened, and could allow for greater 
hydrogen bonding when in contact with template.  The hydrogen bonding interactions of BrOBE 
with a BOC-Tyr template is shown in Figure 2.6.  Here, it is expected that strong electron 
withdrawing appendages could strengthen hydrogen bonding and non-covalent imprinting. 
BrOBE (19) was successfully synthesized in one step in quantitative yield.  When only 
two equivalents of the bromo acrylic acid were used with both DCC/DMAP and DCC/HOBt, the 
yield was only ~10% or lower. When the amount of acid was increased to four equivalents, 
100% of the theoretical yield of product was collected using DCC/DMAP.  After synthesis, this 
monomer was imprinted with 5% L-BOC-Tyrosine.  Polymerization was unsuccessful in the 
typical 13 x 100 mm tubes.  In this case, crosslinked polymer formed only at the edge of the tube 
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and the inside was mostly “soft” polymer indicating that the material was not fully polymerized 
and furthermore not highly crosslinked.   
 
D. Crosslinkers with Hydrogen Bond Donor/Acceptor Proximity and Amide Content 
Another attempt to improve crosslinking monomers for OMNiMIP imprinting was to 
utilize a molecule that was previously demonstrated to be successful as a crosslinker with regard 
to traditional imprinting.  The crosslinker 2-methyl-N-(3-methyl-2-oxobut-3-enyl)acrylamide 
(NAG, 12), whose polymerizable groups were discussed previously, outperformed NOBE as a 
crosslinker in combination with the functional monomer methacrylic acid for separating 
enantiomers of both dansyl-phenylalanine and BOC-Tyrosine.
5
  The improvement in 
enantiomeric separation was attributed to the cooperative effects of the hydrogen bond donor and 
 
 
Figure 2.6:  Hydrogen bonding interactions between the crosslinker BrOBE (19) and the 
template BOC-Tyr (7).  
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acceptor being in closer proximity along with the increased amide content (in relation to the 
number of atoms in the molecule) of the crosslinker.  Although this monomer did show excellent 
traditional imprinting results, it has never been tested as a crosslinking monomer for OMNiMIP 
imprinting.  In this chapter NAG was synthesized and its ability to act as the sole monomer for 
OMNiMIP imprinting was evaluated by HPLC. 
Starting from the Weinreb amide, NAG (12) was synthesized (Scheme 2.7.)  After 
multiple attempts to synthesize molecule 12 on a gram scale, the highest yield achieved was 21% 
and this was obtained when the Grignard reagent was synthesized rather than purchased.  Once 
synthesized, NAG was first polymerized using a photo-initiated radical polymerization protocol; 
however, the material afforded exhibited a “jelly” consistency indicating a low degree of double 
bond conversion.  This material then was subjected to thermal polymerizations to cure the 
material, obtaining a solid material that could be ground and packed into HPLC columns.   
 
E. Crosslinker with Stereochemical Rigidity 
Piletsky and co-workers described the importance of rigidity in the formation of 
imprinted cavities through a series of experiments based on time lengths of polymerization.
11
  In 
this article, the authors also explained that rigidity could influence the binding kinetics as well as 
the mobility of the print molecule into and out of the binding cavity; therefore, a balance of 
rigidity and mass transfer is essential.  Thus, a hypothesis to improve the OMNiMIP imprinting  
Figure 2.7: (2R,3S)-3-methacrylamidobutan-2-yl methacrylate (20). 
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technique is to increase polymer rigidity.  One method to increase rigidity is to alter the present 
model compound, NOBE (1), by adding two relatively small alkyl groups to the spacer of the 
compound.   
The introduction of two methyl groups, one to the alpha amido and one to the alpha ester 
position of NOBE was completed.  This new molecule, (2R,3S)-3-methacrylamidobutan-2-yl 
methacrylate (Figure 2.7, 20), incorporating the two methyl groups is predicted to cause the 
crosslinking monomer to twist in such a way that relieves the methyl-methyl repulsion.  This 
configuration may cause a rigid framework that will lock into place and lead to better binding 
cavity formation.  As pointed out in Chapter One, the addition of a small group, such as a methyl 
appendage at the alpha amido position of NOBE does not inhibit template binding.
12
  It is 
anticipated that adding a second methyl group would continue to have a negligible effect on 
binding interactions and the reactivity of the polymerizable groups.  The effects of this 
crosslinker on the imprinted polymer will be explored to determine if the rigidity from the 
locked-in twist of the crosslinking monomer will provide a better OMNiMIP imprinted cavity to 
form.  Furthermore, this crosslinker is chiral with C2 symmetry, which can improve chiral 
separations and be used for imprinting racemic molecules. 
The synthesis of (2R,3S)-3-methacrylamidobutan-2-yl methacrylate (20) was successfully 
completed in 5 steps.  Addition of trimethoxyethane to the stereochemically pure (2R,3R)-
butane-2,3-diol afforded intermediate 35 in yields ranging from approximately 75-91%.  Next, 
the addition of trimethylsilyl azide was completed.  It should be noted that a color change from 
gold to red occurs when molecule (37) is synthesized.  The highest yield for this reaction was 
43%.  The next two reactions, the de-protection of the alcohol followed by the reduction of the 
azide to the amine, were completed without purification by column chromatography and the 
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crude products were used to continue the synthesis.  The final step involved a DCC/DMAP 
coupling reaction of the amino alcohol to MAA to afford the final product (2R,3S)-3-
methacrylamidobutan-2-yl methacrylate (20.)  Although this molecule has been successfully 
synthesized, a larger amount of material needs to be synthesized in order to study this molecule 
as a crosslinker for OMNiMIP imprinting, and this is ongoing research to be completed in the 
Spivak research group. 
 
2.2 Experimentals 
A. Crosslinkers with Alteration of Polymerizable Groups  
 
Scheme 2.1: Synthesis of NOBE (1). 
 
2-methacrylamidoethyl methacrylate (NOBE, 1):  
NOBE (1) was synthesized according to a published protocol.
13
  In a 500 mL 
roundbottom, ethanolamine (21, 4.017 g, 0.0658 mol) and 225 mL DCM were cooled to 0°C.  
DMAP (1.6374 g, 0.0134 mol) and MAA (8, 12.6523 g, 0.147 mol) were added, followed by 
DCC (29.1370 g, 0.141 mol).  The mixture was slowly warmed to room temperature and stirred 
for 2 days.  The DCU was filtered off by vacuum filtration and the organic solution was washed 
with 1 N HCl (aq) (3 x 100 mL) and sat. NaHCO3 (aq) (7 x 100 mL.)  The organic layer was 
dried over MgSO4 and the solvent evaporated to yield an oil (1, 12.7621 g, 98.4% yield.)  
1
H 
NMR (CDCl3, 400 MHz) δ ppm 6.41 (1H, br, NH), 6.06 (1H, s), 5.64 (1H, s), 5.54 (1H, s), 5.27-
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5.25 (1H, d, J= 8 Hz), 4.25-4.22 (2H, t, J= 6 Hz), 3.58-3.54 (2H, q), 1.90 (3H, s), 1.88 (3H, s.)  
13
C NMR (CDCl3, 100MHz) δ ppm 168.46, 167.65, 139.78, 135.94, 126.20, 119.76, 63.36, 
39.22, 18.58, 18.29. 
 
 
 
Scheme 2.2: Synthesis of 2-acrylamidoethyl acrylate (13). 
 
2-acrylamidoethyl acrylate (13):  
The synthesis of 2-acrylamidoethyl acrylate (13) was adapted from a known literature 
procedure.
14
  Ethanolamine (21, 1.0 mL, 0.0166 mol) in 100 mL DCM was cooled to 0°C.  
Acrylic acid (22, 2.5 mL, 0.036 mol) and DMAP (0.081 g, 0.0036 mol) in 25 mL was added to 
the amino alcohol solution.  After 10 min, DCC (7.5 g, 0.036 mol) in 25 mL DCM was added 
dropwise.  The mixture was slowly allowed to cool to room temperature and was stirred for 3 
days.  After filtration of DCU, extractions using 1 N HCl (aq) (2 x 75 mL) and saturated 
NaHCO3 (aq) (3 x 75 mL) were completed.  The organic layer was dried over MgSO4 and was 
filtered.  After evaporation, the crude product was purified by column chromatography using 
50/50 to 75/25 EtOAc/Hexanes to yield a yellow oil (13, 1.2009 g, 43%.)  
1
H NMR (CDCl3, 400 
MHz) δ ppm 6.50 (1H, br), 6.38 (dd, J = 17.3, 1.3 Hz, 1H), 6.24 (dd, J = 17.1, 1.5 Hz, 1H), 6.18 
– 6.00 (m, 2H), 5.82 (dd, J = 10.4, 1.4 Hz, 1H), 5.60 (dd, J = 10.2, 1.6 Hz, 1H), 4.25 (t, J = 5.4, 
5.4 Hz, 2H), 3.60 (q, J = 5.5, 5.5, 5.5 Hz, 2H.)  
13
C NMR (CDCl3, 100MHz) δ ppm 166.17, 
165.82, 131.40, 130.61, 127.90, 126.58, 63.15, 38.73. 
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Scheme 2.3: Synthesis of 2-acrylamidoethyl methacrylate (14). 
2-acrylamidoethyl methacrylate (14): 
 Hydroxyethyl acrylamide (23, 2.1172 g, 0.018 mol) in 75 mL DCM was cooled to 0°C.  
Methacrylic acid (8, 1.9054 g, 0.022 mol) and DMAP (4.8 mg, 0.039 mmol) in 25 mL DCM was 
added.  DCC (4.46 g, 0.022 mol) in 25 mL DCM was added after 5 minutes and the reaction was 
stirred 2 days.  After filtration of DCU, extractions using 0.5 N HCl (aq) (4 x 75 mL) and 
saturated NaHCO3 (aq) (4 x 75 mL) were completed.  The organic layer was dried over MgSO4 
and was filtered.  After evaporation, the crude product was purified by column chromatography 
using 50/50 EtOAc/hexanes to afford 1.7830 g, 53% yield product (14.)  
1
H NMR (CDCl3, 400 
MHz) δ ppm 6.27 (dd, J = 17.0, 1.5 Hz, 1H), 6.17 – 6.04 (m, 3H), 5.65 (t, J= 8 Hz, J= 8 Hz, 1H), 
5.58 (t, J= 4 Hz, J= 4 Hz, 1H), 4.27 (t, J = 5.4, 5.4 Hz, 2H), 3.64 (q, J = 5.5, 5.5, 5.5 Hz, 2H), 
1.93 (s, 3H).  
13
C NMR (CDCl3, 100MHz) δ ppm 167.54, 165.73, 135.93, 130.61, 126.72, 63.38, 
60.39, 38.95, 18.26. 
 
B. Three-armed Crosslinkers 
 
Scheme 2.4: Synthesis of 1,3-dimethacrylamidopropan-2-yl methacrylate (17). 
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1,3-dimethacrylamidopropan-2-yl methacrylate (17): 
1,3-diaminopropan-2-ol (24, 2.0231 g, 0.02245 mol) was dissolved in 50 mL CHCl3 and 
was cooled to 0°C.  MAA (8, 6.66 mL, 0.0785 mmol) and DMAP (0.9619 g, 7.87 mmol) in 30 
mL chloroform was cooled then added to the amino alcohol solution.  DCC (14.8973 g, 0.0722 
mol) was added and the mixture was allowed to stir for 3.5 days.  The DCU was filtered off and 
the organic layer was washed with 1 N HCl (aq) (4 x 150 mL) then sat. NaHCO3 (aq) (4 x 150 
mL).  The organic layer was dried over MgSO4 and was filtered.  After solvent evaporation, the 
crude product was purified by column chromatography using 75/25 EtOAc/hexanes to yield 
4.2835 g, 65% yield product (17.)  
1
H NMR (CDCl3, 400 MHz) δ ppm 6.88 (br, 2H), 6.10 (s, 
1H), 5.77 (s, 2H), 5.88 (S, 1H), 5.36 (s, 2H), 4.99-4.93 (m, 1H), 3.62-3.34 (m, 4H), 1.97 (s, 6H), 
1.90 (s, 3H).  
13
C NMR (CDCl3, 100MHz) δ ppm 169.14, 166.69, 139.54, 135.85, 126.56, 
120.29, 71.47, 39.16, 18.61, 18.24.   IR νmax  3271.25, 1710.61, 1654.16, 1617.30, 1540.77, 
1181.65, 1077.50. 
 
 
 
Scheme 2.5: Synthesis of (S)-2,3-dimethacrylamidopropyl methacrylate (18). 
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(S)-di-tert-butyl (3-hydroxypropane-1,2-diyl)dicarbamate (26): 
In a 250 mL roundbottom flask, (S)-2,3-bis((tert-butoxycarbonyl)amino)propanoic acid 
(25, 2.9006 g, 9.5 mmol) in 45 mL dry chloroform was cooled to 0°C.  NMM (1.2 mL, 10.45 
mmol) was added dropwise to the solution and the mixture was allowed to cool.  
Isobutylchloroformate (1.36 mL, 10.45 mmol) was added dropwise and the reaction mixture was 
stirred for 15 minutes.  NaBH4 (1.0824 g, 28.5 mmol) was added.  Methanol (90 mL) was added 
dropwise over 15 minutes and the reaction mixture was allowed to stir for an additional 40 
minutes then 18 mL 1 N HCl (aq) was added.  H2O was added and the product was extracted 
using chloroform (4 x 50 mL).  The combined organic layer was washed with 1 N HCl (aq) (1 x 
100 mL), H2O (1 x 100 mL), sat. NaHCO3 (aq) (1 x 100 mL), then H2O (1 x 100 mL.)  The 
organic layer was dried over MgSO4, filtered, and the solvent evaporated.  Column 
chromatography using 50/50 EtOAc/hexanes was used to purify the crude product to afford 
1.8927 g, 68% product (26.)  
1
H NMR (CDCl3, 400 MHz) δ ppm 5.17-5.11 (br, 2H), 3.75 (m, 
1H), 3.73-3.53 (m, 2H), 3.32-3.21 (m, 2H), 1.44 (s, 9H).  
13
C NMR (CDCl3, 100MHz) δ ppm 
157.74, 155.80, 80.30, 79.61, 61.59, 52.31, 40.22, 28.37, 28.30. 
 
(S)-2,3-diaminopropan-1-ol (27): 
 (S)-di-tert-butyl (3-hydroxypropane-1,2-diyl)dicarbamate (26, 1.834 g, 6.3 mmol) was 
stirred in 1.55 M ethereal HCl (81.5 mL, 0.126 mol, 20 eq) overnight.  Triethylamine was added 
to neutralize the solution.  After solvent evaporation, the de-protected product (27) was obtained 
in quantitative yields.  
1
H NMR (CDCl3, 400 MHz) δ ppm 4.24 (br, 1H), 4.01 (m, 1 H), 3.45 (m, 
1H), 2.90 (m, 2 H), 1.63 (m, 3H), 1.44 (m, 2 H).  
13
C NMR (CDCl3, 100MHz) δ ppm 60.71, 
49.82, 38.31. 
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(S)-2,3-dimethacrylamidopropyl methacrylate (18): 
 De-protected amino alcohol (27, 0.811 g, 9.0 mmol) was stirred in 100 mL chloroform.  
Et3N (4 mL) was added dropwise to the suspension and the mixture became clear.  The solution 
was cooled to 0°C.  MAA (8, 2.7 mL, 31.5 mmol) and DMAP (0.3906 g, 3.2 mmol) in 15 mL 
chloroform was cooled then added dropwise to the alcohol solution.  DCC (6.5762 g, 32.0 mmol) 
in 15 mL chloroform was cooled then added dropwise to the reaction mixture.  The reaction 
mixture was allowed to slowly rise to room temperature and was stirred for 5 days.  The DCU 
was filtered using vacuum filtration and the orange solution was washed with 1 N HCl (aq) (4 x 
200 mL) then saturated NaHCO3 (aq) (4 x 200 mL).  The organic layer was dried over MgSO4, 
filtered, and the solvent was evaporated.  Purification by column chromatography using 75/25 
EtOAc/hexane was performed on the crude product.  Pure product (18, 0.8024 g) was obtained in 
30% yield.  
1
H NMR (CDCl3, 400 MHz) δ ppm 7.11 (br, 1H), 6.76 (br 1H), 6.17 (s, 1H), 5.78 (s, 
2H), 5.64 (s, 1H) 5.38-5.37 (d, 2H), 4.32 (s, 1H), 4.13-4.11 (m, 2H), 3.50-3.47 (m 2H), 1.73 (s,3 
H), 1.71 (s, 3H), 1.70 (s, 3H).  
13
C NMR (CDCl3, 100MHz) δ ppm 169.98, 168.99, 167.75, 
139.11, 135.66, 130.92, 128.82, 126.80, 120.77, 63.27, 50.63, 41.19, 18.53, 18.46, 18.30. 
 
Alteration of Polymerizable Groups and Three-armed Crosslinkers Polymer Preparation:  
 Monomer (1.5 g of 1, 3, 14, 17, or 18) was added to the 13 x 100 mm glass tube with a 
solution of the print molecule L-BOC-Tyr (5%) dissolved in 1.5 mL acetonitrile.  AIBN (1%) 
was added to the solution.  Nitrogen was used to purge the sample for 5 minutes.  After the 
sample was purged, the tube was capped and Teflon tape and Parafilm were used to seal the 
system.  The tube was then inserted into a photoreactor apparatus where it was submerged in an 
ethylene glycol/H2O bath to maintain the temperature and was exposed to a 450 W mercury arc 
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lamp surrounded by a borosilicate jacket for 8 hours.  The polymer was then broken out of the 
tube and the template was removed by Soxhlet extraction for 2 days.  The polymers were then 
ground and sized to 25-37 µm using U.S.A. Standard Testing Sieves.  The sized polymer was 
then packed into 100 x 2.1 mm stainless steel columns and their imprinting abilities were 
analyzed by HPLC. 
 
C. Crosslinkers with Electron-withdrawing Groups 
 
 
 
Scheme 2.6: Synthesis of BrOBE (19). 
 
2-(2-bromoacrylamido) ethyl 2-bromoacrylate (19): 
In a 100 mL round bottom, ethanolamine (21, 0.31 mL, 5.1 mmol) was dissolved in 12 
mL DCM the solution was cooled to 0°C.  Bromoacrylic acid (28, 3.0911 g, 20.5 mmol, 4 eq) 
and DMAP (46.1 mg, 0.4 mmol) were dissolved in 12 mL DCM was the solution was added 
dropwise to the amino alcohol solution.  After 10 minutes, DCC (4.2358 g, 20.5 mmol, 4 eq) 
dissolved in 11 mL DCM was added to the reaction mixture by dropwise addition.  The mixture 
was stirred at room temperature for 2 days.  The DCU was filtered off and the DCM solution was 
washed with 1 N HCl (3 x 30 mL) (aq) and saturated NaHCO3 (3 x 30 mL) (aq).  The combined 
organic layers were dried over MgSO4, and after filtration the solvent was evaporated.  Column 
chromatography using 50/50 EtOAc/hexane was run and a colorless oil (19) was afforded in 
100% yield.  
1
H NMR (CDCl3, 400 MHz) δ 7.08 (br, 1H), 6.90 (d, 1H, J= 4Hz), 6.88 (d, 1H, J= 
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4 Hz), 6.21 (d, 1H, J= 4 Hz), 6.0 (d, 1H, J= 4 Hz), 4.29-4.25 (t, 2H, J= 6 Hz), 3.62-3.55 (q, 2H).  
13
C NMR (CDCl3, 100MHz) δ 161.86, 161.23, 131.46, 128.06, 122.37, 120.56, 64.76, 39.46. 
 
2-(2-Bromoacrylamido) ethyl 2-bromoacrylate (19) Polymer Preparation:  
 Monomer (19, 0.5 g) was added to a NMR tube containing a solution of the template L-
BOC-Tyr (5%) dissolved in 0.5 mL acetonitrile.  AIBN (1%) was added and the solution was 
sonicated repeatedly for a few seconds to degas the pre-polymer complex while maintaining a 
room temperature solution.  Nitrogen was flushed over the tube to remove air from the sample.  
The NMR tube was then capped and Teflon tape and Parafilm were used to seal the system.  The 
tube was next inserted into a photoreactor where it was submerged in an ethylene glycol/H2O 
bath to maintain the temperature during polymerization and the reaction mixture was exposed to 
a 450 W mercury arc lamp surrounded by a borosilicate jacket for 8 hours.  The polymer was 
then broken out of the tube and the template was removed by Soxhlet extraction using 
methanol/acetic acid (90/10) for 2 days.  The polymeric material was ground and sized to 20-37 
µm using U.S.A. Standard Testing Sieves and packed into 100 x 2.1 mm stainless steel columns. 
The selectivity of the OMNiMIP chromatographic stationary phase was analyzed by HPLC. 
 
D. Crosslinkers with Hydrogen Bond Donor/Acceptor Proximity and Amide Content 
 
Scheme 2.7: Synthesis of NAG (12). 
 
 34 
 
2-Methyl-N-(3-methyl-2-oxobut-3-enyl) acrylamide (NAG, 12):  
 The synthesis of NAG was modified from a previous publication.
5
  Magnesium turnings 
(0.4099 g, 16.9 mmol, 1.9 eq) were oven dried overnight.  After cooling under N2, the Mg (29) 
was mashed.  Dry THF (10 mL) was added followed by the addition of 2-bromopropene (30, 
1.0709 g, 8.9 mmol).  The colorless solution was refluxed for 30 minutes and became a 
gray/brown dirty dishwater color, indicating the formation of the isopropenyl magnesium 
bromide (31) in THF.  The Weinreb amide (32, 0.6422 g, 3.4 mmol) in 5 mL THF was cooled to 
-5°C.  Isopropenyl magnesium bromide (31) in THF (9.6 mL, 0.89 M, 2.5 eq) was added over 
five minutes and a white solid precipitated out.  The mixture was allowed to slowly warm to 
room temperature and was stirred overnight for 18 hours.  The reaction was quenched with 
saturated NH4Cl (aq), and the THF was evaporated.  Et2O (50 mL) was added and the phases 
were separated.  The organic phase was washed with brine (2 x 30 mL) and water (1 x 50 mL).  
The organic layer was dried over MgSO4, filtered, and the solvent evaporated. Column 
chromatography was run on the yellow oil using 50/50 EtOAc/hexanes.  A yellow oil (12, 121.7 
mg, 21%) pure product based on NMR was collected.  
1
H NMR (CDCl3, 250 MHz) δ 6.76 (br, 
1H), 6.07 (s, 1H), 5.89 (s, 1H) 5.78 (s, 1H), 5.36 (s, 1H), 4.51 (d, 2H, J = 4 Hz), 1.98 (s, 3H), 
1.91 (s, 3H).  
13
C NMR (100 MHz, CDCl3) δ 195.81, 168.16, 142.24, 139.11, 126.14, 120.31, 
45.66, 18.51, 17.30. 
 
NAG Imprint Polymerization: 
NAG (12) was inserted into the photo reactor for 8 hours with 5% L-BOC-Tyr template, 
1% AIBN initiator, and MeCN as the porogen.  After photo-initiated radical polymerization, the 
afforded compound was a gel consistency with a small amount of solvent remaining at the top.  
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The gel was unable to be studied as a solid stationary phase for HPLC, so a curing step was 
required.  The gel and solution was combined with an additional 25% template, 1% AIBN, and 3 
mL MeCN.  This mixture was purged with nitrogen for 5 minutes.  The mixture (mostly an 
insoluble yellow opaque mixture) was allowed to equilibrate at room temperature (stirring 
occasionally) for one hour and was then brought to 80°C for ~8 hrs.  The material became darker 
and harder, but was brittle.  The material was then crushed and sonicated several times in attempt 
to homogenize the mixture.  An additional 1% AIBN was added and the solution was purged 
with nitrogen and then was allowed to equilibrate for four hours before the heat was raised to 
80°C for two days.  This material was then ground and sized to 25-37µm using U.S.A. Standard 
Testing Sieves packed into a 50 x 2.1 mm HPLC column for analysis. 
 
E. Crosslinker with Stereochemical Rigidity 
 
 
Scheme 2.8: Synthesis of ((2R,3S)-3-methacrylamidobutan-2-yl methacrylate (20). 
 
(4R,5R)-2-methoxy-2,4,5-trimethyl-1,3-dioxolane (35): 
 The synthesis of (4R,5R)-2-methoxy-2,4,5-trimethyl-1,3-dioxolane (35) was adapted 
from a literature procedure.
15
  (2R,3R)-butane-2,3-diol (33, 1.2975  g, 0.014 mol) in 45 mL ether 
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was cooled to 0°C.  Trimethoxyethane (34, 3.5 mL, 0.029 mol, 2 eq) followed by 38.4 µL H2SO4 
(aq) were added.  The mixture was allowed to slowly warm to room temperature and was stirred 
overnight.  Triethylamine (1.5 mL) was added to the colorless solution and this was poured into 
75 mL saturated NaHCO3 (aq), and the product was extracted with diethyl ether (3 x 30 mL.) 
After drying over MgSO4 and evaporation of solvent, the crude colorless liquid (1.9158 g, 91% 
product (35)) was used in the next step without additional purification.  
1
H NMR (CDCl3, 
400MHz) δ ppm 3.82-3.73 (m, 1H), 3.71-3.63 (m, 1H), 3.26 (s, 3H, OCH3), 1.51 (s, 3H, CH3), 
1.29-1.27 (d, 3H), 1.23-1.21 (d, 3H).  
13
C NMR (100 MHz, CDCl3) δ 120.84, 79.44, 78.97, 
49.15, 23.42, 17.27, 16.81.  
 
 (2R,3S)-3-azidobutan-2-yl acetate (37):  
 (2R,3S)-3-azidobutan-2-yl acetate (37) was synthesized according to a prior report.
15
  
(4R,5R)-2-methoxy-2,4,5-trimethyl-1,3-dioxolane (35, 2.4418 g 75%/wt product (contained 
trimethoxyethane (34)), 0.013 mol) and TMSN3 (36, 4.3 mL, 0.033 mol) was heated at 60°C for 
four hours turning from a pale yellow to dark gold solution.  The temperature was increased to 
130°C and was stirred overnight.  After evaporation, the dark red liquid was poured into water 
and was extracted using Et2O (3 x 100 mL).  The organic layer was dried over MgSO4 and after 
filtration and evaporation, the crude product was purified by column chromatography (1/3 to 
50/50 EtoAc/hexanes) to yield a yellow liquid (37, 0.8416 g, 43% yield)  
1
H NMR (CDCl3, 
250MHz) δ ppm 4.75-4.69 (m, 1H), 3.73-3.70 (m, 1H), 2.06 (s, 3H, OAc), 1.19 (d, J = 12 Hz, 
3H), 1.16 (d, J = 4 Hz, 3H).  
13
C NMR (100 MHz, CDCl3) δ 170.88, 74.88, 69.87, 21.24, 18.98, 
16.19.  I  νmax 2113.46 (s, azide), 1728.02 (s) cm-1.  HRMS (ESI-TOF): calcd for C6H11N3O2 
(M)
+
: 157.0845. 
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(2R,3S)-3-azidobutan-2-ol:  
 The synthesis of (2R,3S)-3-azidobutan-2-ol was completed according to a prior 
publication.
15
  Methanol (50 mL) was added to (2R, 3S)-3-azidobutan-2-yl acetate (37, 0.7889 g, 
5.02 mmol).  K2CO3 (3.5158 g, 0.025 mmol, 5 eq) was added to the yellow solution and was 
stirred overnight at room temperature.  The white solid was filtered off from the yellow solution.  
The MeOH was removed from the solution and the product was poured into water (20 mL) and 
extracted with Et2O (3 x 20 mL.)  The organic layer was dried over MgSO4 and the solvent was 
evaporated to afford a gold liquid.  A crude 
1
H NMR showed formation of the product with some 
other material present.  This crude product was used in the next step without further purification. 
1
H NMR (CDCl3, 250MHz) δ ppm 3.66-3.60 (m, 1H), 3.59-3.55 (m, 1H), 3.00 (br, 1H), 1.19 (d, 
J = 12 Hz, 3H), 1.16 (d, J = 4 Hz, 3H).  
13
C NMR (100 MHz, CDCl3) δ 70.70, 62.65, 18.30, 
13.79. 
 
(2R,3S)-3-aminobutan-2-ol (38):
15
  
 The synthesis of (2R,3S)-3-aminobutan-2-ol (38) followed the method of a prior report.
15
  
(2R,3S)-3-azidobutan-2-ol (0.3722 g, 3.2 mmol), 0.2020 g Pd/C, and 4 mL MeOH were stirred 
under a H2 balloon at room temperature overnight.  The reaction mixture was filtered through a 
celite cake twice and the filtrate was concentrated.  Upon concentration, the mixture needed to be 
filtered through a celite cake again and was then completely concentrated yielding a pale gold 
colored oil.  The crude product (38) was used in the next step without further purification. 
1
H 
NMR (CDCl3, 250MHz) δ ppm 3.68-3.59 (m, 1H), 2.93-2.81 (m, 1H), 1.86 (br, 3H, OH and 
NH2), 1.09-1.07, d, 3H), 0.98-0.96 (d, 3H.) 
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(2R,3S)-3-methacrylamidobutan-2-yl methacrylate (20): 
(2R,3S)-3-aminobutan-2-ol (38, 0.4047 g, 4.54 mmol crude product) in 50 mL DCM was 
cooled to 0°C.  MAA (8, 0.8689 g, 10.1 mmol, 2.2 eq) was added slowly to the mixture.  DMAP 
(139.9 mg, 1.15 mmol, 0.25 eq) was added and the temperature was allowed to equilibrate.  DCC 
(2.0708 g, 10.0 mmol, 2.20 eq) was then added slowly.  The mixture was allowed to slowly 
warm to room temperature and was stirred under argon for 2 days.  The DCU was removed by 
vacuum filtration and the organic layer was washed with 1 N HCl (aq) (3 x 25 mL) and saturated 
NaHCO3 (aq) (7 x 25 mL).  The organic layer was dried over MgSO4 and was filtered.  After 
evaporation of solvent, column chromatography was run using EtOAc/hexanes (25/75 then 
50/50) to elute the product.  After evaporation, a colorless oil (20, 0.0847 g) was obtained.  
1
H 
NMR (400 MHz, CDCl3) δ 6.30 (br, 1H), 5.63 (s, 1H), 5.56 (s, 1H), 5.28 (s, 1H), 4.98 - 4.95 (m, 
1H), 4.21 – 4.14 (m, 1H), 1.91 (s, 6H), 1.26 (d, J = 6.5 Hz, 3H), 1.15 (d, J = 6.8 Hz, 3H).  13C 
NMR (100 MHz, CDCl3) δ 167.78, 167.27, 140.05, 136.27, 125.85, 119.49, 73.55, 48.73, 18.51, 
18.22, 16.95, 14.69.  I  νmax 1714.35, 1662.89, 1625.67, 1514.40.  MS (ESI-TOF):  calcd for 
C12H19NO3 (M+H)
+
:  226.14; found 226.1434.  
 
2.3 Results and Discussion of New Crosslinkers for Molecular Imprinting 
A. OMNiMIP Performance from Crosslinkers with Alteration of Polymerizable Groups  
Once synthesized, crosslinkers 1, 13, and 14 were used to imprint L-BOC-Tyr using a 
photo-initiated radical polymerization technique.  The OMNiMIPs formed using the crosslinkers 
2-acrylamidoethyl acrylate (13) and 2-acrylamidoethyl methacrylate (14) were explored as 
HPLC stationary phases and their ability to separate BOC-Tyr enantiomers were compared to 
NOBE.  For these trials, the particle size range and HPLC specifications were chosen to mimic 
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the conditions that were previously used to study NOBE.
13
  Herein, the OMNiMIP particles were 
ground using a mortar and pastel and sized to 25–37 μm using U.S.A. Standard Testing Sieves.  
NOBE and 2-acrylamidoethyl methacrylate (14) OMNiMIPs were packed into 100 x 2.1 mm 
stainless steel columns.  Since a smaller amount of OMNiMIP was prepared from 2-
acrylamidoethyl acrylate (13), this material was packed into a smaller 50 x 2.1 mm stainless 
column.  Although the column sizes differed, the results were normalized by calculating the 
capacity factors (k’) for all analytes evaluated.   
For the HPLC analyses, all analytes were run in triplicate at room temperature under 
isocratic conditions with a 99% MeCN 1% acetic acid mobile phase at a 0.1 mL/min flow rate.  
The wavelength of detection for all experiments was 260 nm.  The 1 mM BOC-tyrosine 
enantiomers were injected separately into the column so that effective separation factors (α') 
could be determined, and the total sample volume injected was 5 μL each.  Acetone was used to 
determine the void volume so that the capacity factors (k’) could be calculated according to Eq. 
1.1.  Results from the alteration of polymerizable groups are shown in Table 2.1.  The α’ for 
NOBE was determined to be 3.78 ± 0.4071, while the α' for molecules 13 and 14 were 
determined to be 1.65 ± 0.0457 and 1.89 ± 0.0626, respectively.  All groups studied here were 
able to separate enantiomers of BOC-tyrosine, since all had α' greater than 1.0.  The OMNiMIP 
stationary phase from NOBE performed better than 2-acrylamidoethyl methacrylate (14), and 14 
performed better than 2-acrylamidoethyl acrylate (13). 
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Table 2.1: HPLC results for OMNiMIPs synthesized from the crosslinkers with alteration of 
polymerizable groups
*
. 
 
Monomer k'D k'L α' 
 
2.41 ± 0.0115 9.10 ± 0.979 3.78 ± 0.4071 
 
1.93 ± 0.05033 3.19 ± 0.0300 1.65 ± 0.0457 
 
1.97 ± 0.0577 3.73 ± 0.0577 1.89 ± 0.0626 
*
HPLC conditions: 25–37 μm particles; 100 x 2.1 (used for OMNiMIPs generated from 1 and 
14), 50 x 2.1 (used for OMNiMIP generated from 13) column; mobile phase, MeCN/acetic acid 
(99:1); analytes (1mM BOC-L-tyrosine, 1 mM BOC-D-tyrosine, acetone (used to determine void 
volume)) were all detected at 260 nm; flow rate 0.1 mL/min; sample volume injected 5 μL.  
The composition of the crosslinking monomer’s polymerizable groups affected their 
polymerization and therefore OMNiMIP performance to separate chiral compounds.  NOBE (1) 
contains a methacrylate and methacrylamide group.  The methacrylate group polymerizes 
slightly faster than the methacrylamide group, forming a highly crosslinked rigid polymer with 
excellent imprinting towards BOC-Tyr.  When compound 1 was studied as a stationary phase for 
HPLC, it was able to separate enantiomers of BOC-Tyr with a separation factor of 3.78 ± 0.4071.   
2-acrylamidoethyl acrylate (13) is comprised of acrylate and acrylamide groups and 2-
acrylamidoethyl methacrylate (14) is composed of methacrylate and acrylamide groups, while 
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NOBE (1) contains methacrylate and methacrylamide groups.  For several reasons, it was 
hypothesized that 13 and 14 may provide improved selectivity of the OMNiMIPs synthesized 
using these crosslinkers.  For example, the structures of crosslinkers 13 and 14 are less sterically 
hindered and were anticipated to wrap more closely around the template when compared to 1.  
These less sterically hindered crosslinkers were also expected to solubilize better than 1 in the 
pre-polymer complex, decreasing phase separation during the polymerization.  Furthermore, the 
polymerizable group reactivity order, which consisted of 14 forming linear polymer first 
followed by crosslinking, which was previously shown to be successful for the crosslinker NAG 
in traditional imprinting, was also expected to improve the selectivity of the resulting 
OMNiMIPs; however, the imprinted polymers synthesized from crosslinkers 13 and 14 were 
subordinate to NOBE (1.)   
The inferior performance of molecules 13 and 14 could be explained by the reactivity of 
the polymerizable groups negatively affecting the OMNiMIPs formed.  As mentioned 
previously, secondary radicals are less stable than tertiary radicals and it is predicted that 13 will 
polymerize slower and be less reactive than 1 as it contains two end polymerizable groups that 
will form secondary radicals (both the acrylate and acrylamide) compared to two tertiary radicals 
from the methacrylate and methacrylamide groups of 1.  Molecule 14 will also not polymerize as 
quickly or be as reactive as compound 1, but should polymerize marginally faster and be more 
reactive than compound 13 because 14 is comprised of a methacrylate group, which will form a 
tertiary radical and an acrylamide group that will form a secondary radical.  The delay and lower 
reactivity of the crosslinkers 13 and 14 may result in early termination of the polymerization and 
form less crosslinked polymers.  Polymers that are less crosslinked may have less structured 
selective binding sites, which would result in poor HPLC separation factors during the 
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OMNiMIPs analysis.  The separation factor of compounds 13 and 14 are similar, α' = 1.65 ± 
0.0457 and 1.89 ± 0.0626 respectively.  Although these separation factors do show that these 
OMNiMIPs have the ability to be imprinted and can separate enantiomers of BOC-Tyr, they do 
not show any improvement to the original crosslinking monomer NOBE.  With both 
polymerizable groups forming two stable tertiary radicals, crosslinker 1 performed the best 
followed by 14, which contained groups that form one tertiary and one secondary radical.  
Finally, crosslinker 13 containing two polymerizable groups that form secondary radicals 
performed the worst.  The order of performance suggests that the stability of the radical formed 
by the polymerizable groups of the crosslinkers plays a vital part in OMNiMIP formation.   
 
B. Three-armed Crosslinkers 
Two new crosslinkers with three polymerizable groups, (S)-2,3-dimethacrylamidopropyl 
methacrylate (18) and 1,3-dimethacrylamidopropan-2-yl methacrylate (17) were synthesized.  
Both 17 and 18 contain two methacrylamide groups that could participate in hydrogen bonding 
and one methacrylate group, and these crosslinkers differ only by the position of these groups.  
Crosslinker 18 was determined to be insoluble in acetonitrile, tetrahydrofuran, 
dimethylformamide, H2O, and chloroform (common porogens) at 1 g/mL, a typical concentration 
for the photo-initiated radical polymerizations of imprinted polymers (Table 2.2.)  The 
insolubility of crosslinker 18 prohibited its use as an OMNiMIP. 
 Crosslinker 17 was partially soluble in the polymerization solvent and was able to be 
tested as an OMNiMIP.  The OMNiMIP resulting from the crosslinker 1,3-
dimethacrylamidopropan-2-yl methacrylate (17) was analyzed by HPLC following a procedure  
similar to the analysis of NOBE presented previously and the results are shown in Table 2.2.  
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After optimization of chromatographic conditions, the best performance in selectivity was 
achieved using 1 mL/min as the flow rate.  Although 17 was successful at separating enantiomers 
of BOC-Tyr (α’ = 1.2), it did not perform better than NOBE (α' = 3.78 ± 0.4071.)   
Table 2.2: HPLC results of the OMNiMIPs synthesized from the three-armed crosslinkers
*
. 
Monomer k'D k'L α' 
 
3.3 3.9 1.2 
 
- - Not Soluble 
*
HPLC conditions: 25–37 μm particle size; 100 x 2.1 column; MeCN/acetic acid (99:1) mobile 
phase; analytes (1mM BOC-L-tyrosine, 1 mM BOC-D-tyrosine, acetone (used to determine void 
volume)) were all detected at 260 nm; flow rate 1 mL/min; sample volume injected  was 5 μL.  
There are several possible reasons the additional amide appendage could have caused inferior 
(compared to NOBE) OMNiMIP selectivity, and an illustration of the predicted binding behavior 
is shown in Figure 2.8.  Although three polymerizable groups are anticipated to form more rigid 
selective binding sites, this is only the case if all of the polymerizable groups react and if 
hydrogen bonding is not disrupted due to steric interactions.  In the case of crosslinker 17, the 
OMNiMIP could be negatively impacted because of the increased sterics (extra methacrylamide 
group compared to NOBE) of the crosslinker.  Steric interference is increased in 17 compared to 
 44 
 
NOBE because of the additional methacrylamide group.  The trifunctional crosslinker will 
neither be able to stack to form the polymer backbone nor wrap around BOC-Tyr 
 
 Figure 2.8: Predicted binding behavior of NOBE (1) with itself and BOC-Tyr (a).  Predicted 
binding behavior of a trifunctional crosslinker (17) with itself and BOC-Tyr (b). 
   
  
(a) 
 
     
 
(b) 
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as compactly as in the case with NOBE; thus, 17 will form less structured binding cavities as 
shown in Figure 2.8.  Another possible problem associated with the additional functional group 
is the risk of phase separation of the pre-polymer complex before the imprinted binding cavities 
are formed.  Additionally, the extra methacrylamide group could cause more non-specific 
binding interactions to occur.  These additional interactions would lower selectivity and may 
account for differences observed in the α’ values seen between 17 and NOBE. 
 
C. Crosslinkers with Electron-withdrawing Groups 
 HPLC analysis was conducted on the OMNiMIP synthesized from the new molecule 
BrOBE (19).  The analysis was conducted in triplicate under the same conditions used for NOBE 
(1) mentioned previously, with the only difference being the particle size range of the two 
imprinted polymers.  The NOBE polymer used was the typical size range 25-37 μm while 20-37 
μm was used to analyze BrOBE (19).  This small difference in size range is not expected to 
significantly impact the chromatographic results.  The reason for the slightly larger size range for 
BrOBE (19) was due to the difficulty that arose with grinding 19 as it was a much “softer” 
polymer than NOBE.  Despite the irregular consistency of the imprinted polymer formed, it was 
still packed onto an HPLC column for evaluation.  With an increased backpressure when 
packing, the column containing this “soft” polymer was more difficult to fill than rigid 
crosslinked polymers.  Once the packed column was put on the HPLC, the separation of L and D 
BOC-Tyr enantiomers was attempted.  The results shown in Table 2.3 indicate that there was no 
separation of enantiomers by BrOBE (α' = 1.08 ± 0.051.)  Having not even a partial separation of 
enantiomers indicated that there were no specific binding cavities formed.  The lack of selective 
binding sites was not surprising as the “soft” polymer formed indicates poor crosslinking, and 
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therefore would not contain well structured binding sites needed for recognition.  The “soft” 
nature of the polymer was attributed to a defective polymerization.  This fault in the photo-
initiated radical polymerization was attributed to the bromine affecting the polymerization by 
inhibition of the alkyl radicals.   
Table 2.3: HPLC results for OMNiMIPs from the addition of EWG
*
. 
Monomer k'D k'L α' 
 
2.41 ± 0.0115 9.10 ± 0.979 3.78 ± 0.4071 
 
0.062 ± 0.0023 0.057 ± 0.0017 1.08 ± 0.051 
*
HPLC conditions: particle size 25-37 (for OMNiMIP generated from 1) and 20–37 μm (for 
OMNiMIP generated from 19); 100 x 2.1 column; mobile phase, MeCN/acetic acid (99:1); 
analytes (1mM BOC-L-tyrosine, 1 mM BOC-D-tyrosine, acetone (to determine void volume)) 
were detected at 260 nm; flow rate 0.1 mL/min; sample volume injected 5 μL. 
 After using a two step method (photo-initiated radical polymerization followed by 
thermal curing) an OMNiMIP generated from the crosslinker (12) NAG was obtained and this 
OMNiMIP was analyzed by HPLC using two methods.  The first method followed the same 
protocol as the one used to analyze NOBE and the results are shown in Table 2.4.  The 
separation factor (α’) for the NAG OMNiMIP was determined to be 2.39, indicating a good 
separation of BOC-Tyr enantiomers; however, this value is lower than the one obtained from 
imprinting NOBE (using only photo-initiated radical polymerization conditions.)   
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 The successful results obtained using method one initiated further examination of the 
system.  The second method used differed from the typical NOBE analysis.  Here, the column  
Table 2.4: HPLC results for the OMNiMIPs synthesized from NAG (100 x 2.1 mm column
*
). 
 
Analyte RT (min) k' α’ 
1 mM L-BOC-Tyr 
 
35.39 9.79 
2.39 
1 mM D-BOC-Tyr 
 
16.74 4.10 
*
HPLC conditions: 25-37 µm particle size; column size, 100 x 2.1 mm; 99/1 MeCN/AcOH 
mobile phase; flow rate: 0.1 mL/min; injected volume: 5 µL; analytes (1mM BOC-L-tyrosine, 1 
mM BOC-D-tyrosine, acetone (used to determine void volume)) were all detected at 260 nm. 
 
length was 50 x 2.1 mm instead of 100 x 2.1 and the flow rate was 0.2 mL/min as opposed to 
0.1mL/min.  This analysis also examined the analytes at 0.5 mM rather than the 1mM 
concentrations used during the analysis of NOBE.  The results in Table 2.5 show similar 
enantiomeric selectivity as method 1 with the α’ being 2.5.  Again, this OMNiMIP generated 
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from the NAG (12) crosslinker was successful at separating enantiomers of BOC-Tyr, but did 
not improve the current NOBE system.    
Table 2.5: HPLC results for the OMNiMIPs synthesized from NAG (50 x 2.1 mm column)
*
. 
 
Analyte RT (min) k' α’ 
Acetone (void volume) 1.03 - - 
0.5 mM L-BOC-Tyr 
 
9.47 8.2 
2.5 
0.5 mM D-BOC-Tyr 
 
4.48 2.8 
*
HPLC conditions: 25-37 µm particle size; column size, 50 x 2.1 mm; 99/1 MeCN/AcOH 
mobile phase; flow rate: 0.2 mL/min; injected volume: 5 µL; analytes (0.5 mM BOC-L-
tyrosine, 0.5 mM BOC-D-Tyr, acetone (used to determine void volume)); were all detected at 
260 nm. 
 HPLC results (Table 2.4 and Table 2.5) using NAG as chromatographic stationary phase 
for enantiomeric separations showed that although it performs better as an OMNiMIP than many 
other crosslinking monomers, such as the trifunctional and altered polymerizable group 
monomers, it did not out perform NOBE at separating BOC-Tyr enantiomers.  The lower 
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selectivity could be attributed to the formation of the polymer.  Unlike the NOBE OMNiMIP, 
which was completely polymerized into a crosslinked network by photo-initiated radical 
polymerization, the NAG polymer did not photo polymerize as an OMNiMIP as effectively.  The 
“jelly” nature of the NAG polymer that was formed from photo-initiated polymerization was not 
applicable for analysis on HPLC in its current state, so it was subsequently treated under thermal 
conditions.  Although the polymer was hardened, it was not as selective as NOBE using only 
photo-initiated polymerization.  It has been previously reported that imprinted polymers made by 
thermal polymerization do not imprint as well as those formed by photoradical polymerization 
due to the enhanced ability for the pre-polymer complex to form at lower temperatures.
16,17
  
Thus, a more appropriate comparison of the crosslinkers NAG and NOBE would be to imprint 
both using a thermal polymerization technique.  
 
2.4 New Crosslinking Monomers Overall Conclusions 
Several attempts to improve OMNiMIPs by altering the crosslinking monomer have been 
explored.  The use of two different types of polymerizable groups on a crosslinker; such as, with 
13 and 14 did provide a successful system to separate enantiomers of BOC-Tyr (α’ = 1.65 ± 
0.0457 and 1.89 ± 0.0626 respectively); however, there was no improvement in selectivity in 
comparison to the model OMNiMIP system made from NOBE, which had an α’ = 3.78 ± 0.4071.  
The outcomes of the radical stabilities of the crosslinkers when undergoing photo-initiated 
radical polymerization can explain why the OMNiMIPs synthesized from crosslinkers 13 and 14 
did not perform as well as NOBE.  For example, the stability of the radicals formed could 
negatively influence the rate of polymerization by causing a delay in the polymerization as well 
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as resulting in early termination of the polymerization, which in turn can affect polymer 
morphology and quality of binding sites.   
The addition of polymerizable groups was also examined.  Here, only molecule 17 was 
polymerized because the chiral trifunctional monomer 18 was insoluble in polymerization 
solvents.  Although compound 17 did form an OMNiMIP that was selective for L-BOC-Tyr (α’ 
= 1.2), it did not improve selectivity of the OMNiMIP model.  In this case, the sterics caused by 
the extra methacrylamide group may have negatively affected the polymer backbone by not 
enabling the crosslinker to stack.  With fewer shape selective binding sites, the separation 
efficiency diminished.  Also, the additional methacrylamide group may have increased non-
specific binding interactions, which would also lower the separation effectiveness of the 
OMNiMIP towards BOC-Tyr.   
The addition of electron withdrawing groups to the structure of the NOBE crosslinking 
monomer was partially investigated in an attempt to improve hydrogen bonding between the 
monomer and the template and lead to better imprinted cavities.  However, crosslinker 19 did not 
lead to greater selectivity of the imprinted cavities (α’ = 1.08 ± 0.051.)  Here, bromine may have 
inhibited photo-initiated radical polymerization of the alkene groups of the crosslinker therefore 
leading to the formation of a “soft” polymer without shape selective binding sites.   
In the case of NAG (12), the polymer had to be subjected to a two-step photo-initiated 
polymerization followed by thermal curing conditions in order to create a solid OMNiMIP that 
could be studied by HPLC.  Although this polymer did have an α’ as large as 2.5, it was still 
unable to outperform NOBE.  This could be attributed to the additional harsh thermal 
polymerization conditions that were required to generate the NAG OMNiMIP.  The new 
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crosslinker 20 was successfully synthesized, but more material is required to test its ability to 
perform as a crosslinking monomer for OMNiMIP imprinting. 
 
2.5 Future Work 
Further work for the new three-armed crosslinker 17 can be explored for improvements 
in traditional imprinting.  While the three-armed crosslinker did not improve OMNiMIP 
imprinting, it is anticipated that it may perform better in traditional imprinting.  The problems of 
the three-armed monomer with overly dense crosslinking groups will decrease when a separate 
functional monomer (up to 50%) is added.  These new systems can then be compared to 
traditional systems that utilize MAA as the functional monomer with TRIM as the crosslinker. 
Designs for additional crosslinkers for OMNiMIP and traditional imprinting should also 
be explored.  More crosslinkers containing electron withdrawing moieties to enhance hydrogen 
bonding should be examined.  It was ultimately reasoned that the brominated NOBE derivative 
19 failed to form a well-structured imprinted polymer because of its polymerization inhibition.  
Utilization of other electron withdrawing groups, such as CF3 may provide the desired increase 
in hydrogen bonding without interfering with the polymerization of the OMNiMIP.   
Literature precedent for the addition of phthalyl dichloride to 2-(trifluoromethyl)acrylic 
acid to form 2-(trifluoromethyl)acryloyl chloride followed by addition of a primary alcohol to 
form an ester is available. 
10
    However, the addition of 2-(trifluoromethyl)acryloyl chloride to 
ethanolamine to form both ester and amide linkages has not yet been successfully achieved. 
Optimization of the conditions shown in Scheme 2.9 or a different synthetic route are required to 
generate the trifluorinated crosslinker 2-(2-(trifluoromethyl)acrylamido)ethyl 2-
(trifluoromethyl)acrylate (43.) 
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Scheme 2.9: Synthesis of the crosslinker 2-(2-(trifluoromethyl)acrylamido)ethyl 2-
(trifluoromethyl)acrylate (43). 
     
The nature of the OMNiMIP polymerizations should also further be explored.  When 
comparing the selectivity of the imprinted material, NOBE has shown to be the best crosslinker 
for OMNiMIP imprinting synthesized by photo-initiated radical polymerizations reported thus 
far.
4,13
  When NOBE OMNiMIPs were made thermally, poor results were obtained.  Obtaining 
efficient OMNiMIPs by thermal polymerization would have several advantages, such as 
elimination of the requirement of expensive photoreactor equipment or a radical initiator.  Since 
NAG has shown success in OMNiMIP imprinting by utilization of a combination of photoradical 
and thermal polymerization it should be studied further using only thermal polymerization.  
Another study that should be explored is a combination of photoradical and thermal 
polymerizations to synthesize NOBE OMNiMIPs to determine if there are any improvements 
that can be made to its synthetic process.  The combination of thermal and photo-initiated radical 
polymerization as well as the exclusively using thermal polymerizations in relation to selectivity 
can be compared between the NOBE and NAG OMNiMIPs. 
With additional thermal polymerization studies being performed on OMNiMIPs 
synthesized from the NAG crosslinker, a higher yielding synthetic route to synthesize NAG 
should be developed.  One alternative route to synthesize NAG is as follows:  First couple 
methacrylic acid to the amine in the presence of DCC and DMAP.  Next, oxidize the alcohol of 
44 to the aldehyde using pyridinium chlorochromate (PCC A Grignard reaction on the aldehyde 
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followed by a Swern oxidation with oxalyl chloride in DMSO will yield NAG as shown in 
Scheme 2.10.  This synthesis is expected to be higher yielding and therefore more efficient as it 
has a simplified Grignard reaction than the previous approach to synthesize NAG. 
Scheme 2.10: Synthesis of the crosslinker N-(3-methyl-2-oxobut-3-en-1-yl)methacrylamide (47). 
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CHAPTER 3: RACEMIC AND SCALEMIC IMPRINTING 
3.1 Introduction to Racemic and Scalemic Imprinting 
Approximately 50% of all pharmaceutical drugs used today are chiral molecules.
1
  
Therapeutic effects can be explored for each enantiomer of chiral molecules to determine their 
individual effectiveness in biological systems if incorporated into drugs.  Each enantiomer of the 
chiral molecule may provide the same or different magnitudes of pharmaceutical benefits or 
toxic side effects.  For example, one enantiomer could be active while the other is inactive, or 
one could be therapeutic while the other enantiomer is harmful.
2,3,4  
Which effects result from 
chiral molecules is dependent on the individual recognition and reaction of the enantiomer with 
the biological system.
3
  Although not all enantiomers will cause harmful side effects, having 
inactive forms will still increase the weight of the drug formulation and lower the amount of 
valuable medicine that can be loaded.  Furthermore, the reason that enantiomers may behave 
differently in the body is due to 
their differences in configuration.  
While chiral molecules have the 
same molecular formula, the 
spatial arrangement of atoms 
differs.  For example, the 
enantiomers 2-(6-
methoxynaphthalen-2-yl) 
propanoic acid are shown in 
Figure 3.1.  Here, differences in spatial configurations cause differences in drug effectiveness.  
The S enantiomer of 2-(6-methoxynaphthalen-2-yl) propanoic acid, also known as naproxen, is a 
 
    
                   (a)                                            (b) 
Figure 3.1: (+)-S-2-(6-methoxynaphthalen-2-yl) propanoic 
acid (a) and (-)-R-2-(6-methoxynaphthalen-2-yl) 
propanoic acid (b). 
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beneficial pharmaceutical used to treat fever and pain, while the R enantiomer causes harmful 
side effects.
5
   
Another example of the importance of separating enantiomers is shown throughout 
asymmetric syntheses.
6,7
  Many reactions, such as SN1 type reactions, can produce a racemic 
mixture of products.
8
  The ability to separate the chiral mixtures formed to obtain enantiopure 
products is crucial in the advancement of synthetic methods.  Developing improved separation 
methods will not only simplify numerous purifications that are often required in multi-step 
syntheses, but new approaches will also allow mixtures of enantiomers that had previously been 
deemed inseparable to be separated. 
As the importance of enantiomeric separations is growing, more techniques are being 
developed to isolate enantiomers.
1
  Pirkle and other chiral affinity columns are often used to 
separate mixtures of enantiomers.
9,10
  Although these columns can be useful in separating 
enantiomers, there are many disadvantages.  These columns often cost thousands of dollars.  
Also, the analytes that can be separated by these columns are very specific, requiring the 
purchase of many different chiral columns for use in multi-step syntheses.  
Molecularly imprinted polymer columns are useful stationary phases for chromatography 
because they are made from inexpensive materials, straightforward to synthesize, and are tolerant 
to a range of conditions such as variable pH and temperature changes.  Abundant with 
advantages, MIPs are not found overwhelmingly in the literature for chiral separations in large 
part because of a lack of templates used to synthesize them.  Currently, almost all of the chiral 
imprinting papers published use a single enantiomer as the print molecule.
11,12,13,14
  Although 
imprinting a single enantiomer has applications in sensors and other recognition devices, its 
utility in preparative chromatographic separations of enantiomers is limited.  The problem 
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associated with imprinting a single enantiomer is the requirement to have the enantiopure 
enantiomer in order to use it as a template for imprinting.  If one was already able to isolate the 
print molecule needed to make the MIP, then synthesizing a chromatographic MIP column to 
isolate that enantiomer would not be as important. 
Imprinting different molecules that have similar shapes and stereo-structures is one way 
MIPs have been synthesized to overcome the disadvantage of needing an enantiopure print 
molecule identical to the compound desired to be separated.  Several papers have been published 
that use the cross-reactivities of similar compounds to separate racemic mixtures.
15,16,17,18
  In one 
paper, the authors imprinted similarly structured melamines (Figure 3.2) substituted with alkyl 
groups; such as, triethylmelamine (TEM, 48), triisopropylmelamine (TPM, 49), and 
tributylmelamine (TBM, 50) to form recognition cavities for atrazine herbicides.  It was 
important to use the cross-reactivities of the alkyl substituted melamines for selectivity of 
Figure 3.2: Structures of alkyl substituted melamines: triethylmelamine (48), 
triisopropylmelamine (49), tributylmelamine (50), atrazine (R= iPr) (51), simazine (R= Et) (51), 
cyanazine (R= C(CH3)2CN) (51), terbutylazine (R= tBu) (51), propazine (52), and ametryn 
(R1= Et R2= iPr) (53), prometryn (R1= iPr R2= iPr) (53), terbutryn (R1= Et R2= tBu) (53). 
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atrazine (Figure 3.2, 51) and not atrazine itself because of concerns of template leaching 
interfering with quantitative measurements.  In this study, MIPs synthesized using TEM as the 
template, in comparison to the other template molecules explored, had the best selectivity for 
atrazine.  The better selectivity obtained using TEM was attributed to the smaller steric 
interferences caused by its smaller alkyl appendages.  Furthermore, the cross-reactivity of TEM 
afforded binding cavities that most closely fit atrazine.  Although it is possible to achieve 
selectivity for atrazine when imprinting a dummy molecule, its separation is less successful 
compared to imprinting the actual atrazine molecule.
18
 
Another approach to separate racemic mixtures without using an enantiopure molecule as 
the template is to imprint a mixture of enantiomers.  This technique eliminates the need to do 
cross-reactivity studies of multiple compounds with different molecular formulas while also 
eliminating enantiomer pre-isolation, which both enhance the efficacy of the MIP stationary 
phase for preparative chromatographic separations.  Although this technique exists, only a 
handful of papers (discussed below) have been published in the past twenty years that attempt to 
imprint racemic mixtures, and there are currently no papers published on scalemic 
imprinting.
19,20,21
  
In 1998, the first reported racemic imprint was completed by Hosoya and co-workers.
19
  
Here, the authors used (S)-(-)-N-methacryloyl-1-naphthylethylamine (Figure 3.3, 54) as the   
Figure 3.3: (S)-(-)-N-methacryloyl-1-naphthylethylamine (54), N-(3,5-Dinitrobenzoyl)-α-
methylbenzylamine (55), and ethylene dimethacrylate (3). 
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chiral functional monomer and ethylene dimethacrylate (Figure 3.3, 3) as the crosslinker to 
imprint a racemic mixture of N-(3,5-Dinitrobenzoyl)-α-methylbenzylamine (DNB (55), Figure 
3.)  In this case, the authors obtained a partial, but not baseline separation of DNB enantiomers 
using HPLC.  Here, the authors only mention that the partial separation of DNB enantiomers is 
attributed to the more desirable interactions of the template and recognition cavity upon re-
binding compared to the non-imprinted control, which showed no separation. 
In a later paper by Torres et al., the 
authors imprinted a racemic mixture of bis[1-
phenylethyl]amine (PEA) using the chiral 
functional monomer (S)-2-(2-methyl-
acryloylamino)-3-phenyl propionic acid (MAPP) 
and EGDMA as the crosslinker (Figure 3.4.)
20
  
This paper also presented partial separation of 
enantiomers when the MIP was used as a 
chromatographic stationary phase for HPLC.  In 
this case, the authors studied the mechanisms 
leading to enantiomeric separation through 
computational studies of the template and 
functional monomer in the pre-polymer complex 
as well as adsorption isotherms of the imprinted 
polymer and template.  The results of the computational analysis of the pre-polymer complexes 
did not show any preference in binding of the functional monomer to either enantiomer.  The 
authors’ results from the binding isotherms showed that the small differences in the stability of 
 
 
 
Figure 3.4: (S)-2-(2-methyl-
acryloylamino)-3-phenyl propionic acid 
(56), S-bis[1-phenylethyl]amine (57), 
and R-bis[1-phenylethyl]amine (58). 
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the diastereomeric complexes of the template and functional monomer on the polymer’s surface 
upon re-binding may be the cause of the observed enantioseparation.   
A third publication briefly mentions the attempt to resolve enantiomers using an 
imprinted polymer made with a racemic print molecule.
21
  In this study, the sterics of OMNiMIP 
crosslinking monomers were first studied in the formation of OMNiMIPs that were imprinted 
with single enantiomers.  (S)-2-methacrylamidopropyl methacrylate (L-NALA), the least 
sterically hindered chiral OMNiMIP which performed the best in single enantiomer imprinting, 
was used to attempt racemic imprinting.  In this experiment, the chiral monomer was unable to 
generate a MIP that resolved enantiomers and had an α = 1.0 indicating no selective recognition.  
Further studies of this crosslinking monomer as well as another chiral crosslinking monomer, 2-
methacrylamido-3-(methacryloyloxy)propanoic acid (NOS, 61), in regards to racemic imprinting 
are the topics of Chapter Three.  The concept of imprinting a scalemic mixture, which has never 
been shown in the literature, is also presented using the L-NALA crosslinking monomer for 
OMNiMIP imprinting. 
 
3.2 Experimentals: Syntheses of Crosslinking Monomers and OMNiMIP Polymerizations  
 
Scheme 3.1: Synthesis of NOS (61). 
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2-methacrylamido-3-methoxy-3-oxopropyl methacrylate (60):
22
 
 L-Serine methyl ester hydrochloride (2.0230g, 13.0 mmol) in 100 mL DCM was cooled 
to 0°C.  Et3N (3.6 mL, 26.0 mmol) was added dropwise.  In a separate roundbottom flask, MAA 
(2.2 mL, 26 mmol) and DMAP (0.3177 g, 2.6 mmol) in 25 mL dry DCM was cooled to 0°C.  
After both mixtures equilibrated to 0°C, the L-serine methyl ester hydrochloride solution was 
added to the MAA and DMAP solution.  After 5 minutes, DCC (5.4083 g) in 25 mL DCM was 
added slowly.  The reaction mixture was stirred at 0°C and was allowed to slowly cool to room 
temperature.  The mixture stirred at room temperature for 5 days.  The DCU was filtered off to 
give a yellow solution.  The yellow solution was extracted with 0.5 M NaHCO3 (aq) (2 x 75 mL) 
then 0.5 M sodium citrate (aq) (2 x 75 mL).  The organic layer was dried over MgSO4 and was 
filtered.  Evaporation afforded the crude product as a yellow oil.  Column chromatography using 
EtOAc/hexane (50/50) was used to purify the sample.  The pure product (60) obtained was a 
yellow oil (2.4749 g) in 74.6% yield.  
1
H NMR (CDCl3, 400 MHz) δ ppm 6.70 (br, 1H), 6.08 (s, 
1H), 5.76 (s, 1H), 5.60-5.59 (d, 1H J= 4Hz), 5.41 (s, 1H), 4.95-4.91 (m, 1H), 4.57-4.46 (m, 2H), 
3.79 (s, 3), 1.98 (s, 3H), 1.91 (s, 3H).  
13
C NMR (CDCl3, 100MHz) δ ppm 170.07, 167.92, 
166.96, 139.17, 135.54, 126.57, 120.71, 64.08, 52.90, 52.09, 18.43, 18.20.  IR νmax 3365.33, 
2956.86, 1724.59, 1668.25, 1626.80, 1521.83, 1163.51, 1019.28, 943.85. 
 
2-methacrylamido-3-(methacryloyloxy)propanoic acid (61):
22
 
NOS-methyl ester (60, 1.3433 g, 5.3 mmol) was dissolved in 20 mL acetone in an amber 
bottle.  168 mL of 0.1 M phosphate buffer, pH 7.5, was added.  Porcine pancreatic lipase EC 
232-619-3087 (0.4267 g) was added and the mixture was sonicated for one minute.  The reaction 
was rocked for 4 days at room temperature.  1 N HCl (aq) was added to acidify the mixture to pH 
 62 
 
3, and it was extracted with EtOAc (4 x 100 mL.)  The combined organic layers were dried with 
MgSO4 and were filtered.  After evaporation, the product (61, 1.2383 g) was collected in 97.5% 
yield.  
1
H NMR (CDCl3, 400 MHz) δ ppm 10.64 (br, 1H), 6.89-6.87 (d, 1H, J =7.28 Hz), 6.08 (s, 
1H), 5.78 (s, 1H), 5.58-5.57 (t, 1H, J = 1.42Hz), 5.40 (s, 1H), 4.94-4.90 (m, 1H), 4.56-4.55(d, 
2H, J = 3.88 Hz), 1.95 (s, 3H), 1.89 (s, 3H).  
13
C NMR (CDCl3, 100MHz) δ ppm 171.71, 168.83, 
167.18, 138.63, 135.48, 126.72, 121.61, 63.90, 52.26, 18.32, 18.13.  IR νmax  3401.69, 2959.39, 
1717.91, 1653.46, 1623.43, 1539.49, 1166.75,1021.11, 945.17.  HRMS (ESI-TOF): C11H15NO5 
(M+Na)
+
: calcd for 264.0848; found 264.0685. 
 
 
 
Scheme 3.2: Synthesis of L-NALA (9). 
 
 
(S)-alaninol (63):
21
 
 Dry THF (200 mL) was cooled to 0°C.  LAH (6.2820 g, 0.17 mol) was added and the 
temperature was allowed to equilibrate.  S-alanine (9.8695 g, 0.11 mol) was added slowly.  The 
mixture was refluxed overnight.  Sat. potassium carbonate (aq) (20 mL) was added to quench the 
reaction.  After vacuum filtration, the THF was removed to yield a colorless oil (4.5864 g, 55% 
yield.)  
1
H NMR (CDCl3, 400 MHz) δ ppm 3.55 (m, 1H), 3.23 (m, 1H), 3.01 (m, 1H), 2.01 (br, 
3H), 1.06 (s, 3H).  
13
C NMR (CDCl3, 100MHz) δ ppm 68.27, 48.22, 20.09. 
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(S)-2-methacrylamidopropyl methacrylate (9):
21
 
 S-alaninol (63, 0.2626 g, 3.5 mmol) in 30 mL DCM was cooled to 0°C.  MAA (0.6810 g, 
7.9 mmol) and DMAP (0.1061 g, 0.87 mmol) were added and the temperature was allowed to 
equilibrate for 5 minutes.  DCC (1.6317 g, 8.1 mmol) was added and the mixture was allowed to 
slowly warm to room temperature and was stirred for 3 days.  After the DCU was filtered off, the 
material was washed with 1N HCl (aq) (3 x 20 mL) and sat. NaHCO3 (aq) (4 x 20 mL).  The 
combined organic layers were dried over MgSO4 and the solvent was evaporated after filtration.  
Purification by column chromatography with 50/50 EtOAc/hexane was completed to yield 434.5 
mg, 59% yield of (S)-2-methacrylamidopropyl methacrylate (9.)  
1
H NMR (CDCl3, 400 MHz) δ 
ppm 6.12 (s, 1H), 6.01 (br, 1H), 5.99 (s, 1H), 5.66 (s, 1H), 5.59 (s, 1H) 4, 4.39-4.36 (m, 1H), 
4.16-4.09 (m, 2H), 1.94 (s, 6H), 1.24 (d, 3H, 4Hz).  
13
C NMR (CDCl3, 100MHz) δ ppm 171.14, 
167.89, 140.02, 135.93, 126.16, 119.51, 67.10, 44.89, 18.56, 18.27, 17.31. 
 
Polymer Preparation:  
 Crosslinking monomer (1 g, 61 or 9) was added to the 13 x 100 mm glass tube with a 
solution of racemic 1,2-diphenyl ethylene-diamine (61 templates) or racemic BOC-Tyr (9 
templates) (5%) dissolved in 1.3 mL acetonitrile to mimic conditions that were previously 
explored using single enantiomers.
 13, 22
  AIBN (1%) was added to the solution and nitrogen was 
used to purge the sample for 5 minutes.  The tube was then capped, and Teflon tape and Parafilm 
were used to seal the system.  The tube was then inserted into a photoreactor apparatus where it 
was submerged in an ethylene glycol/H2O bath to maintain the temperature and was exposed to a 
450 W mercury arc lamp surrounded by a borosilicate jacket for 8 hours.  The polymer was then 
broken out of the tube and the template was removed by Soxhlet extraction for 2 days.  The 
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polymers were then ground and sized to 25-37 µm using U.S.A. Standard Testing Sieves and 
was packed into stainless steel columns and their selectivities were analyzed by HPLC. 
 
3.3 Racemic and Scalemic Template Imprinting Results and Discussion 
The performance of chiral OMNiMIPs synthesized using racemic templates was 
examined as stationary phases for HPLC.  The results of the separation of enantiomers of 1, 2-
diphenyl ethylene-diamine (64 and 65) and BOC-Tyr (7) when the analytes are studied 
individually using NOS and L-NALA as the crosslinking monomer in the OMNiMIP 
formulation is shown in Table 3.1.  In the case of NOS, mobile phases composed of 90% MeCN  
Table 3.1: Racemic Imprinting HPLC Results
*
. 
Templates:        
Monomer k'64
 (a)
 or D-BOC-Tyr
(b) 
k'65
(a)
 or L-BOC-Tyr
(b) α' 
(a) 
0.34
(a)
 0.55
(a)
 1.6 
(b) 
4.48
(b)
 2.87
(b)
 1.6 
*
HPLC conditions: 25–37 μm particles; 100 x 2.1 (a), 250 x 2.1 (b) columns; mobile phase, 
MeCN/acetic acid (90:10 (a), 99:1 (b); analytes (1mM 64, 1mM 65, 1mM BOC-L-tyrosine, 1 
mM BOC-D-tyrosine, acetone (used to determine void volume)) were all detected at 260 nm; 
flow rate 0.1 mL/min; sample volume injected 5 μL. 
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and 10% acetic acid (method 1) as well as 99% MeCN and 1% acetic acid (method 2) were 
studied.  The analyses from both mobile phases resulted in the analytes eluting near the dead 
volume.  Method 1 resulted in a small difference in capacity factors between the enantiomers 
whereas method 2 did not display any variation.  The small capacity factors (k’ 0.34 and 0.55) 
that were obtained on the NOS OMNiMIPs are not reliable because these values are not 
significantly different from the amount of error that may appear in these measurements.  The 
selectivity factor for the OMNiMIP synthesized using L-NALA was determined to be 1.6 with 
capacity factors of 4.48 and 2.87 for the D and L enantiomers respectively.  Here, the capacity 
factors larger than 1.0 acquired from the HPLC experiments using the L-NALA OMNiMIP are 
more reliable because each analyte eluted at a much later retention time than the void volume, 
indicating that it had better binding to the stationary phase and differed greatly from any error 
that may occur in the measurements. 
 The HPLC conditions for the OMNiMIP generated from L-NALA were thoroughly 
examined in an attempt to improve enantioseparation resolution of the analytes when they were 
run as a pair (Figure 3.5.)  The effects of mobile phase polarity were first explored using 5 and 
10% acetic acid in acetonitrile as the mobile phase; however, the ability to separate enantiomers 
of BOC-Tyr diminished.  This is because the higher concentrations of acetic acid disrupted the 
ability of the analytes to bind well to the stationary phase, which forced the analytes to elute 
quickly from the chromatographic column and not separate from each other as indicated by the 
lower capacity factors in Figure 3.5.  At 0.5 and 1% acetic acid in acetonitrile, the analytes were 
shown to have better resolution.  The better selectivity is achieved because the acetic acid is not 
in a high enough concentration to disrupt the hydrogen bonding between the analyte and the 
imprinted polymer.  Although there was a slightly better selectivity of enantiomers using 0.5% 
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acetic acid, 1% was chosen to proceed with the study because it provided a comparable 
separation with faster elution times.  
Figure 3.5: L-NALA imprinted with racemic BOC-Tyr (7) Mobile Phase Polarity Studies.  
 
*
HPLC conditions: particle size 25–37 μm; column, 50 x 4.1; mobile phase, MeCN/acetic acid 
(99:1); analytes (1mM BOC-L-tyrosine, 1 mM BOC-D-tyrosine, acetone (used to determine void 
volume)) were all detected at 260 nm; flow rate 1 mL/min; the sample volume injected was 5 μL. 
 Next, the amount of imprinted packing material was increased in attempt to improve 
enantiomeric resolution.  Columns with 100 x 2.1 mm, 50 x 4.1, and 250 x 2.1 mm dimensions 
were packed with the L-NALA OMNiMIP stationary phase.  Although there was a small 
improvement in resolution using 2.5 times the imprinted material, the cost of requiring more 
imprinted material outweighed the benefit of the diminutive improved selectivity; therefore, it 
was decided that the 100 x 2.1 mm column size was sufficient to be used in further studies of the 
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racemic imprinted material.  After optimization of conditions, the best selectivity achieved is 
shown by the chromatogram in Figure 3.6.  Although baseline resolution is not achieved, it is 
comparable in resolution to the few imprinted systems that are presented in the literature 
(discussed previously.)   
Figure 3.6: Chromatogram of racemic (7) imprinted polymer using L-NALA*.   
 
*
HPLC conditions: particle size 25–37 μm; column, 250 x 2.1; mobile phase, 
MeCN/acetic acid (99:1); analytes (1mM Boc-L-tyrosine, 1 mM Boc-D-tyrosine, acetone (used 
to determine void volume)) were all detected at 260 nm; flow rate 0.1 mL/min; sample volume 
injected 5 μL.  
 After conditions were optimized, a cascade of scalemic analytes was tested on the L-
NALA racemic OMNiMIP column (Figure 3.7) to determine if separation of scalemic analytes 
could be achieved and to determine the elution order.  Partial separation was achieved for all 
scalemic analytes tested and the most retained enantiomer was determined to be D-BOC-Tyr.  To 
explore reproducibility, nine additional OMNiMIPs were prepared using the crosslinking 
monomer L-NALA and the print molecule racemic BOC-tyrosine.  These OMNiMIPs were also 
 
 
 
 68 
 
evaluated by HPLC and the results showed that the elution order did not always favor the D 
enantiomer being most retained; therefore, while mixtures of enantiomers can be separated using 
this racemic imprinted system, the stereochemistry of the separated enantiomer must be 
determined.   
Figure 3.7: Scalemic analytes on L-NALA racemic imprinted polymer*.   
*
HPLC conditions: particle size 25–37 μm; column, 100 x 2.1; mobile phase, MeCN/acetic acid 
(99:1); analytes (1mM Scalemic Mixtures of BOC-Tyrosine, acetone (used to determine void 
volume)) were all detected at 260 nm; flow rate 0.1 mL/min; sample volume injected 5 μL.
 It should also be noted that the two peaks resulting from the chromatograms of analytes 
containing separated enantiomers are, in fact, the individual enantiomers and not just a 
complexation of the two enantiomers.  This was validated not only by the cascade of 
chromatograms showing the ratios of peaks increasing and decreasing upon percentage changes 
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of enantiomer in the analytes, but also by NMR studies.  According to a paper by Sellegren and 
Mosbach, 
1
H NMR can be used to provide evidence for hydrogen bonding interactions between 
template and monomer in pre-polymer complex solutions.
23
  In a similar manner, if complexes 
formed between the D and L enantiomers, they would also be expected to display differences in 
chemical shifts.  Analysis by 
1
H NMR was first carried out separately for D-BOC-Tyr (16 mg) in 
0.5 mL acetonitrile and acetic acid (100/0 and 99/1) and L-BOC-Tyr in acetonitrile and acetic 
acid (100/0 and 99/1).  The chemical shift results of the NH proton of single enantiomers of 
BOC-Tyr were then compared to spectra obtained for a racemic mixture of BOC-Tyr in both 
acetonitrile and acetic acid (100/0 and 99/1) and the spectra are shown in Appendix B.  The 
differences in chemical shifts were ≤ 0.005 ppm in all cases when studied using 100% MeCN 
and ≤ 0.015 ppm in all cases when studied using 99/1 MeCN/AcOH.  Since there was no 
significant change in the chemical shifts of the NH proton of the single enantiomer and racemic 
mixture of BOC-Tyr, it was concluded that a complex between the D and L BOC-Tyr 
enantiomers was not formed in the pre-polymer complex or the analyte solutions.  As a 
comparison, the crosslinking monomer L-NALA (40 mg) and each enantiomer of the BOC-Tyr 
template (1:1 monomer:template and 1:2 monomer:template) were also studied (spectra are 
shown in Appendix B) in acetonitrile and acetic acid (100/0 and 99/1.)  The NH protons shifted 
by at least 0.1 ppm in all cases, signifying that non-covalent interactions were present, thus the 
basis for the formation of imprinted sites in the polymer.   
After successfully partially resolving BOC-Tyr enantiomers using racemic imprinting, 
scalemic mixtures as print molecules were explored using L-NALA as the crosslinker to 
synthesize OMNiMIPs.  OMNiMIPs were imprinted with either 25% L-BOC-Tyr and 75% D-
BOC-Tyr or 25% D-BOC-Tyr and 75% L-BOC-Tyr, and chromatographic evaluation revealed 
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that the polymers separated single enantiomers of BOC-Tyr with separation factor values of 1.7 
and 1.5 respectively as shown in Table 3.2. 
Table 3.2: Scalemic Imprinting HPLC Results
*
. 
 
(Crosslinker) 
 
(Template) 
k'D 
 
k'L 
α' 
25% L 75% D 3.64 2.13 1.7 
75% L 25% D 2.53 3.81 1.5 
*
HPLC conditions: particle size 25–37 μm; column 100 x 2.1; mobile phase, MeCN/acetic acid 
(99:1); analytes (1mM BOC-L-tyrosine, 1 mM BOC-D-tyrosine, acetone (used to determine void 
volume)) were all detected at 260 nm; flow rate 0.1 mL/min; sample volume injected 5 μL. 
 The ability to separate mixtures of BOC-Tyr at different percentages of each enantiomer 
in the analyte was also studied.  Figure 3.8 shows chromatograms obtained from the elution of 
several different analyte mixtures containing different percentages of enantiomers on the 25% L 
75% D-BOC-Tyr OMNiMIP columns.  Here, the chromatograms show the partial separation of 
BOC-Tyr enantiomers as different percentages of enantiomer in each analyte were tested.  As 
expected, L-BOC-Tyr elutes quicker than D-BOC-Tyr on this chromatographic stationary phase 
because the template used contained 75% D-BOC-Tyr and 25% L-BOC-Tyr and in accord with 
chromatographic theory, molecules that fit into more binding sites will be retained longer.  
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Similarly, analyte mixtures were studied on the 25% D and 75% L-BOC-Tyr OMNiMIP 
columns.  In this case, the L-BOC-Tyr analyte displayed a longer retention time compared to the 
D-BOC-Tyr because there were more chromatographic recognition sites accessible for the L 
enantiomer to specifically bind in comparison to those available to the D enantiomer.  
Figure 3.8: Scalemic Imprinted Chromatograms*.   
*
HPLC for 9 imprinted with 25% L 75% D BOC-Tyr; HPLC conditions: 25–37 μm particles; 
column 100 x 2.1; MeCN/acetic acid (99:1); analytes (1mM BOC-tyrosine analytes, acetone 
(used to determine void volume)) were detected at 260 nm; flow rate 0.1 mL/min; sample 
volume injected 5 μL.  
 The effects of temperature were also examined to determine if resolution of enantiomers 
could be improved on the scalemic imprinted columns.  The columns were tested at 25°C, 40°C, 
and 55°C.  As temperature was increased, the analytes tested eluted in a shorter amount of time 
as shown in Figure 3.9.  Slight differences in resolution are due to the mass transfer changes that 
occur when temperature is increased.  An increased temperature causes mass transfer to occur 
more quickly so that less time is needed for the analyte to equilibrate between the mobile phase 
and stationary phase.  Although faster mass transfer equilibration can lead to a better resolution, 
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the increased temperature did not lead to any significant improvement in resolution.  The lack of 
improvement can be attributed to increased longitudinal diffusion and these results are shown in 
Figure 3.9.  Because there was no significant improvement of resolution achieved by increasing 
the temperature, all future studies were carried out at room temperature.  Another important 
observation is the elution order of the enantiomers based on the HPLC column temperature.  
While the focus of this study was improvement of resolution by altering the temperature, it is 
interesting to note that the elution order may have changed when the temperature was raised 
from 40°C to 55°C as indicated by the chromatograms.  Since a poor baseline was obtained for 
the chromatogram at 55°C, further studies would need to be completed to confirm that the 
elution order did in fact change.  
 
Figure 3.9: Temperature Experiments on 75% L and 25% D-BOC-Tyr Imprinted Columns.  
*
HPLC for monomer 9 imprinted with 75% L 25% D BOC-Tyr; HPLC conditions: particle size 
25–37 μm; column 100 x 2.1; mobile phase, MeCN/acetic acid (99:1); analytes (1mM racemic 
BOC-tyrosine analyte, acetone (used to determine void volume)) were all detected at 260 nm; 
flow rate 0.1 mL/min; sample volume injected 5 μL.  
 
 
25°C 
40°C 55°C 
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3.4 Racemic and Scalemic Imprinting Conclusions 
Not only does imprinting racemic and scalemic templates allow MIPs to be useful 
stationary phases for preparative chromatographic separations, it also simplifies the overall 
general approach to imprinting polymers.  As seen throughout Chapters 1 and 2, the 
simplification and improvement of chiral separations is an important and ongoing task for 
chromatographers using molecular imprinting worldwide.  Using the OMNiMIP technique as 
opposed to the traditional non-covalent imprinting approach that utilizes a separate functional 
monomer and crosslinker was one way to make imprinting easier.  The ability to imprint 
mixtures of enantiomers rather than an isolated enantiomer is another extremely important and 
useful approach that provides an exponentially wider range of chiral molecules to be separated 
using imprinted polymers. 
Racemic imprinting using either L-NALA (9) or NOS (61) as the crosslinking monomers 
for synthesizing OMNiMIPs has shown partial separation of enantiomers.  Both L-NALA and 
NOS OMNiMIPs showed selectivity when enantiomers were run individually on HPLC 
stationary phase.  L-NALA was able to achieve a partial separation of enantiomers while NOS 
was completely unable to separate enantiomers when the analytes for HPLC contained various 
mixtures of BOC-Tyr enantiomers.  Further studies using the monomer L-NALA to imprint 
scalemic mixtures were also investigated.  In this study, imprinted polymers made using 
scalemic mixtures composed of 75% D-BOC-Tyr and 25% L-BOC-Tyr or 75% L-BOC-Tyr and 
25% D-BOC-Tyr were used to study scalemic analytes.  In both cases partial separation of 
enantiomers was achieved; and although baseline resolution would be optimal, a partial 
separation is still useful in chromatographic separations.  For example, some enantiopure 
25°C 
40°C 55°C 
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material can be collected at the beginning and end of a HPLC run and the remaining mixture can 
be run again for further separations.   
 
3.5 Racemic and Scalemic Imprinting Future Work 
Further work studying the conditions during the photo-initiated radical polymerizations 
of L-NALA should be completed to determine which enantiomer becomes more selective during 
racemic imprinting.  Studies that vary the temperature of the solution at -20°C to 20°C during 
polymerization should be examined to determine if these conditions alter the properties of the 
resulting racemic imprinted polymer.  Once these conditions are evaluated, the optimum 
conditions for selective binding can be applied to scalemic imprinting.  The optimized conditions 
could then be used to study different ratios of scalemic templates in the pre-polymer solution.  
The different ratios of scalemic templates evaluated by HPLC will show at what point resolution 
diminishes from the single imprinted molecule.  This information will give valuable insight on 
the capacity of racemic and scalemic imprinting. 
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CHAPTER 4: EXPLORATION OF ABSOLUTE CONFIGURATION   
USING AN ENATIOMERIC PAIR OF                                                          
MOLECULARLY IMPRINTED POLYMERS 
4.1 Introduction to the Determination of Absolute Configuration 
In the mid 1800’s, Louis Pasteur proposed that molecular asymmetry of molecules causes 
their ability to display distinct optical activity.  In 1874, LeBel and van’t Hoff further suggested 
that molecules possessed three-dimensional shapes, and that asymmetric molecules may rotate a 
plane of polarized light based on their spatial structure.
1,2
  Since the proposal of the tetrahedral 
structure of sp
3
 hybridized carbons, the determination of which stereoisomer is present in a 
sample has been the subject of extensive research.  The identification of absolute configuration 
(AC) is important in both academia and industry because molecules with different spatial 
features cause them to display various characteristics (e.g. the S enantiomer of thalidomide 
causes teratogenic effects while the R enantiomer acts as a sedative) as previously discussed in 
chapter three.
3,4,5,6,7,8,9
   
As an ongoing problem among scientists, the determination of absolute stereochemical 
configuration of compounds is continuously being developed using fundamental and 
technological approaches.  There are several techniques that are currently employed to determine 
stereochemistry; such as, x-ray crystallography which can be used to directly determine absolute 
configuration from molecular 3-D structures.  One large advantage of this method is that neither 
prior knowledge (e.g. binding strengths) nor both pairs of enantiomers is required to determine 
absolute configuration.  However, a large drawback to this technique is that it requires the ability 
to form a crystal of the desired molecule and most compounds do not crystallize; therefore all 
oils and liquids are unable to be studied by this approach.  In addition, the requirement of 
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expensive equipment and skilled technicians to perform the x-ray crystallographic experiments is 
a disadvantage.
10
 
Another approach to determine absolute configuration is the Mosher method, which uses 
the chiral derivitizing agent α-methoxy-α-
trifluoromethylphenylacetic acid (Figure 4.1) to 
react with alcohols and amines to determine their 
absolute configurations.  The esters and amides 
produced from the derivatization reaction are then 
studied by NMR.  The diasteriomeric complexes 
display different 
1
H and or 
19
F NMR shifts for each diastereomer and these chemical shift 
differences allow the stereochemistry to be determined.
11
  Although this method is reliable, it 
requires the synthesis or purchase of Mosher’s acid, a nucleophile (e.g. –OAc or –NH2), and a 
synthetic step to perform the derivatization on each compound of interest.  The required 
reactions using this reagent are similar for other chiral derivatization agents (when they are 
available), which makes these approaches disadvantageous.
12
 
Vibrational circular dichroism (VCD) and Raman optical activity are two optical methods 
used to determine absolute configuration of molecules.
13,14,15
  In both cases vibrational energies 
cause a change in dipole moment.  The square of the dipole moment change and its interactions 
with a magnetic component is proportionate to IR intensity in VCD.  The interactions of the 
magnetic component that cause a change in polarizabililty are studied in optical activity and the 
square of these values is proportionate to Raman intensity.
13
  A large disadvantage of these 
methods is that the enantiomeric pair, known literature values, or computational analysis is 
required for comparison.   
 
 
Figure 4.1: S (66) and R (67) α-
methoxy-α-trifluoromethylphenylacetic 
acid (MTPA) (Mosher's acid). 
 
 79 
 
Recent papers published by Rychnovsky and co-workers explore another technique to 
determine absolute configuration, which they named competing enantioselective conversions 
(CEC).
16,17,18,19,20
  In these papers, the authors studied the rate of reaction between the molecule 
with unknown stereochemistry and each enantiomer of a chiral catalyst to determine the absolute 
stereochemistry.  For example, both enantiomers of Birman’s acylation catalyst 
homobenzotetramisole (HBTM (68), Figure 4.2) are used to determine the absolute configuration  
Figure 4.2: The catalyst homobenzotetramisole (HBTM) is used for CEC analysis.  The molecule 
with the R group (alkyl group) forward reacts faster with the S catalyst compared to the R 
catalyst.  The molecule with the R group (alkyl group) pointing backwards reacts faster with the 
R catalyst than the S catalyst.  The difference in reaction rates of each enantiomer with the 
enantiomerically pure catalyst enables stereochemical determination. 
 
of oxazolidinones and lactams.
18,21
  Advantages of this method are that only one enantiomer of 
the desired unknown compound is needed to determine its stereochemistry and this technique 
can be performed on a nanomolar scale.  A great disadvantage to this approach however is the 
need to perform several reactions with the molecule containing unknown stereochemistry.  First 
the molecule with unknown stereochemistry must be reacted with both enantiomers of the 
catalyst to determine the reactions rates.  After the reaction rates with the catalyst are studied and 
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the absolute stereochemical configuration is determined, additional reactions are then required to 
convert the unknown molecule back to its original form if the product of the CEC analysis was 
not the desired overall product.  
The use of chiral chromatography is another approach used to explore absolute 
configuration of molecules.
22,23
  Chiral chromatography has primarily been most useful for the 
separation of enantiomers and determination of % ee.  With respect to AC determination, chiral 
chromatography has only been shown to identify stereochemistry when in combination with 
other analytical techniques or from examination of the elution order of each enantiomer with 
prior literature knowledge of their retention behaviors.  In fact, a recent publication states, 
“Chiral chromatography will never be able to assign the absolute configuration of a single 
enantiomer without information about the retention of the second one.  Therefore, it will not be 
possible to determine the absolute configuration of a single optically pure product…”.22  In 
Chapter Four, a solution to this conundrum is presented.  The approach presented here uses 
molecularly imprinted polymer chiral stationary phases to determine absolute stereochemistry.
24
  
This method has several advantages, one being that it requires only one enantiomer for 
stereochemical determination, similar to Rychnovsky’s CEC approach, which also required only 
a single enantiomer.  Unlike the CEC and other derivatization methods, the new MIP technique 
to determine AC has the advantage that it does not require any reactions to be executed on the 
enantiomer of interest.  This method also does not require highly sophisticated instruments as 
with x-ray crystallography or any literature precedents for the molecule with unknown 
stereochemistry. 
The goal of this project was to develop a new technique to determine the absolute 
configuration of organic molecules.  This approach utilized two MIP stationary phase HPLC 
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columns, coined “DuoMIPs” to determine stereochemistry.  Here, each MIP was imprinted with 
a generic template print molecule bearing either R or S stereochemistry.  Analytes that include 
and differ from the print molecule were run on each enantiomeric DuoMIP column.  The 
retention on each column was subsequently studied and the absolute configuration of the analyte 
was determined based on the energetic differences of the diasteriomeric complexes formed 
between the analyte and the DuoMIPs.  A mnemonic was also developed to aid in the 
understanding of the stereochemical determination.  This new approach has the advantage that it 
only requires one enantiomer with unknown stereochemistry and does not require any reactions 
to be performed on the molecule of interest. 
 
4.2 DuoMIP Design and Synthesis* 
Due to larger uptake capacity and good recognition abilities, the OMNiMIP approach 
was selected to synthesize the DuoMIPs for exploration of AC determination.  The crosslinking 
monomer along with the print molecule and its percentage in the polymer formulation were 
important design features examined.  In most cases, NOBE was enlisted as the chemical 
crosslinking monomer for OMNiMIP imprinting.  Another DuoMIP system was synthesized 
using the chiral monomer S-NALA with R or S-BOC-Tyr as the print molecules to study AC 
determination.  NOBE DuoMIPs were synthesized using R or S-BOC-Tyr, R or S-BOC-Phe, R or 
S-BOC-Phe-OMe, or R or S-4-benzyl-2-oxazolidinone as the print molecules (Figure 4.3.)  An 
 
*Reprinted with permission from Organic Letters 2014 16 (5), 1402-1405.  Copyright 2014 
American Chemical Society. 
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Figure 4.3: Structures of print molecules used for the DuoMIP syntheses: S-BOC-Tyr (7a), R-
BOC-Tyr (7b), S-BOC-Phe (72a), R-BOC-Phe (72b), S-BOC-Phe-OMe (73a), R-BOC-Phe-OMe 
(73b), S-4-benzyl-2-oxazolidinone (74a) and R-4-benzyl-2-oxazolidinone (74b). 
example of the synthesis of the S-MIP binding cavity of the DuoMIP system using NOBE as the 
crosslinking monomer and S-BOC-Tyr as the print molecule is illustrated in Scheme 4.1.   
Scheme 4.1: Synthesis of the S-MIP of DuoMIP System 
 
 
tboc-S-tyrosine
template 
crosslinking monomer 
(N,O-bismethacryloyl ethanolamine)
+
Form pre-
polymer complex
polymerize
remove
template
add
template
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 A simple mnemonic was developed to aid in the understanding of the DuoMIP system of 
AC determination (depicted in Figure 4.4.)  Contributions by both hydrogen bonding and steric  
Figure 4.4:  DuoMIP system. S-BOC-Tyr fits into the S-BOC-Tyr imprinted site (a), R-BOC-Tyr 
fits into the R-BOC-Tyr imprinted site (b), and S-BOC-Tyr does not fit into the R-BOC-Tyr 
imprinted site (c). 
interactions are the key influences of this mnemonic.  Labels such as strong, moderate, big, and 
small are used to describe these interactions.  The stronger hydrogen bonding group is labeled 
“strong” and kept forward with respect to the plane of the page, and the weaker is labeled 
“moderate.”  The hydrogen bonding groups are categorized to put the “stronger” in the 
carboxylate imprinted site and the weaker “moderate” group in the carbamate location.  The 
label “big” denotes larger steric interactions and “small” labels the smaller steric interactions.  It 
is also important to note that the BOC group is not categorized as “big” in spite of being large 
because of its distant position from the chiral center in the molecule.  The BOC group and the 
stereocenter are three atoms apart and consequently has a smaller effect on enantiomeric 
stereodifferentiation compared to the aromatic group.  Features of an analyte that do not fit the 
mnemonic and decrease interactions with the DuoMIP are labeled with an “X.”  For example, c 
in Figure 4.4 illustrates the “big” aryl group poorly positioned in the “moderate” space and is 
labeled with an “X” to denote the lack of fit towards the mnemonic.   In particular, this example 
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of the mnemonic illustrates the NOBE binding cavities of the DuoMIP system created with 
BOC-Tyr.  As depicted, the S-BOC-Tyr fits into the S-BOC-Tyr imprinted site (Figure 4.4, a) 
and the R-BOC-Tyr fits into the R-BOC-Tyr imprinted site (Figure 4.4, b); while the S-BOC-Tyr 
does not fit into the R-BOC-Tyr imprinted site (Figure 4.4, c.)  The better the fit into an 
imprinted site signifies better recognition between the analyte and the imprinted site.  When the 
imprinted polymer is used as the stationary phase for HPLC, better binding is indicated by longer 
retention.  Selective binding for molecules that match the mnemonic is the basis for absolute 
configuration determination, and a set of rules to ensure confidence in the determination has 
been devised (vide infra). 
 
Synthesis 
The NOBE crosslinker was synthesized according to the protocol in Chapter Two.  All 
material used in the polymer formulation was purchased from Sigma-Aldrich and Chem-Impex, 
except D-BOC-Phe-OMe (73b), which was synthesized from the amino acid according to the 
protocol below (Scheme 4.2). 
 
 
Scheme 4.2: Synthesis of D-BOC-Phe-OMe. 
 
Synthesis of D-BOC-Phe-OMe (73b): 
D-BOC-Phe-OH (72b, 0.5056 g, 1.9 mmol) was dissolved in 20 mL MeOH and cooled to 
0°C.  DMAP (30.0 mg, 0.25 mmol, 0.13 eq) was added and the solution was allowed to 
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equilibrate for 10 minutes.  DCC (0.4554 g, 2.2 mmol, 1.15 eq) was added and the solution was 
slowly warmed to room temperature and stirred overnight.  DCU was filtered off and methanol 
evaporated.  The crude product was dissolved in DCM and washed with 0.5 N HCl (aq) (2 x 25 
mL) and sat. NaHCO3 (aq) (3 x 25 mL).  The organic layer was dried over MgSO4, filtered, and 
the solvent evaporated.  The crude product was an oil containing a small amount of solid; by 
NMR it appeared to contain DCU, so it was filtered again.  After drying under high vacuum for 
two hours, 
1
H NMR showed a small amount of impurities remained.  A preparatory plate was 
then run using 50/50 EtOAc/hexanes to afford pure D-BOC-Phe-OMe (73b.) 
 
DuoMIP Polymer Formulation: 
One example of a DuoMIP synthesis was depicted previously in Scheme 4.1.  In all 
NOBE DuoMIP syntheses completed, the protocol was as follows: NOBE (3 g) was added to a 
solution of R or S-BOC-Tyr
a
, R or S-4-benzyl-2-oxazolidinone
b
, R or S-BOC-Phe
c
, and R or S-
BOC-Phe-OMe
d
 (4%
a
, 5%
a,b,c,d
, or 20%
a
 template) dissolved in 3 mL acetonitrile.  AIBN (1%) 
was added to the solution and this was placed into a 13 x 100 mm glass tube.  Nitrogen was used 
to purge each sample for 5 minutes.  After the sample was purged, the tube was capped, and 
Teflon tape and Parafilm were used to seal the system.  The tube was then inserted into a 
photoreactor apparatus where it was submerged in a H2O bath to maintain room temperature and 
was exposed to a 450 W mercury arc lamp surrounded by a borosilicate jacket for 8 hours.  The 
polymer was then broken out of the tube and the template was removed by Soxhlet extraction 
with methanol for 2 days.  The polymers were then ground and sized to 25-37 µm using U.S.A. 
Standard Testing Sieves and were then packed into 100 x 2.1 mm stainless steel columns and 
their ability to determine absolute configuration were analyzed by HPLC. 
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4.3 Results and Discussion of NOBE DuoMIPs* 
 Each enantiomer of the DuoMIP stationary phases was packed into separate HPLC 
columns for AC analysis.  The difference in retention of the analyte on each of the stationary 
phases was examined to determine AC.   Since a clear difference in binding and selectivity was 
imperative to this analysis, a set of rules based on these factors were implemented to ensure 
confidence of the DuoMIP AC determination method.  For this system, the capacity factors of 
the analytes must be greater than 1.0 because values larger than 1.0 indicate the ability of 
analytes to sufficiently bind the imprinted stationary phases for analysis.  Significant binding is 
important for analysis as acknowledged in 1907 by Paul Ehrlich when he said, “Corpora non 
agunt nisi fixate,” which is translated to “Substances will not act if they do not bind.”25   
 Another rule to provide confidence in the analysis of AC fixes the minimum value of a 
new term, the γ factor.  To determine the γ values, the capacity factors of the analyte on each 
DuoMIP are compared.  For analytes that fit the S imprinted cavity, the γ factor is defined as the 
capacity factor of that analyte obtained from the S imprinted column (k'SMIP) divided by the 
capacity factor obtained from the R imprinted column (k'RMIP.)  Conversely, the γ factor for 
analytes that selectively fit into the R imprinted cavities puts the k'RMIP in the numerator and  
k'SMIP is in the denominator as shown in (Eq. 4.1).  For unknown analytes, the larger k' is 
positioned in the numerator and the smaller in the denominator.  Based on similar limits 
employed by Rychnovsky and coworkers, minimum γ values of 1.2 were established to signify 
that the analyte’s selectivity for one enantiomer of the imprinted polymers is significant beyond 
error to determine absolute configuration by the DuoMIP system. 
*Reprinted with permission from Organic Letters 2014 16 (5), 1402-1405.  Copyright 2014 
American Chemical Society. 
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                                                             γ=
k'SMIP
k' MIP
  (or  γ=
k' MIP
k'SMIP
)                                             Eq. 4.1 
 The k’ factor and γ values were used to evaluate all DuoMIPs synthesized, which 
included polymers made using 4%, 5%, and 20% R or S-BOC-Tyr as the print molecule.  The 
DuoMIPs synthesized using 4% template displayed low separation factors compared to the 
DuoMIPs imprinted with higher percentages of template because there were less imprinted sites 
formed, and DuoMIPs imprinted with 5% BOC-Tyr template displayed partial success.  As 
shown in Table 4.1, the absolute configuration could be determined for the analytes S-BOC-Tyr, 
R-BOC-Tyr, S-Z-Trp, S-Z-Ser, and S-2-phenyl glycinol based on the rules pertaining to capacity 
factor and γ values listed previously.  S-Z-Phe, R-Z-Phe, R-Z-Trp, S-phenyl lactic acid, S-
methoxy(trifluoromethyl)phenyl AcOH, S-phenyl butyric acid, R-phenyl butyric acid, R-phenyl 
butanol, S-chloro phenyl ethanol, R-chloro phenyl ethanol, S-binapthol, and R-binapthol did not 
meet the minimum k’ and γ requirements required to determine AC, while the incorrect 
stereochemistry was determined in one case, R-Z-Ser.   
Table 4.1: NOBE DuoMIPs imprinted with 5% S-BOC-Tyr or R-BOC-Tyr
*. 
Analyte 
k' on 
R column 
k' on 
S column 
γ 
 
S-BOC-Tyr 1.8 5.6 3.1 
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Table 4.1 NOBE DuoMIP imprinted with 5% S-BOC-Tyr or R-BOC-Tyr continued. 
 
R-BOC-Tyr 6.9 1.8 3.8 
 
S-Z-Phe 0.6
a
 0.9
a
 1.5 
R-Z-Phe 0.7
a
 0.6
a
 1.2 
 
S-Z-Trp 1.2 1.6 1.3 
R-Z-Trp 1.4 1.4 1.0
b
 
 
S-Z-Ser 1.3 1.5 1.2 
R-Z-Ser 1.3 1.5 1.2
 
 
S-2-phenyl glycinol 2.2 4.0 1.8 
  
S-phenyl lactic acid 0.7
a
 0.9
a
 1.3 
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Table 4.1 NOBE DuoMIP imprinted with 5% S-BOC-Tyr or R-BOC-Tyr* continued. 
 
S-methoxy 
(trifluoro- methyl) 
phenyl AcOH 
0.6
a
 0.8
a
 1.3 
 
 
S-phenyl butyric 
acid 
0.3
a
 0.3
a
 1.0
b
 
R-phenyl butyric 
acid 
0.3
a
 0.4
a
 1.3 
 
R-phenyl butanol 0.1
a
 0.1
a
 1.0
b
 
 
S-chloro phenyl 
ethanol 
0.1
a
 0.1
a
 1.0
b
 
R-chloro phenyl 
ethanol 
0.1
a
 0.1
a
 1.0
b
 
  
S-binapthol 0.5
a
 0.5
a
 1.0
b
 
R-binapthol 0.5
a
 0.5
a
 1.0
b
 
*HPLC conditions: particle size, 25-37 µm; column size, 100 x 2.1 mm; flow rate: 99/1 
MeCN/AcOH; 0.1 mL/min; injected volume: 5 µL; analytes/wavelength detection: 5 mM S-
CBZ-Phe/260 nm, 5 mM R-CBZ-Phe/260 nm, 1 mM BOC-S-tyrosine/260 nm, 1 mM BOC-R-
tyrosine/260 nm, 0.2 mM Cbz-S-tryptophan/260 nm, 0.2 mM Cbz-R-tryptophan/260 nm, 1 mM 
0.2 mM (R)-(-)-1,1’-bi-2-naphthol/300 nm, 10 mM S-2-phenyl-glycinol/262 nm, 5 mM S-2- 
chloro-1-phenyl ethanol/262 nm, 5 mM R-2-chloro-1-phenyl ethanol/262 nm, 2 mM S-(+)-2- 
phenyl butyric acid/262 nm, 2 mM R-(-)-2-phenyl butyric acid/262 nm, 1 mM S-phenyl-lactic 
acid/262 nm, 1 mM S-methoxy (trifluoro-methyl) phenyl acetic acid/262 nm, 1 mM R-1-phenyl-  
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Table 4.1 NOBE DuoMIP imprinted with 5% S-BOC-Tyr or R-BOC-Tyr* continued. 
CBZ-S-serine/260 nm, 1 mM CBZ -R-serine/260 nm, 0.2 mM (S)-(-)-1,1’-bi-2-naphthol/300 nm, 
1-butanol/262 nm.  
aThe k’ does not meet the minimum binding requirements and cannot be used 
to determine AC.  
bThe γ factor is lower than minimum criteria and cannot be used to determine 
AC. 
The partial successes achieved from the NOBE DuoMIP system formed from imprinting 
5% R or S-BOC-Tyr led to the development of another NOBE DuoMIP system where 20% 
BOC-Tyr template was chosen for the synthesis.  It is important to note that the amount of 
template can be increased to 20% in this system as the OMNiMIP approach to imprinting was 
used.
26
  OMNiMIPs allow a greater capacity of print molecule to be used because the polymer 
consists of 100% of the crosslinking monomer.  The addition of a larger amount of template in 
the construction of the DuoMIPs led to the formation of a greater number of selective and strong 
binding imprinted cavities, which therefore led to a larger number of successful determinations 
of absolute configuration.   
The results for the determination of AC using NOBE and 20% BOC-Tyr are shown in 
Table 4.2.  Using the 20% imprinted DuoMIP system, the absolute configuration could be 
accurately determined for S-BOC-Tyr, R-BOC-Tyr, S-Z-Phe, R-Z-Phe, S-Z-Trp, R-Z-Trp, S-2-
phenyl glycinol, S-phenyl lactic acid, and (S)-N-acetyl-tyrosine as each of these analytes 
exhibited capacity factors greater than 1.0 and γ values larger than 1.2.  The AC of S-2-chloro-1-
phenyl ethanol, R-2-chloro-1-phenyl ethanol, R-(-)-O-acetyl mandelic acid, S-(+)-2-phenyl 
butyric acid, R-(+)-2-phenyl butyric acid, S-nicotine, R-nicotine, R-phenyl butanol, S-1,1’-bi-2-
naphthol, and R-1,1’-bi-2-naphthol could not be determined because these analytes had poor 
retention to the DuoMIPs (i.e. low k’ values.)  The AC of S-Z-Ser, R-Z-Ser, S-Naphthylethyl 
amine, and R-naphthylethyl amine were also could not be determined because, although each of 
these analytes displayed k’ values larger than 1.0, the retention on both enantiomers of the 
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DuoMIPs were similar therefore their γ values were below the 1.2 minimum requirement.  It is 
important to note that there were no incorrect assignments of stereochemistry when the k’ and γ 
criteria for binding and selectivity were followed. 
Table 4.2: NOBE DuoMIP imprinted with 20% S-BOC-Tyr or R-BOC-Tyr
*
. 
Analytes 
k’ on 
L-imprinted 
column 
k’ on 
D-imprinted 
column 
γ 
 
S-BOC-Tyr 15.1 4.1 3.7 
R-BOC-Tyr 4.5 13.0 2.9 
 
S-Z-Phe 1.9 1.5 1.3 
R-Z-Phe 1.6 2.3 1.4 
 
S-Z-Trp 4.0 3.0 1.3 
R-Z-Trp 3.0 3.7 1.2 
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Table 4.2 NOBE DuoMIP imprinted with 20% S-BOC-Tyr or R-BOC-Tyr
*
 continued. 
 
S-2-Phenyl glycinol 5.1 3.2 1.6 
 
S-Phenyl lactic acid 1.8 1.4 1.3 
 
(S)-N-acetyl-
tyrosine 
11.2 6.5 1.7 
 
S-2-Chloro-1-
phenyl ethanol 
0.2
a
 0.1
a
 2.0 
R-2-Chloro-1-
phenyl ethanol 
0.2
a
 0.1
a
 2.0 
 
R-(-)-O-Acetyl 
mandelic acid 
0.8
a
 0.8
a
 1.0
b
 
 
S-(+)-2-Phenyl 
butyric acid 
0.5
a
 0.5
a
 1.0
b
 
R-(-)-2-Phenyl 
butyric acid 
0.5
a
 0.5
a
 1.0
b
 
 93 
 
Table 4.2 NOBE DuoMIP imprinted with 20% S-BOC-Tyr or R-BOC-Tyr
*
 continued. 
 
S-Nicotine 0.5
a
 0.5
a
 1.0
b
 
R-Nicotine 0.5
a
 0.6
a
 1.2 
 
S-Z-Ser 2.7 2.5 1.1
b
 
R-Z-Ser 2.7 2.5 1.1
b
 
 
R-Phenyl butanol 0.2
a
 0.1
a
 2.0
b
 
 
S-Naphthylethyl 
amine 
3.4 3.4 1.0
b
 
R-Naphthylethyl 
amine 
3.4 3.1 1.1
b
 
 
S-1,1’-bi-2-
naphthol 
0.9
a
 0.8
a
 1.1
b
 
R-1,1’-bi-2-
naphthol 
0.9
a
 0.8
a
 1.1
b
 
*
HPLC conditions: 25-37 µm particle; 100x2.1 mm column; 99/1 MeCN/AcOH; 0.1 mL/min; 
injected: 5 µL; analytes: 2.5 mM S-BOC-Tyr, 2.5 mM R-BOC-Tyr, 1 mM S-Z-Phe, 1 mM R-  
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Table 4.2 NOBE DuoMIP imprinted with 20% S-BOC-Tyr or R-BOC-Tyr continued 
 
Z-Phe, 0.2 mM S-Z-Trp, 0.2 mM R-Z-Trp, 1 mM S-2-phenyl glycinol, 1 mM S-phenyl lactic 
acid, 1 mM (S)-N-acetyl-tyrosine, 5 mM S-2-Chloro-1-phenyl ethanol, 5 mM R-2-Chloro-1- 
phenyl ethanol, 1 mM R-(-)-O-Acetyl mandelic acid, 2 mM S-(+)-2-Phenyl butyric acid, 2 
mM R-(-)-2-Phenyl butyric acid, 1 mM S-Nicotine, 1 mM R-Nicotine, 1mM S-Z-Ser, 1 mM R-
Z-Ser, 1 mM R-Phenyl butanol, 1 mM S-naphthylethyl amine, 1 mM R-naphthylethyl amine, 
0.2 mM S-1,1’-bi-2-naphthol, 0.2 mM R-1,1’-bi-2-naphthol.  aThe k’ does not meet the 
minimum binding requirements and therefore cannot be used γ factor calculation to determine 
AC.  
bThe γ value calculated is lower than minimum requirements and cannot be used to 
determine AC.
 
The mnemonic shown previously in Figure 4.4 can be extended to assist in the 
explanation of the AC determination of analytes that differ from the print molecule.  For 
example, Figure 4.5 illustrates the analyte (S)-N-acetyl-tyrosine in the binding cavity of both the 
S and the R-MIP enantiomers of the DuoMIP system imprinted with BOC-Tyr.  Here, (S)-N-
acetyl-tyrosine fits into the S-MIP cavity (Figure 4.5, a), but does not show a good fit into the R- 
Figure 4.5: Absolute configuration analysis of (S)-N-acetyl-tyrosine absolute using the DuoMIP 
system imprinted with S (a) and R (b)-BOC-Tyr. 
MIP cavity (Figure 4.5, b.)  With the aid of the mnemonic, the analyte binding results from the 
chromatography analyses are better understood.  When the analyte (S)-N-acetyl-tyrosine was 
eluted on both the R and the S imprinted DuoMIPs, it was retained longer on the S imprinted 
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column than the R imprinted column (Figure 4.6.)  This difference in retention is due to the 
selectivity of (S)-N-acetyl-tyrosine in the binding cavity of each enantiomer of the DuoMIP 
system, and accounts for its ability to be useful for AC determination of unknown molecules. 
 
Figure 4.6: S-Acetyl-Tyr analyte (85) on NOBE imprinted with 20% S-BOC-Tyr (S-MIP)
a
 and S-
Acetyl-Tyr analyte on NOBE imprinted with 20% R-BOC-Tyr (R-MIP)
b
. 
 
Figure 4.7 can be used to further aid in the understanding of the AC determination of 
non-amino acids using the mnemonic.  Figure 4.7, a depicts that (S)-phenyllactic acid fits into the 
S-MIP enantiomer of the DuoMIP system; and Figure 4.7, b illustrates that (S)-phenyllactic acid 
exhibits a poor fit into the R-MIP enantiomer.  This result correlates to the values shown in Table 
4.2 where the k’ was 1.8 on the S-MIP and 1.4 on the R-MIP with a γ value of 1.3.  Figure 4.7, c 
portrays (S)-phenyl glycinol fitting into the S-MIP; and Figure 4.7, d shows that the same (S)-
phenyl glycinol does not fit into the R-MIP binding cavity.  These illustrations in the mnemonic 
also aid in understanding the experimental data in Table 4.2 where (S)-phenyl glycinol had a k’ 
of 5.1 on the S-MIP and 3.2 on the R-MIP with a 1.6 γ value. 
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 Figure 4.7: (S)-phenyllactic acid in the binding cavity of the NOBE OMNiMIP imprinted 
with 20% S-BOC-Tyr (a), (S)-phenyllactic acid in the binding cavity of the NOBE OMNiMIP 
imprinted with 20% R-BOC-Tyr (b), (S)-phenyl glycinol in the binding cavity of the NOBE 
OMNiMIP imprinted with 20% S-BOC-Tyr (c), and (S)-phenyl glycinol in the binding cavity of 
the NOBE OMNiMIP imprinted with 20% R-BOC-Tyr (d). 
The NOBE DuoMIP system was studied further to demonstrate the importance of the 
hydrogen bonding and steric interactions in the DuoMIP design.  NOBE DuoMIPs were 
synthesized using 5% R or S-4-benzyl-2-oxazolidinone as the print molecules.  These templates 
were chosen as a means to compare the DuoMIP system directly to  ychnovsky’s kinetic 
resolution methods where he studied the absolute configuration of oxazolidinones.
18
  For this 
system, nearly all of the k’ and or γ values for each of the analytes were below the minimum 
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criteria required for confidence in AC determination.  It is not surprising that these DuoMIPs 
could not be used to determine the absolute configuration of unknown analytes because these 
MIPs were not synthesized with a design that led to a distribution of strong hydrogen bonding 
and steric interactions around the chiral center significant for differentiating diasteriomeric 
complex energies of the enantiomeric adsorbents and analyte as shown in Figure 4.8. 
Figure 4.8:  The “strong” and “moderate” hydrogen bonding groups and the “small” and “big” 
groups are illustrated for BOC-Tyr (7) and the “strong/moderate” group and the “small” and 
“big” groups are shown for 4-benzyl-2-oxazolidinone (74) print molecules. 
 Two other DuoMIP systems were subsequently synthesized with 5% R or S-BOC-Phe 
and R or S-BOC-Phe-OMe as the print molecules to further show the importance of the binding 
site formation in the determination of AC.  The BOC-Phe DuoMIPs were used to determine the 
AC accurately for four analytes while the BOC-Phe-OMe DuoMIPs only accurately determined 
three AC examples as shown in Table 4.3.  The BOC-Phe DuoMIPs determined AC for more 
analytes, and provided larger γ values indicating that the reliability of the BOC-Phe DuoMIP 
system was also better than the sytem based on the BOC-Phe-OMe.  These results are not 
surprising as the BOC-Phe system that performed the best had a print molecule with a carboxylic 
acid as illustrated in Figure 4.9.  The carboxylic acid group is important because it is a strong 
hydrogen bond donor.  The strong hydrogen bond accounts for some of the recognition between 
the binding cavity of the DuoMIP adsorbents and the analytes studied by HPLC.  Although there  
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Figure 4.9: The “strong” and “moderate” hydrogen bonding groups and the “small” and big” 
groups are illustrated for BOC-Phe (72) and BOC-Phe-OMe (73). 
were some successes by these DuoMIPs it should be noted that the AC of S-Z-Ser on the BOC-
Phe DuoMIPs and R-Z-Trp and R-Z-Ser on the BOC-Phe-OMe were incorrectly identified.  
These results show that there are further difficulties to the DuoMIP system formed with BOC-
Phe and BOC-Phe-OMe, which might be overcome by using a larger amount of template (20%) 
as in the case of the BOC-Tyr systems. 
Table 4.3: NOBE DuoMIPs imprinted with BOC-Phe or BOC-Phe-OMe templates
*
.
 
Analyte 
γ from BOC-Phe 
imprinted columns 
γ from BOC-Phe-
OMe imprinted 
columns 
 
S-BOC-Tyr 1.1
b
 1.2 
R-BOC-Tyr 1.1
b
 1.2 
 
S-BOC-Phe-OMe n/a 1.0
a,b 
R-BOC-Phe-OMe n/a 1.0
 a,b
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Table 4.3: NOBE DuoMIPs imprinted with BOC-Phe or BOC-Phe-OMe templates
*
 continued. 
 
S-BOC-Phe 1.6
 a
 n/a
c 
R-BOC-Phe 1.2
 a,b
 n/a
c 
 
S-Z-Phe 1.2
a
 1.0
 a,b
 
R-Z-Phe 1.6
a
 1.2
a
 
 
S-Z-Trp 1.1
b
 1.3 
R-Z-Trp 1.1
b
 1.3
d 
 
S-Z-Ser 1.3
d 
1.2 
R-Z-Ser 1.1
b
 1.3
d 
 
S-2-phenyl glycinol 1.4 1.1
b 
 
 
S-phenyl lactic acid 1.4
a
 1.1
 a,b
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Table 4.3 NOBE DuoMIPs imprinted with BOC-Phe or BOC-Phe-OMe templates
*
 continued. 
 
S-
methoxy(trifluorom
ethyl)phenylAcOH 
1.7 1.1
b
 
 
S-phenyl butyric 
acid 
1.5 1.0
 a,b
 
R-phenyl butyric 
acid 
1.7
a
 1.0
 a,b
 
 
R-phenyl butanol 1.3
a
 1.0
 a,b
 
 
S-chloro phenyl 
ethanol 
2.6
a
 1.0
 a,b
 
R-chloro phenyl 
ethanol 
2.0
a
 1.0
 a,b
 
 
S-binapthol 1.0
a,b
 1.0
 a,b
 
R-binapthol 1.0
a,b
 1.0
 a,b
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Table 4.3 NOBE DuoMIPs imprinted with BOC-Phe or BOC-Phe-OMe templates
*
 continued.
 
*
HPLC conditions: 25-37 µm particles; 100 x 2.1 mm column; 99/1 MeCN/AcOH; 0.1 mL/min; 
injected 5 µL; 1 mM BOC-S-tyrosine/260 nm, 1 mM BOC-R-tyrosine/260 nm, 5 mM S-BOC-Phe-
OMe/260 nm, 5 mM R-BOC-Phe-OMe/260 nm, 1 mM BOC-S-Phe/260 nm, 1 mM BOC-R-Phe/260 
nm, 5 mM S-CBZ-Phe/260 nm, 5 mM R-Z-Phe/260 nm, 0.2 mM Z-S-tryptophan/260 nm, 0.2 mM 
Z-R-tryptophan/260 nm, 1 mM Z-S-serine/260 nm, 1 mM Z-R-serine/260 nm, 10 mM S-2-phenyl-
glycinol/262 nm, 1 mM S-phenyl-lactic acid/262 nm, 1 mM S-methoxy (trifluoro-methyl) phenyl 
acetic acid/262 nm, mM S-(+)-2-phenyl butyric acid/262 nm, 2 mM R-(-)-2-phenyl butyric acid/262 
nm, 1 mM R-1-phenyl-1-butanol/262 nm, 5 mM S-2-chloro-1-phenyl ethanol/262 nm, 5 mM R-2-
chloro-1-phenyl ethanol/262 nm, 0.2 mM (S)-(-)-1,1’-bi-2-naphthol/300 nm, 0.2 mM (R)-(-)-1,1’-
bi-2-naphthol/300 nm.  
ak’ and bγ do not meet criteria and cannot be used to determine AC. cValues 
not available are listed as n/a. 
d
AC was incorrect.
 
 
4.4 Exploration of a Chiral OMNiMIP for AC Analysis 
The exploration of a chiral monomer for synthesizing DuoMIPs was also studied and 
compared to NOBE DuoMIPs.  Here, L-NALA was chosen as the chiral crosslinking monomer 
because its structure only differs from NOBE by a single methyl group in the position alpha to 
the amide group (Figure 4.10.)  As shown in Table 4.4, AC could correctly be identified for S- 
Figure 4.10: The structure of L-NALA (9) differs from NOBE (1) by one methyl group in the 
alpha amido position. 
 
BOC-Tyr, R-BOC-Tyr, R-Z-Trp, R-Z-Ser, S-phenyl glycinol and (S)-N-acetyl tyrosine.  
Although there were some successes using L-NALA as the crosslinking monomer for the 
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DuoMIP synthesis it was decided that the ease of preparation and results of the NOBE DuoMIP 
system is the most effective for AC determination thus far. 
Table 4.4: L-NALA DuoMIP system imprinted with R or S-BOC-Tyr
*
. 
Analytes 
k’on 
L-MIP 
k’on 
D-MIP 
γ 
 
S-BOC-Tyr 10.9 2.5 4.4 
R-BOC-Tyr 2.1 5.3 2.4 
 
S-Z-Phe 0.9
a
 1.0
a
 1.1
b
 
R-Z-Phe 0.7
a
 1.0
a
 1.4
a 
 
S-Z-Trp 1.5 1.6 1.1
b
 
R-Z-Trp 1.3 1.7 1.3 
 
S-Z-Ser 1.4 1.5 1.1
b
 
R-Z-Ser 1.2 1.5 1.3 
 
S-Nicotine 0.3
a
 0.3
a
 1.0
a,b
 
R-Nicotine 0.3
a
 0.3
a
 1.0
 a,b
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Table 4.4 L-NALA DuoMIP system imprinted with R or S-BOC-Tyr
*
 continued. 
 
S-2-phenyl 
glycinol 
2.5 3.1 1.2 
 
S-phenyl lactic 
acid 
0.8
a
 1.0 1.3
a
 
 
S-methoxy 
trifluoro methyl 
phenyl acetic acid 
1.9 2.0 1.0
b
 
 
S-
Cyclohexylethyla
mine 
2.4 2.2 1.1
b
 
R-
Cyclohexylethyla
mine 
2.3 2.3 1.0
b
 
 
S-methyl benzyl 
amine 
2.8 2.6 1.1
b
 
R-methyl benzyl 
amine 
2.7 2.7 1.0
b
 
 
S,S-trans amino 
indanol 
4.4 4.7 1.1
b
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Table 4.4 L-NALA DuoMIP system imprinted with R or S-BOC-Tyr
*
 continued. 
 
(S)-N-Acetyl-
Tyrosine 
4.9 4.0 1.2 
 
S-methyl nitro 
benzyl amine 
2.5 2.4 1.0
b
 
*
HPLC conditions: particle size, 25-37 µm; column size, 100 x 2.1 mm; flow rate: 0.1 mL/min, 
99/1 MeCN/AcOH mobile phase; injected volume: 5 µL; 260 nm wavelength detection, analytes: 
1 mM S-BOC-Tyr, 1 mM R-BOC-Tyr, 1 mM S-Z-Phe, 1 mM R-Z-Phe, 0.2 mM S-Z-Trp, 0.2 
mM R-Z-Trp, 1 mM S-Z-Ser, 1 mM R-Z-Ser, 1 mM S-2-phenyl glycinol, 1 mM S-phenyl lactic 
acid, 1 mM S-methoxy trifluoro methyl phenyl acetic acid, 1 mM, 1 mM S-Nicotine, 1 mM R- 
Nicotine, 1 mM S-Cyclohexylethylamine, 1 mM R-Cyclohexylethylamine, 1 mM S-methyl 
benzyl amine, 1 mM R-methyl benzyl amine, 1 mM S,S-trans amino indanol, 1 mM (S)-N-
Acetyl-Tyrosine, 1 mM S-methyl nitro benzyl amine.  
aThe k’ does not meet the criteria and 
cannot be used to determine AC.  
bThe γ value is  lower than criteria and cannot be used to 
determine AC. 
 
4.5 Absolute Configuration Determination Conclusions 
As shown throughout the many approaches to determine absolute configuration in the 
literature, the determination of stereochemistry is an ongoing important research topic.  Current 
methods encompass numerous drawbacks; such as, the requirement of multiple reactions or 
derivatizations, need for prior literature values, computational studies, or both enantiomers for 
comparison; and therefore, methodological improvements are needed in the determination of 
absolute stereochemistry of compounds.  In Chapter Four, a new technique, the DuoMIP method, 
was developed as another solution to the AC determination quandary.  DuoMIP systems were 
synthesized from the crosslinking monomers NOBE and L-NALA using OMNiMIP imprinting.  
The importance of a large template loading in the polymer formulation was demonstrated as the 
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best performance in relation to AC determination was when 20% (as compared to 4 and 5% 
template) R or S-BOC-Tyr was used as the print molecules with NOBE as the crosslinker.  In this 
case, each enantiomeric adsorbent of the DuoMIP system contained a greater number of 
recognition cavities formed from the strong hydrogen bonding and steric interactions.  The 
binding affinity (k’ ≥ 1) and selectivity (γ ≥ 1.2) of the unknown analyte with each enantiomer of 
the DuoMIP system allowed the correct AC determination of a series of molecules.  
 
4.6 Absolute Configuration Future Work 
Further studies synthesizing NOBE DuoMIPs for AC determination should be completed 
with different print molecules (including non-amino acid derivatives), such as R and S-phenyl 
glycinol.  Optimizing the cross-reactivity of the template and series of analytes studied could 
broaden the scope of the DuoMIP system for absolute configuration determinations.  Other 
crosslinkers for the creation of DuoMIPs synthesized using OMNiMIP and traditional imprinting 
approaches should also be examined.  For example, the crosslinker NAG (12) introduced in 
Chapter 2 could be used to imprint R and S-Z-Trp by traditional and OMNiMIP imprinting and 
evaluation of these polymers as DuoMIPs can be studied by HPLC.  In addition to OMNiMIP 
and traditional imprinting, other chromatographic stationary phases could also be studied to gain 
knowledge in the dual column method of AC determination.  Pirkle or other chiral separation 
columns can be purchased or synthesized and tested to see if they too can be used in a dual 
system for determination of AC. 
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CHAPTER 5: SYNTHESIS OF A NEW CHIMERIC ANTIOXIDANT 
5.1 Introduction to Diseases Associated with Oxidative Stress 
According to the Global Action Plan published by the World Health Organization in 
2013, it was estimated that over 17 million deaths were caused by cardiovascular disease in 2008 
and that number is expected to exceed 25 million by the year 2030.
1
  Increasing mortality due to 
cardiovascular disease is a worldwide problem that has escalated research attention.
2
  Research 
has shown that the development of cardiovascular disease as well as neurodegenerative diseases 
such as Alzheimer’s and Parkinson’s are linked to oxidative damage in vivo.3,4  In particular, 
oxidative damage in arteries leads to atherosclerosis, a major origin of cardiovascular disease.
5
  
The early stages of atherosclerosis have been associated with free radical oxidation of low 
density lipoproteins (LDLs), which occurs on the lipid and or protein portions of the 
lipoprotein.
6,7
  The uptake of oxidized LDLs (ox-LDLs) by macrophages leads to foam cell 
formation in the subendothelial space.  The accumulation of these foam cells results in plaque 
formation in the arterial intima and thus triggers atherosclerosis (Figure 5.1).
8,9
   
Figure 5.1: Diagram of Atherosclerosis development. 
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One approach to minimize atherosclerosis and other diseases that are caused by oxidative 
stress is to reduce or eliminate the free radical species formed in the body.
10
  There are numerous 
antioxidant molecules that have been shown to reduce oxidative damage.
11
  These antioxidants 
can be categorized based on the environments that they thrive in, either lipophilic or hydrophilic.  
For example, vitamin E is a term used to describe a group of eight lipophilic antioxidant 
molecules, which include four tocopherols and four tocotrienols (Figure 5.2).  The structural 
features of the tocopherols and tocotrienols differ only by the unsaturated double bonds found in  
Figure 5.2: Structures of vitamin E molecules: α-tocopherol (93), β-tocopherol (94), γ-tocopherol 
(95), δ-tocopherol (96), α-tocotrienol (97), β- tocotrienols (98), γ- tocotrienols (99), and δ- 
tocotrienols (100). 
 
the latter.  The variations among the individual molecules in each category are distinguished by 
the methyl groups attached on the benzene ring.   
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The subtle structural differences of these antioxidants dictate how recognition and 
antioxidant activity occurs.  For example, the methyl appendage arrangement on the benzene 
ring of α-tocopherol is specifically recognized by the 32 kDa α-tocopherol transferase protein (α-
TTP).
12,13
  After recognition by the transferase protein, α-TOC is transported into lipoproteins 
and is further transported to tissues.
14
  Here, the lipophilic α-tocopherol antioxidant is able to 
inhibit oxidation of the lipid portion of LDLs.
15,16,17 
 A limitation to this antioxidant molecule 
and many other lipophilic molecules is its inability to penetrate hydrophilic media.  For instance, 
although lipophilic molecules are successful at oxidation inhibition in the lipid portion of LDLs, 
they are unable to prevent oxidation in hydrophilic apolipoproteins; such as, Apo B-100.
16,17  
 
Another category of antioxidants 
consists of hydrophilic molecules.  In a 
similar manner, hydrophilic antioxidants 
such as vitamin C (101), carnosine (102), 
and folic acid
 
(103) are successful at 
prevention of oxidative stress in 
hydrophilic environments as represented 
in the cell cytosol and blood plasma 
(Figure 5.3).
18,19,20,21
  While these 
antioxidants are equipped to reduce 
oxidation in hydrophilic media, they are 
unable to sufficiently enter into 
hydrophobic environments.  The inability of hydrophilic molecules to infiltrate the hydrophobic 
regions makes them incapable of therapeutic activity in these environments. 
 
 
 
Figure 5.3: Structures of hydrophilic antioxidant 
molecules: vitamin C (101), carnosine (102), and 
folic acid
 
(103). 
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The failure to gain access to both hydrophobic and hydrophilic regions simultaneously in 
biological environments is a problem addressed in the literature.  For example, conjugation of 
lipophilic vitamin E with other moieties to improve water solubility has been 
accomplished.
22,23,24
  Takata and co-workers derivatized an isomer of vitamin E to form a water-
soluble molecule (Figure 5.4, 104).  Ogata describes a series of derivatives containing several 
different amino acids attached to the hydroxyl group on tocopherol, which make these isomers of 
vitamin E also water-soluble (Figure 5.4, 105.)
25
  In these examples, once the derivatives 
permeate the hydrophilic environment, they can hydrolyze to form the original vitamin E     
Figure 5.4 Water-soluble vitamin E derivatives. 
structure.  Although these vitamin E derivatives can enter hydrophilic media, a problem that 
arises from these analogues and others that utilize the hydroxyl group of vitamin E is the loss of 
recognition by α-TTP while the hydrophilic moiety is attached since the OH appendage is an 
area of key enzymatic recognition.
26
  Until hydrolysis to free the hydroxyl group is achieved, 
strong recognition by α-TTP is not accomplished.  This reduction in recognition results in the 
reduced ability to penetrate LDLs through the α-TTP mechanism and consequently the 
molecules do not achieve antioxidant activity in both hydrophilic and lipophilic regions of LDLs 
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at the same time.  To address this conundrum, the design and synthesis of a novel chimeric 
antioxidant that leaves the hydroxyl group intact is discussed throughout Chapter 5.  Here, the 
introduction of carnosine, a hydrophilic moiety, to the lipophilic antioxidant α-tocopherol at the 
end of the phytyl chain is synthetically accomplished, and the rate of radical inhibition examined 
using a 1,1-diphenyl-2-picrylhydrazyl (DPPH) assay.
27,28
 
5.2 VECAR Design 
Vitamin E Carnosine (VECAR, 106) was designed to provide both lipophilic and 
hydrophilic antioxidant moieties in a single chimeric molecule.  There are three main regions of 
the VECAR structure that impart its unique lipophilic and hydrophilic abilities (Figure 5.5).
27
  
Figure 5.5 VECAR (106) design. 
The left hand portion of VECAR keeps the chromanol ring of α-tocopherol intact as it 
encompasses key zones of enzymatic recognition by α-TTP as identified by Meier et al.26  Meier 
and co-workers generated crystal structures of α-TTP and used computational studies to identify 
that the hydroxyl and methyl groups on the chromanol ring are important recognition sites 
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between the enzyme and α-toc.  The authors determined that the hydroxyl groups participate in 
hydrogen bonding with the serine and valine moieties of α-TTP’s binding pocket while the 
methyl appendages interact through van der Waals forces.   
Another region of design importance is the middle section, the phytyl chain, of VECAR.  
Diplock and co-workers performed in vivo studies on rats to examine phytyl chain features.  
They determined that the length of the phytyl chain was important as shown when they 
decreased (n ≤ 11) or increased (n ≥ 16) the number of carbons and the effectiveness of the 
derivative diminished.
29
  For these reasons, the length of  ECA ’s phytyl chain is retained to 12 
carbons so that hydrophobic interactions within the binding pocket are maintained.  The methyl 
appendages found on the phytyl chain of α-toc are removed in the design of VECAR to afford a 
more simplistic synthesis.  Precedents for the elimination of the methyl groups on the phytyl tail 
without decreased α-TTP recognition arise from prior research reported in the literature.26,30  
Ingold et al., completed a rat curative myopathy assay, which studied the pyruvate kinase activity 
in plasma to show that the removal of methyl groups in the 4’, 8’, and 12’ positions do not hinder 
α-TTP recognition in vivo.30  Studies completed by Diplock and co-workers have also shown the 
insignificance of the 4’, 8’, and 12’ methyl appendages.29   
The last design segment is the right hand portion of VECAR, which contains the 
hydrophilic moiety attached to the end of the phytyl tail.  Unlike many systems that couple 
molecules to the hydroxyl group of vitamin E, carnosine is a unique antioxidant to be coupled to 
the phytyl chain end.  This conjugation is anticipated to provide antioxidant activity to more 
universal regions in vivo while maintaining its ability to be recognized by α-TTP for transfer into 
LDLs.  Recent publications by Atkinson and co-workers have explored the synthesis of vitamin 
E analogues conjugated to fluorescent markers and studied their pathways in cells; for example 
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the vitamin E derivatives incorporating dipyrrometheneboron difluoride (BODIPY) and 7-
nitrobenz-2-oxa-1,3-diazole (NBD) at the end of the phytyl chain.
13,31
  The successful 
recognition obtained by α-TTP suggests the possibility that alterations at the phytyl chain end 
will not affect cellular uptake.  Although lipophilic molecules have been attached to the phytyl 
tail, a hydrophilic antioxidant moiety has not been explored; thus, the addition of carnosine, a 
hydrophilic dipeptide, has been chosen for the chimeric VECAR design.  Kohen and co-workers 
have shown that the imidazole moiety of carnosine is important for its antioxidant mechanism.
32
  
Through their studies, they concluded that the proton on the nitrogen in the imidazole ring as 
well as on the carbon directly next to the ring were involved in the antioxidant activity; therefore, 
leaving the imidazole portion of carnosine intact was crucial for the VECAR design.  
 
5.3 VECAR Synthesis and Experimentals 
The synthesis of the chimeric antioxidant vitamin E carnosine is depicted in Scheme 5.1.  
The overall synthesis comprised nine total steps, with seven being linear and had an overall yield 
of 26.1%.  Protocols for several intermediates were based on the prior work of Lei and 
Atkinson.
33
  The introduction of stereochemistry in the molecule arises from the commercially 
available starting material S-Trolox™ (107).  At first, the synthesis of 109 was completed 
following a literature protocol using methanol and p-toluenesulfonic acid to esterify S-Trolox™ 
(107), which led to typical yields of about 50%.
33
  To optimize the conditions for the 
esterification of S-Trolox™ (107), the protocol was changed to use thionyl chloride (108) instead 
of p-toluenesulfonic acid and the yields of 109 were improved to 83-92%.   
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Scheme 5.1 VECAR (106) Synthesis. 
After esterification of S-Trolox™ (107), the addition of the TBDMS protecting group to 
form the ester molecule containing a protected hydroxyl group (110) was high yielding; 91% 
yield was typical after purification.  Reduction of the ester (110) with DIBAL-H generated the 
aldehyde (111.)  The purification of the aldehyde (111) from the ester (110) was not trivial.  The 
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retention of the aldehyde and ester on chromatographic columns is very similar and separation of 
these molecules required gradient elution as well as multiple purifications in some cases.  
Avoiding formation of the ester is the key for improved yields and easier purification and this 
can be accomplished by using DIBAL-H and the aldehyde product free from all water 
contaminants.  After optimization, the aldehyde (111) was synthesized in 77% yield and was 
used subsequently in a Wittig reaction.  In a separate pot, 12-bromododecanoic acid (112) and 
triphenylphosphine (113) were reacted to form the phosphonium salt (114) in high yields, 93.6% 
at optimum.   
The Wittig reaction proceeded as expected and the red ylide (114) solution turned yellow 
upon addition of the aldehyde (111) to form the unsaturated molecule (116) with typical yields of 
about 86%.  The alkene of molecule 117 was reduced using H2 and Pd/C.  This reaction often 
required filtering multiple times through a celite cake, but was still high yielding with typical 
yields above 95%.  The first several attempts to couple carnosine to molecule 117 were 
unsuccessful and this was attributed to the insolubility of carnosine in the reaction solvents that 
were explored (methanol, acetonitrile, THF, and DMF.)  To improve solubility of carnosine, the 
carnosine methyl ester was synthesized (115.)  Thionyl chloride (108) was used to convert 
carnosine (102) to the methyl ester salt (115), which upon addition of Et3N formed the carnosine 
methyl ester (118) in quantitative yields.  The addition of carnosine methyl ester 118 to 117 was 
not a trivial synthetic step.  Multiple attempts using DCC and HOBt to perform the coupling 
were unsuccessful because many impurities were formed and separation from the desired product 
119 was difficult.  The formation of a mixed anhydride using isobutyl chloroformate and NMM 
were also unsuccessful as the desired product was not formed.  Finally, 118 and 117 were 
coupled using HBTU and DMAP yielding the protected VECAR molecule (119) in yields above 
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50%, 60.6% at optimal after purification by reverse phase chromatography.  The protecting 
group was then removed from 119 using TBAF, and after purification by reverse phase 
chromatography, VECAR (106) was obtained in 80.9% yield at optimal. 
 
 (S)-methyl 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylate (109):
27
  
Commercially available S-Trolox™ (Sigma-Aldrich) (107, 3.04 g, 12.1 mmol) was 
dissolved in 25 mL dry methanol.  Triethylamine (2.4 mL, 17.0 mmol) was added to the solution 
and the reaction mixture stirred for 15 minutes at 0°C.  Thionyl chloride (108, 1.06 mL, 14.6 
mmol, 1.2 eq) was added to the mixture and this was stirred at 0°C for 10 additional minutes.  
The solution was refluxed at 70°C for 1 hour.  After completion of the reaction, the solution was 
cooled to room temperature and was purged with nitrogen to remove any thionyl chloride that 
remained.  After solvent evaporation, the brown solid was recrystallized from 75 mL methanol to 
afford white crystals (109, 2.95 g, 92%). 
1
H (CDCl3, 400 MHz) δ 4.31 (br, 1H, OH), 3.69 (s, 3H, 
OCH3), 2.68 (m, 2H), 2.45 (m, 1 H), 2.20 (s, 3H), 2.16 (s, 3H), 2.07 (s, 3H), 1.87 (m, 1H), 1.62 
(s, 3H, CH3).  
13
C NMR (CDCl3, 100MHz) δ 174.53, 145.52, 145.31, 122.56, 121.30, 118.45, 
116.87, 77.03, 52.38, 30.63, 25.45, 20.97, 12.21, 11.84, 11.26.  I  νmax 3527.61, 2989.30, 
2926.84, 1738.34, 1454.75, 1193.27, 1113.77 cm
-1
.  MS (ESI-TOF):  calcd for C15H20NaO4 
(M+Na)
+
:  287.1260; found:  287.1241.  
 
(S)-methyl-6-(tert-butyldimethylsilyloxy)-2,5,7,8-tetramethylchroman-2-carboxylate (110):
33,27
  
Tert-butyldimethylsilyl chloride (1.081g, 7.2mmol) and imidazole (1.339 g, 19.7 mmol) 
was added to a solution of (S)-methyl-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylate 
(109, 1.254 g, 4.7 mmol) in 10 mL dry dimethylformamide (10 mL).  The reaction mixture was 
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stirred under argon in an oil bath for 5 hours at 85°C until no starting material (109) was detected 
by TLC.  The mixture was poured into brine (100 mL) and was extracted with ethyl acetate (4 X 
50 mL).  The organic extracts were combined and dried over magnesium sulfate followed by 
solvent evaporation to afford a light yellow colored oil.  Purification of the crude product was 
completed using column chromatography on silica gel using the mobile phase CH2Cl2:hexane 
(3:1) to yield 1.62 g (91%) white solid product (110.)  
1
H (CDCl3, 400 MHz) δ ppm 3.66 (s, 3H, 
OCH3), 2.57 (m, 2H), 2.44 (m, 1H), 2.15 (s, 3H), 2.11 (s, 3H), 2.02 (s, 3H), 1.88 (m, 1H), 1.60 
(s, 3H), 1.04 (s, 9H), 0.11 (s, 6H). 
13
C NMR (CDCl3, 100MHz) δ ppm 174.55, 145.90, 144.81, 
126.14, 123.48, 122.70, 117.06, 77.02, 52.30, 30.58, 26.11, 25.41, 21.07, 18.62, 14.34, 13.39, 
12.00, -3.28, -3.34. I  νmax 2957.55, 2928.25, 2856.92, 1746.92, 1464.01, 1260.53, 1110.79 cm
-
1
. MS (ESI-TOF):  calcd for C21H34NaO4Si (M+Na)
+
: 401.2124; found 401.2171. 
 
(S)-6-(tert-butyldimethylsilyloxy)-2,5,7,8-tetramethylchroman-2-carbaldehyde (111):
33,27
  
Compound 110 (3.282 g, 8.67 mmol) in 35 mL dry hexane was cooled to -75°C in a dry 
ice/ acetone bath.  Diisobutylaluminum hydride, DIBAL-H, (1.0 M in hexane, 16 mL, 16 mmol) 
was added dropwise through a syringe maintain a temperature below -70°C.  After 2 hours, 25 
mL methanol was added and stirred for 15 minutes.  The reaction vessel was lifted from the dry 
ice/acetone bath and was allowed to slowly warm to -28°C.  Upon warming 15 mL water was 
added to the solution.  The solution was then poured into brine (100 mL) and was extracted with 
hexane/ethyl acetate (2:1) (4 X 100 mL).  After the organic layers were combined and dried over 
magnesium sulfate, the solvent was evaporated.  Purification of the crude product by column 
chromatography using 1:1 to 3:1 CH2Cl2:hexane led to 2.33 g product (111, 77% yield.)  
1
H 
(CDCl3, 400 MHz) δ ppm 9.63 (s, 1H), 2.55 (m, 2H), 2.27 (m, 1H), 2.17 (s, 3H), 2.12 (s, 3H), 
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2.02 (s, 3H), 1.82 (m, 1H), 1.39 (s, 3H), 1.05 (s, 3H), 0.12 (s, 6H).  
13
C NMR (CDCl3, 100MHz) 
δ ppm 204.91, 145.56, 145.13, 126.50, 123.89, 122.84, 117.62, 80.28, 27.93, 26.08, 21.62, 20.49, 
18.60, 14.35, 13.38, 12.06, -3.31, -3.34.  I  νmax 2928.40, 2857.11, 2799.65, 1741.47, 1463.23, 
1255.44, 1101.77, 836.53 cm
-1
. MS (ESI-TOF):  calcd for C20H33O3Si (M+H)
+
:  349.2199; found 
349.2023. 
 
11-carboxyundecyl)triphosphonium bromide (114):
33,27
  
12-bromododecanoic acid (112, 1.66 g, 5.9 mmol) was dissolved in 13 mL dry 
acetonitrile when heated and stirred.  Triphenylphosphine (113, 1.637 g, 6.2 mmol) and 13 mL 
dry acetonitrile were heated and stirred, and this solution was added to the 12-
bromododecanoic/MeCN solution and the reaction mixture was refluxed overnight.  After 
cooling, the solvent was evaporated.  The resulting crystals were dissolved in 14 mL DCM and 
transferred to an Erlenmeyer flask.  Toluene (40 mL) was added to the dissolved crystals and the 
solution was stirred and heated.   After the solution was cooled, the phosphonium salt was 
allowed to slowly crystallize and was removed by filtration, yielding 3.01 g (114, 93.6%.)  
1
H 
NMR (CDCl3, 400 MHz) δ ppm 7.76-7.67 (m, 9H), 7.67-7.27 (m, 6H), 3.56-3.51 (m, 2H), 2.28 
(t, 2H, J = 7.42 Hz), 1.53-1.45 (m, 6H), 1.17-1.11 (m, 12H). 
13
C NMR (CDCl3, 100 MHz) δ ppm 
177.51, 135.11, 135.09, 133.61, 133.51, 130.61, 130.48, 118.60, 117.75, 34.50, 30.37, 30.21, 
29.09, 29.07, 28.97, 28.94, 28.81, 24.73, 22.88, 22.52, 22.48, 22.39. I  νmax 2925.16, 2848.82, 
1715.11, 1436.26, 1113.18 cm
-1
. MS (ESI-TOF):  calcd for C30H39BrO2P (M+H-Br)
+
:  461.2831; 
found 461.2332.  
 
 121 
 
(S,E)-13-(6-(tert-butyldimethylsilyloxy)-2,5,7,8-tetramethylchroman-2-yl)tridec-12-enoic acid 
(116):
33,27 
The phosphonium salt (114) (2.50 g, 11.5 mmol) was dissolved in 40 mL dry THF under 
argon at room temperature.  LiHMDS in THF (1 M in THF, 16.5 mL, 11.5 mmol) was added by 
dropwise addition to the phosphonium salt (114) solution and the red ylide was stirred under 
argon for 2 hours.  A solution of the aldehyde (111, 1.45 g) in 8 mL dry THF was added 
dropwise to the reaction vessel and a color change from red to pale yellow was observed. After 
the suspension was stirred for 3 additional hours, the reaction was quenched with 80 mL 
saturated NH4Cl (aq) and 80 mL water.  Extractions were completed with ethyl acetate, and the 
organic extracts were combined and dried over magnesium sulfate.  After solvent evaporation, 
the crude product was triturated with cold hexane to remove the triphenylphosphine oxide.  Next, 
the hexane was evaporated and the crude product was purified using column chromatography 
with ethyl acetate:hexane (1:1) mobile phase yielding 1.90 g (116, 86%.)  
1
H NMR (CDCl3, 400 
MHz) δ ppm 5.33-5.31 (m, 2H), 2.55-2.53 (m, 2H), 2.36-2.33 (m, 2H), 2.11 (s, 3H), 2.10 (s, 3H), 
2.08-2.01 (m, 2H), 2.04 (s, 3H), 1.65-1.62 (m, 2H), 1.47 (s, 3H), 1.29-1.22 (m, 16H) 1.05 (s, 9 
H), 0.12 (s, 6H).  
13
C NMR (CDCl3, 100MHz) δ ppm 179.99, 146.06, 144.13, 133.26, 132.49, 
125.77, 123.46, 122.42, 117.83, 75.52, 34.04, 33.40, 29.97, 29.54, 29.42, 29.23, 29.05, 27.97, 
27.23, 26.09, 24.67, 21.27, 18.58, 14.34, 13.40, 12.17, -3.35.  I  νmax 2927.02, 2855.11, 1709.96, 
1462.79, 1254.07, 1090.75, 837.25 cm
-1
.  MS (ESI-TOF):  calcd for C32H54O4Si (M)
+
:  
530.3791; found 530.3740.  
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(R)-13-(6-(tert-butyldimethylsilyloxy)-2,5,7,8-tetramethylchroman-2-yl)tridecanoic acid 
(117):
33,27
 
116 (0.95 g, 3.67mmol) was dissolved in 85 mL ethyl acetate, and Pd/C (0.505 g) was 
added.  A syringe connected to a balloon containing hydrogen was added to the reaction vessel 
and was stirred at room temperature for 18 hours.  After the mixture was filtered through a celite 
cake and the solvent evaporated, an oil (117) was collected.  Trace amounts of Pd/C were 
removed by column chromatography using the mobile phase hexane:ethyl acetate (4:1), yielding 
117 (0.91 g 96%.)  
1
H NMR (CDCl3, 400 MHz) δ ppm 2.60 (t, 2H, J= 7.40), 2.40 (t, 2H, J= 
6.28), 2.16 (s, 3H), 2.13 (s, 3H), 2.11 (s, 3H), 1.79-1.92 (m, 2H), 1.59-1.70 (m, 4H), 1.47-1.53 
(m, 2H), 1.32 (br, 16H), 1.28 (s, 3H), 1.11 (s, 9H), 0.18 (s, 6H).  
13
C NMR (CDCl3, 100MHz) δ 
ppm 180.52, 145.97, 144.10, 125.86, 123.52, 122.72, 117.52, 77.31, 39.66, 34.18, 31.60, 30.26, 
29.71, 29.68, 29.52, 29.33, 29.14, 26.18, 24.74, 23.88, 23.70, 20.97, 18.65, 14.39, 13.47, 12.01, -
3.29.  I  νmax 2928.58, 2853.19, 1711.92, 1252.43, 1087.10, 836.06 cm
-1
.  MS (ESI-TOF):  calcd 
for C32H56O4Si (M+H)
+
:  533.4026; found 533.4011.  
 
Carnosine Methyl Ester Dihydrochloride (115):
34,27 
Carnosine (102) (602.9 mg, 2.7 mmol) was suspended in 24 mL anhydrous methanol and 
was cooled to 0°C.  Thionyl chloride (108, 0.25 mL, 3.3 mmol) was added to the reaction by 
dropwise addition and reaction mixture was stirred at 0°C for 10 additional minutes.  Next, the 
solution was heated and refluxed for 1 hour at 75°C.  After the reaction mixture was cooled to 
room temperature, the solvent was evaporated to afford 115 in quantitative yield.  115 was 
utilized in the next step without subsequent purification.  
1
H NMR ((CD3)2SO) δ 9.04 (s, 1H), 
8.89-8.87 (d, 1 H), 8.09 (br, 3H), 7.49, (s, 1H), 4.62-4.56 (m, 1H), 3.65 (s, 3H), 3.19-3.05 (m, 
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2H), 2.92 (br, 2H), 2.57 (t, 2H, J= 6.82).  
13C NM  (DMSO, 100MHz) δ ppm 171.36, 170.15, 
134.06, 129.33, 117.50, 52.71, 52.01, 35.38, 32.31, 26.23.  I  νmax 3417.02, 3138.25, 1737.08, 
1660.26, 1624.71.  MS (ESI-TOF):  calcd for C10H17ClN4O3 (M-H)
+
:  275.0911; found 
275.0912. 
 
(R)-methyl-2-(3-(13-((R)-6-((tert-butyldimethylsilyl)oxy)-2,5,7,8-tetramethylchroman-2-
yl)tridecanamido)propanamido)-3-(1H-imidazol-4-yl)propanoate (119):
35,36,37,38,27
  
117 (840 mg, 1.59 mmol), carnosine-methyl ester hydrochloride (115) (662 mg, 2.39 
mmol), DMAP (19 mg, 0.16 mmol), and triethylamine (1.67 mL, 5 eq) were added to 13.4 mL 
anhydrous DMF.  After the reaction solution was cooled to 0°C, HBTU (721 mg, 1.9 mmol) 
dissolved in anhydrous 3 mL DMF was added drop wise.  The reaction mixture was stirred at 
0°C for an additional 20 minutes and was then allowed to slowly warm to room temperature 
where it was allowed to stir overnight.  After solvent evaporation under high vacuum, the crude 
product was dissolved in chloroform and washed with water.  The organic layer was collected 
and the solvent was evaporated.  Purification of the crude product was completed using 300 Å 
reverse phase silica gel (C18).  The C18 was prepared by taking 100 mg silica gel and suspending 
it in 500 mL toluene.  Octadecyltrichlorosilane (C18, 21 ml, 0.52 mol) was added to the 
suspension drop wise.  After 10 min, triethylamine (28 ml, 4 equiv.) was added and the 
suspension was refluxed at 125°C for 24 hours.  Next, toluene (1 L), DCM (1 L), ethyl acetate (1 
L), and methanol (4 L) were used to wash the synthesized C18 silica.  Finally, the C18 reversed 
phase silica was dried under high vacuum.  Chromatography using the C18 reversed phase silica 
and a methanol:water (7:3) mobile phase afforded 119 (0.62 g, 60.6%).  
1H NM  (MeOD) δ 7.58 
(s, 1H), 6.87 (s, 1H), 4.69-4.66 (m, 1H), 3.72 (s, 3H), 3.41-3.37 (m, 2H), 3.12-2.96 (m, 2H), 2.54 
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(t, 2H, J = 6.62 Hz), 2.41 (t, 2H, J = 6.66 Hz), 2.15 (t, 2H, J = 7.60 Hz), 2.07 (s, 3H), 2.03 (s, 3H; 
s, 3H), 1.82-1.71 (m, 2H), 1.57 (m, 3H), 1.44 (m, 3H), 1.26 (br, 16H), 1.20 (s, 3H), 1.04 (s, 9H), 
0.10 (s, 6H).  
13C NM  (MeOD, 100MHz) δ ppm  176.30, 173.64, 173.46, 147.22, 145.32, 
136.37, 126.56, 124.42, 123.52, 118.68, 75.51, 54.10, 52.76, 40.31, 37.11, 36.82, 36.36, 32.81, 
31.20, 30.74, 30.63, 30.46, 30.33, 26.94, 26.68, 24.57, 24.22, 21.84, 19.50, 14.86, 13.91, 12.26, -
3.07.  I  νmax 3446.06, 2927.19, 2854.43, 1733.62, 1716.69, 1683.57, 1652.84, 1646.99, 
1256.82, 1090.42, 837.37 cm
-1
.  MS (ESI-TOF):  calcd for C42H70N4O6Si (M+H)
+
:  755.5134; 
found 755.5127. 
 
(R)-methyl-2-(3-(13-((R)-6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)tridecanamido) 
propanamido)-3-(1H-imidazol-4-yl)propanoate, VECAR (106):
27
 
119 (255 mg) was dissolved in 10 mL dry THF.  TBAF (2.9 mL of a 1 M THF solution) 
was added drop wise via a syringe and the solution was stirred at room temperature for 1.5 hours. 
After the THF was evaporated, the crude product was taken up in 200 mL chloroform and the 
solution was washed three times with water.  The crude product was purified using column 
chromatography on 60 Å reverse phase silica gel by gradient elution with methanol:water 
(30/70) and methanol:water:ammonium hydroxide (8:1:1) as the mobile phases. The first two 
fractions eluted were impurities and finally the pure VECAR was obtained in the last fraction, 
yielding 106 (175 mg, 80.9%.)  
1H (MeOD, 400 MHz) δ 7.68 (s, 1H), 6.89 (s, 1H), 4.69-4.65 (m, 
1H), 3.69 (s, 3H), 3.39-3.34 (m, 2H), 3.12-2.95 (m, 2H), 2.57 (t, 2H, J = 6.9Hz), 2.39 (t, 2H, J = 
6.7Hz), 2.14 (t, 2H, J = 3.6Hz), 2.11 (s, 3H), 2.07 (s, 3H), 2.03 (s, 3H), 1.79-1.72 (m, 2H), 1.59-
1.53 (m, 3H), 1.43-1.39 (m, 3H), 1.27-1.26 (br, 16H), 1.19 (s, 3H).  
13
C NMR (MeOD, 100MHz) 
δ ppm 176.43, 173.70, 173.36, 146.74, 136.25, 124.42, 122.99, 122.06, 118.26, 75.42, 53.99, 
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52.81, 40.22, 37.11, 36.85, 36.38, 32.99, 31.21, 30.71, 30.61,30.44, 30.31, 29.87, 26.96, 24.58, 
24.15, 21.77, 12.80, 12.02, 11.83.  I  νmax 3445.78, 2962.90, 2928.89, 2854.65, 1733.63, 
1652.73, 1646.86, 1260.60, 1083.82, 844.71 cm
-1
. MS (ESI-TOF):  calcd for C36H56N4O6 
(M+H)
+
: 641.4278; found 641.4293. 
 
VECAR (106) Antioxidant Activity: 
The antioxidant activity of VECAR was 
examined in vitro using a 1,1-diphenyl-2-
picrylhydrazyl (DPPH) assay.  DPPH (120) is a 
molecule containing a stable free radical and this 
stability allows for its use in assays (Figure 5.6.)
39
  To 
determine antioxidant performance, the ability of an 
antioxidant to scavenge the free radical of DPPH is 
analyzed spectroscopically.  The purple DPPH radical turns to pale yellow when the radical is 
quenched.  The antioxidant activity of VECAR was studied by Astete following a protocol 
employed by Luo and co-workers.
27,28
  Here, a 0.4 mM DPPH in methanol stock solution was 
prepared and stored at -20°C in the absence of light.  An acetic acid in water mixture was used to 
dilute the sample to 1 mL maintaining a pH of 3.5.  The sample was then added to the diluted 
DPPH solution attaining 0.1 mM DPPH and a 2 mL total sample volume, keeping the ratio of 
water to methanol at 1/1 v/v.  Pure methanol and 1 mL water (pH = 3.5) were used to prepare the 
blank and the controls were made using 1 mL DPPH/methanol solution and 1 mL water (pH = 
3.5.)  After equilibrating for 30 mins, the absorptions of solutions at five different concentrations 
(0.01, 0.0125, 0.015, 0.02, and 0.025 mM) were taken at 518 nm in triplicate using a Geminys 6 
 
 
Figure 5.6 The structure of DPPH 
(120). 
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spectrophotometer (Thermo Scientific, Waltham, MA).  The percent inhibition was calculated 
according to Eq. 5.1. 
                                                             
Abscontrol – Abssample
Abscontrol
                       Eq. 5.1 
 A plot of the inhibition percentages versus the concentration of the antioxidant sample is 
shown in Figure 5.7 and the linear regressions were used to determine the moment that 50% 
DPPH was reduced by the antioxidant (the IC50 value.)  It was determined that the IC50 values for 
VECAR (106) and α-tocopherol (93) were 24.9±1.4 μM and 24.4±1.5 μM respectively.  These 
values for VECAR (106) and α-tocopherol (93) are essentially identical and verify that there was 
no loss of antioxidant activity in vitro.  The retention of antioxidant activity shown by the DPPH 
assay was expected because the main component of vitamin E carnosine (106) is α-tocopherol 
(93) and both molecules contain the free hydroxyl functional group that is able to function as an 
antioxidant.  To test whether the antioxidant activity is improved in LDLs by the addition of the 
carnosine moiety, studies will be performed in vivo. 
 
Figure 5.7 DPPH Assay used to determine the inhibition values. 
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5.4 VECAR Conclusion 
A chimeric antioxidant, vitamin E carnosine (106), was successfully designed and 
synthesized, and its antioxidant activity was compared to α-toc in vitro.  Three important regions 
were accounted for in the VECAR design; the chromanol ring, the phytyl tail, and the 
hydrophilic tail end.  Two essential design features were to keep the chromanol ring intact and to 
use a 12 carbon tail to maintain the key regions of recognition by α-TTP.  To accomplish this, 9 
total, 7 linear synthetic steps were required.  In the first synthetic step, thionyl chloride was used 
to convert the carboxylic acid of commercially available S-Trolox (107) to the methyl ester in 
92% yield.  Tert-Butyldimethylsilyl chloride (TBDMS-Cl) was used to protect the hydroxyl 
group of compound 107 in 91% yield.  The resulting ester (109) was reduced to the aldehyde 
(111) in 77% yield using diisobutylaluminum hydride (DIBAL-H).  Triphenylphosphine (113) 
and 12-bromododecanoic acid (112) were refluxed to form the phosphonium salt (114, 93.6% 
yield) for the Wittig reaction with compound 116 (86% yield).  H2 in the presence of Pd/C was 
used to hydrogenate the alkene resulting in 117 in 96% yield.  After several failed attempts to 
attach carnosine directly to the carboxylic acid end of compound 117, it was determined that the 
carnosine methyl ester (118) should be formed.  Carnosine (102) was converted to the methyl 
ester salt (115) in quantitative yields using thionyl chloride.  After the addition of triethylamine, 
the carnosine methyl ester (118), which was more soluble in the coupling reaction than the prior 
acid moiety was coupled to 117 using HBTU to generate compound 119 in 60.6% yield.  The 
TBDMS protecting group of 119 was removed to yield the final product, VECAR (106), in 
80.9% yield (26.1% overall yield) using TBAF.  The final product (106) was studied using a 
DPPH assay which showed that  ECA  and α-toc had nearly identical antioxidant activities, 
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and therefore, it was determined that there was no loss of antioxidant activity of the chimeric 
molecule in vitro. 
 
5.5 VECAR Future Work 
Further studies will be completed to examine the antioxidant activity of VECAR (106.)  
At this time, only a DPPH assay was used to determine if the antioxidant activity of VECAR 
through the chromanol ring was maintained in comparison to α-tocopherol.  While this is 
important to show that there is no loss in antioxidant activity, the efficacy of the α-tocopherol 
transport system needs to be studied in biological systems.  In vivo studies will be used to 
compare the uptake and bioavailability of  ECA  to α-toc using an animal model.  Once 
accessibility of VECAR in an animal model is shown, further results on its utility in prevention 
of atherosclerosis and other diseases caused by oxidative damage will be acquired.  
 
5.6 References 
1. World Health Organization, W. H. O. Global action plan for the prevention and control of 
noncommunicable diseases 2013-2020. 
http://www.who.int/iris/handle/10665/94384#sthash.1ddcKrsp.dpuf. 
 
2. Psarros, C.; Lee, R.; Margaritis, M.; Antoniades, C., Nanomedicine for the prevention, 
treatment and imaging of atherosclerosis. Maturitas 2012, 73, 52-60. 
 
3. Halliwell, B., Oxidative stress and neurodegeneration: where are we now? J. Neurochem. 
2006, 97, 1634-1658. 
 
4. Young, I. S.; Woodside, J. V., Antioxidants in health and disease. J Clin Pathol 2001, 54, 
176-86. 
 
5. Cai, A.; Zheng, D.; Qiu, R.; Mai, W.; Zhou, Y., Lipoprotein-associated phospholipase A2 
(Lp-PLA(2)): a novel and promising biomarker for cardiovascular risks assessment. Dis Markers 
2013, 34, 323-31. 
 129 
 
6. Yuan, X. M.; Brunk, U. T.; Olsson, A. G., Effects of Iron- and Hemoglobin-Loaded 
Human Monocyte–Derived Macrophages on Oxidation and Uptake of LDL. Arteriosclerosis, 
Thrombosis, and Vascular Biology 1995, 15 (9), 1345-1351. 
 
7. Ursini, F.; Davies, K. J. A.; Maiorino, M.; Parasassi, T.; Sevanian, A., Atherosclerosis: 
another protein misfolding disease? Trends in Molecular Medicine 2002, 8 (8), 370-374. 
 
8. Morel, D.; DiCorleto, P.; Chisolm, G., Endothelial and smooth muscle cells alter low 
density lipoprotein in vitro by free radical oxidation. Arteriosclerosis, Thrombosis, and Vascular 
Biology 1984, 4 (4), 357-364. 
 
9. Esterbauer, H.; Dieber-Rotheneder, M.; Striegl, G.; Waeg, G., Role of vitamin E in 
preventing the oxidation of low-density lipoprotein. The American Journal of Clinical Nutrition 
1991, 53 (1), 314S-321S. 
 
10. Theriault, A.; Chao, J.-T.; Wang, Q.; Gapor, A.; Adeli, K., Tocotrienol: a review of its 
therapeutic potential. Clin. Biochem. 1999, 32, 309-319. 
 
11. Shetti, N.; Patil, R., Antioxidants: its beneficial role against health damaging free radical. 
World J. Sci. Technol. 2011, 1, 46-51. 
 
12. Moure, A.; Cruz, J. M.; Franco, D.; Dom  nguez, J. M.; Sineiro, J.; Dom  nguez, H.; José 
Núñez, M. a.; Parajó, J. C., Natural antioxidants from residual sources. Food Chemistry 2001, 72 
(2), 145-171. 
 
13. Zhang, W.; Frahm, G.; Morley, S.; Manor, D.; Atkinson, J., Effect of Bilayer 
Phospholipid Composition and Curvature on Ligand Transfer by the α-Tocopherol Transfer 
Protein. Lipids 2009, 44 (7), 631-641. 
 
14. Blatt, D. H.; Leonard, S. W.; Traber, M. G., Vitamin e kinetics and the function of 
tocopherol regulatory proteins. Nutrition 2001, 17 (10), 799-805. 
 
15. Noguchi, N.; Niki, E., [51] Apolipoprotein B protein oxidation in low-density 
lipoproteins. In Methods in Enzymology, Lester, P., Ed. Academic Press: 1994; Vol. Volume 
233, pp 490-494. 
 
16. Fuller, C. J.; Agil, A.; Lender, D.; Jialal, I., Superoxide production and LDL oxidation by 
diabetic neutrophils. J Diabetes Complications 1996, 10, 206-10. 
 
17. Mashima, R.; Yoshimura, S.; Yamamoto, Y., Reduction of Lipid Hydroperoxides by 
Apolipoprotein B-100. Biochem. Biophys. Res. Commun. 1999, 259, 185-189. 
 
18. McClements, D. J.; Decker, E. A., Lipid Oxidation in Oil-in-Water Emulsions: Impact of 
Molecular Environment on Chemical Reactions in Heterogeneous Food Systems. Journal of 
Food Science 2000, 65 (8), 1270-1282. 
 130 
 
19. Mishra, R.; Bisht, S. S., Antioxidants and their charecterization. J. Pharm. Res. 2011, 4, 
2744-2746. 
 
20. Rehman, A.; Collis, C. S.; Yang, M.; Kelly, M.; Diplock, A. T.; Halliwell, B.; Rice-
Evans, C., The effects of iron and vitamin C co-supplementation on oxidative damage to DNA in 
healthy volunteers. Biochem. Biophys. Res. Commun. 1998, 246, 293-298. 
 
21. Cooke, M. S.; Evans, M. D.; Mistry, N.; Lunec, J., Role of dietary antioxidants in the 
prevention of in vivo oxidative DNA damage. Nutr. Res. Rev. 2002, 15, 19-41. 
 
22. Chen, W.; Park, S. K.; Yu, W.; Xiong, A.; Sanders, B. G.; Kline, K., Synthesis and 
screening of novel vitamin E derivatives for anticancer functions. European Journal of 
Medicinal Chemistry 2012, 58 (0), 72-83. 
 
23. Takata, J.; Hidaka, R.; Yamasaki, A.; Hattori, A.; Fukushima, T.; Tanabe, M.; 
Matsunaga, K.; Karube, Y.; Imai, K., Novel d-γ-tocopherol derivative as a prodrug for d-γ-
tocopherol and a two-step prodrug for S-γ-CEHC. Journal of Lipid Research 2002, 43 (12), 
2196-2204. 
 
24. Elnagar, A. Y.; Wali, V. B.; Sylvester, P. W.; El Sayed, K. A., Design and preliminary 
structure-activity relationship of redox-silent semisynthetic tocotrienol analogues as inhibitors 
for breast cancer proliferation and invasion. Bioorg Med Chem 2010, 18 (2), 755-68. 
 
25. Ogata, K.; Nakao, H. C. T. Tocopherol derivatives. EP683164A1, 1995. 
 
26. Meier, R.; Tomizaki, T.; Schulze-Briese, C.; Baumann, U.; Stocker, A., The Molecular 
Basis of  itamin E  etention: Structure of Human α-Tocopherol Transfer Protein. Journal of 
Molecular Biology 2003, 331 (3), 725-734. 
 
27. Astete, C. E.; Songe Meador, D.; Spivak, D.; Sabliov, C., Synthesis of Vitamin E-
Carnosine (Vecar): New Antioxidant Molecule with Potential Application in Atherosclerosis. 
Synthetic Communications 2012. 
 
28. Luo, X.-D.; Basile, M. J.; Kennelly, E. J., Polyphenolic Antioxidants from the Fruits of 
Chrysophyllum cainito L. (Star Apple). J. Agric. Food Chem. 2002, 50, 1379-1382. 
 
29. Diplock, A. T.; Xu, G.; Yeow, C.; Okikiola, M., Relationship of tocopherol structure to 
biological activity, tissue uptake, and prostaglandin biosynthesis. Ann. N. Y. Acad. Sci. 1989, 
570, 72-84. 
 
30. Ingold, K. U.; Burton, G. W.; Foster, D. O.; Hughes, L., Is methyl-branching in α-
tocopherol's tail important for its in vivo activity? Rat curative myopathy bioassay measurements 
of the vitamin E activity of three 2RS-n-alkyl-2,5,7,8-tetramethyl-6-hydroxychromans. Free 
Radical Biol. Med. 1990, 9, 205-10. 
 
 131 
 
31. West, R.; Panagabko, C.; Atkinson, J., Synthesis and Characterization of BODIPY-α-
Tocopherol: A Fluorescent Form of Vitamin E. J. Org. Chem. 2010, 75, 2883-2892. 
 
32. Kohen, R.; Yamamoto, Y.; Cundy, K. C.; Ames, B. N., Antioxidant activity of carnosine, 
homocarnosine, and anserine present in muscle and brain. Proc. Natl. Acad. Sci. U. S. A. 1988, 
85, 3175-3179. 
 
33. Lei, H.; Atkinson, J., Synthesis of Phytyl- and Chroman-Derivatized Photoaffinity Labels 
Based on α-Tocopherol. J. Org. Chem. 2000, 65, 2560-2567. 
 
34. Abdo, M.-R.; Joseph, P.; Boigegrain, R.-A.; Liautard, J.-P.; Montero, J.-L.; Koehler, S.; 
Winum, J.-Y., Brucella suis histidinol dehydrogenase: Synthesis and inhibition studies of a series 
of substituted benzylic ketones derived from histidine. Bioorg. Med. Chem. 2007, 15, 4427-4433. 
 
35. Zhao, M.; Bi, L.; Bi, W.; Wang, C.; Yang, Z.; Ju, J.; Peng, S., Synthesis of new class 
dipeptide analogues with improved permeability and antithrombotic activity. Bioorg. Med. 
Chem. 2006, 14, 4761-4774. 
 
36. Wu, G.; Liu, J.; Bi, L.; Zhao, M.; Wang, C.; Baudy-Floc'h, M.; Ju, J.; Peng, S., Toward 
breast cancer resistance protein (BCRP) inhibitors: design, synthesis of a series of new simplified 
fumitremorgin C analogues. Tetrahedron 2007, 63, 5510-5528. 
 
37. Montalbetti, C. A. G. N.; Falque, V., Amide bond formation and peptide coupling. 
Tetrahedron 2005, 61, 10827-10852. 
 
38. Sudo, Y.; Wada, T., Characteristics of octadecylsilylated silica gels end-capped by high-
temperature silylation. Journal of Chromatography A 1998, 813 (2), 239-246. 
 
39. Apak, R.; Gorinstein, S.; Bohm, V.; Schaich, K. M.; Ozyurek, M.; Guclu, K., Methods of 
measurement and evaluation of natural antioxidant capacity/activity (IUPAC Technical Report). 
Pure Appl. Chem. 2013, 85, 957-998. 
 
 
 
 
 
 
 
 
 
 
 132 
 
APPENDIX A: SPECTRA FOR CHAPTER TWO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1: 2-methacrylamidoethyl methacrylate (NOBE (1)) 
1
H NMR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2: 2-methacrylamidoethyl methacrylate (NOBE (1)) 
13
C NMR. 
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Figure A3: 2-acrylamidoethyl acrylate (13) 
1
H NMR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A4: 2-acrylamidoethyl acrylate (13) 
13
C NMR. 
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Figure A5: 2-acrylamidoethyl methacrylate (14) 
1
H NMR. 
 
 
 
 
 
 
 
 
 
 
Figure A6: 2-acrylamidoethyl methacrylate (14) 
13
C NMR. 
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Figure A7: 1,3-dimethacrylamidopropan-2-yl methacrylate (17) 
1
H NMR. 
 
 
 
 
 
 
 
 
 
 
Figure A8: 1,3-dimethacrylamidopropan-2-yl methacrylate (17) 
13
C NMR. 
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Figure A9: 1,3-dimethacrylamidopropan-2-yl methacrylate (17) IR. 
 
 
 
 
 
 
 
 
 
Figure A10: (S)-di-tert-butyl (3-hydroxypropane-1,2-diyl)dicarbamate (26) 
1
H NMR. 
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Figure A11: (S)-di-tert-butyl (3-hydroxypropane-1,2-diyl)dicarbamate (26) 
13
C NMR. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A12: (S)-2,3-diaminopropan-1-ol (27) 
1
H NMR. 
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Figure A13: (S)-2,3-diaminopropan-1-ol (27) 
13
C NMR. 
 
 
 
 
 
 
 
 
 
 
Figure A14: (S)-2,3-dimethacrylamidopropyl methacrylate (18) 
1
H NMR. 
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Figure A15: (S)-2,3-dimethacrylamidopropyl methacrylate (18) 
13
C NMR. 
 
 
 
 
 
 
 
 
 
 
 
Figure A16: 2-(2-bromoacrylamido)ethyl 2-bromoacrylate (19) 
1
H NMR. 
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Figure A17: 2-(2-bromoacrylamido)ethyl 2-bromoacrylate (19) 
13
C NMR. 
 
 
 
 
 
 
 
 
 
 
 
Figure A18: N-(3-methyl-2-oxobut-3-en-1-yl)methacrylamide (NAG (12)) 
1
H NMR. 
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Figure A19: N-(3-methyl-2-oxobut-3-en-1-yl)methacrylamide (NAG (12)) 
13
C NMR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A20: (4R,5R)-2-methoxy-2,4,5-trimethyl-1,3-dioxolane (35) 
1
H NMR. 
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Figure A21: (4R,5R)-2-methoxy-2,4,5-trimethyl-1,3-dioxolane (35) 
13
C NMR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A22: (2R,3S)-3-azidobutan-2-yl acetate (37) 
1
H NMR. 
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Figure A23: (2R,3S)-3-azidobutan-2-yl acetate (37) 
13
C NMR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A24: (2R,3S)-3-methacrylamidobutan-2-yl methacrylate (20) 
1
H NMR. 
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Figure A25: (2R,3S)-3-methacrylamidobutan-2-yl methacrylate (20) 
13
C NMR. 
 
 
 
Figure A26: (2R,3S)-3-methacrylamidobutan-2-yl methacrylate (20) IR. 
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Chromatograms.  The following chromatograms of the selected were analyzed at different chart 
speeds making them appear to be different sizes; however, all chromatograms were normalized 
in size with respect to time using the void volume (Dv.) 
 
 
 
Figure A27: Acetone used to determine DV for OMNiMIPs synthesized with NOBE (1.) 
 
Figure A28: 1 mM L-BOC-Tyr on the OMNiMIP synthesized from NOBE (1.) 
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Figure A29: 1 mM D-BOC-Tyr on the OMNiMIP synthesized from NOBE (1.) 
 
 
 
 
 
 
 
 
 
 
 
Figure A30: Acetone used to determine DV for OMNiMIPs synthesized with 2-acrylamidoethyl 
acrylate (13.) 
 
 
 
 
 
 
 
 
 
 
Figure A31: 1 mM L-BOC-Tyr on the OMNiMIP synthesized from 2-acrylamidoethyl acrylate 
(13.) 
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Figure A32: 1 mM D-BOC-Tyr on the OMNiMIP synthesized from 2-acrylamidoethyl acrylate 
(13.) 
 
 
 
Figure A33: Acetone used to determine DV for OMNiMIPs synthesized with 2-acrylamidoethyl 
methacrylate (14.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A34: 1 mM L-BOC-Tyr on the OMNiMIP synthesized from 2-acrylamidoethyl 
methacrylate (14.) 
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Figure A35: 1 mM D-BOC-Tyr on the OMNiMIP synthesized from 2-acrylamidoethyl 
methacrylate (14.) 
 
 
Figure A36: Acetone used to determine DV for OMNiMIPs synthesized with 1,3-
dimethacrylamidopropan-2-yl methacrylate (17.) 
 
 
 
Figure A37: 1 mM L-BOC-Tyr on the OMNiMIP synthesized from 1,3-
dimethacrylamidopropan-2-yl methacrylate (17.) 
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Figure A38: 1mM D-BOC-Tyr on the OMNiMIP synthesized from 1,3-
dimethacrylamidopropan-2-yl methacrylate (17.) 
 
 
 
Figure A39: 1mM L-BOC-Tyr on the OMNiMIP synthesized from BrOBE (19) (DV = 3.0.) 
 
 
 
Figure A40: 1mM D-BOC-Tyr on the OMNiMIP synthesized from BrOBE (19) (DV = 3.0.) 
 
 150 
 
 
Figure A41: Acetone used to determine DV (0.1 mL/min) for OMNiMIPs synthesized with NAG 
(12.) 
 
 
 
 
Figure A42: 1 mM L-BOC-Tyr (0.1 mL/min) on the OMNiMIP synthesized from NAG (12.) 
 
 
 
 
 
 
Figure A43: 1 mM D-BOC-Tyr (0.1 mL/min) on the OMNiMIP synthesized from NAG (12.) 
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Figure A44: Acetone used to determine DV (0.2 mL/min) for OMNiMIPs synthesized with NAG 
(12.) 
 
 
 
 
Figure A45: 0.5 mM L-BOC-Tyr (0.2 mL/min) on the OMNiMIP synthesized from NAG (12.) 
 
 
 
Figure A46: 0.5 mM D-BOC-Tyr (0.2 mL/min) on the OMNiMIP synthesized from NAG (12.) 
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APPENDIX B: SPECTRA FOR CHAPTER THREE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B1: 2-methacrylamido-3-methoxy-3-oxopropyl methacrylate (NOS Step 1) 
1
H NMR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B2: 2-methacrylamido-3-methoxy-3-oxopropyl methacrylate (NOS Step 1) 
13
C NMR. 
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Figure B3: 2-methacrylamido-3-methoxy-3-oxopropyl methacrylate (NOS Step 1) IR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B4: 2-methacrylamido-3-(methacryloyloxy)propanoic acid (NOS) 
1
H NMR. 
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Figure B5: 2-methacrylamido-3-(methacryloyloxy)propanoic acid (NOS) 
13
C NMR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B6: 2-methacrylamido-3-(methacryloyloxy)propanoic acid (NOS) IR. 
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Figure B7: S-alaninol 
1
H NMR. 
 
 
 
 
 
 
 
 
 
 
 
Figure B8: S-alaninol 
13
C NMR. 
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Figure B9: (S)-2-methacrylamidopropyl methacrylate (L-NALA) 
1
H NMR. 
 
 
 
 
 
 
 
 
 
 
 
Figure B10: (S)-2-methacrylamidopropyl methacrylate (L-NALA) 
13
C NMR. 
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Figure B11: L-BOC-Tyrosine in 100% MeCN 
1
H NMR. 
 
Figure B12: D-BOC-Tyrosine in 100% MeCN 
1
H NMR. 
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Figure B13: Racemic-BOC-Tyrosine in 100% MeCN 
1
H NMR. 
 
Figure B14: L-BOC-Tyrosine in 99% MeCN 1% AcOH 
1
H NMR. 
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Figure B15: D-BOC-Tyrosine in 99% MeCN 1% AcOH 
1
H NMR. 
 
Figure B16: Racemic-BOC-Tyrosine in 99% MeCN 1% AcOH 
1
H NMR. 
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Figure B17: L-NALA in MeCN 
1
H NMR. 
 
Figure B18: D-NALA in MeCN 
1
H NMR. 
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Figure B19: L-NALA and L-BOC-Tyr (1:1) in MeCN 
1
H NMR. 
 
Figure B20: L-NALA and D-BOC-Tyr (1:1) in MeCN 
1
H NMR. 
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Figure B21: L-NALA and L-BOC-Tyr (1:2) in MeCN 
1
H NMR 
 
Figure B22: L-NALA and D-BOC-Tyr (1:2) in MeCN 
1
H NMR. 
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Chromatograms.  The following chromatograms of the selected were analyzed at different chart 
speeds making them appear to be different sizes; however, all chromatograms were normalized 
in size with respect to time using the void volume (Dv.) 
 
Figure B23: 1 mM S,S 1,2-diphenyl ethylene-diamine onthe OMNiMIP synthesized from NOS. 
 
 
Figure B24: 1 mM R,R 1,2-diphenyl ethylene-diamine onthe OMNiMIP synthesized from NOS. 
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Figure B25: Acetone used to determine DV (100 x 2.1 mm column) for OMNiMIPs synthesized 
with L-NALA (9.) 
 
 
Figure B26: 1 mM L-BOC-Tyr on the OMNiMIP (100 x 2.1 mm column) synthesized with L-
NALA (9.) 
 
 
Figure B27: 1 mM D-BOC-Tyr on the OMNiMIP (100 x 2.1 mm column) synthesized with L-
NALA (9.) 
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Figure B28: 0.5 mM racemic-BOC-Tyr on the OMNiMIP (100 x 2.1 mm column) synthesized 
with L-NALA (9.) 
 
 
Figure B29: Acetone used to determine DV (250 x 2.1 mm column) for OMNiMIPs synthesized 
with L-NALA (9.) 
 
 
 
Figure B30: 1 mM L-BOC-Tyr on the OMNiMIP (250 x 2.1 mm column) synthesized with L-
NALA (9.) 
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Figure B31: 1 mM D-BOC-Tyr on the OMNiMIP (250 x 2.1 mm column) synthesized with L-
NALA (9.) 
 
 
Figure B32: 1 mM racemic-BOC-Tyr on the OMNiMIP (250 x 2.1 mm column) synthesized 
with L-NALA (9.) 
 
 
Figure B33: Acetone used to determine DV (50 x 4.1 mm column) for OMNiMIPs synthesized 
with L-NALA (9.) 
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Figure B34: 1 mM L-BOC-Tyr on the OMNiMIP (50 x 4.1 mm column) synthesized with L-
NALA (9.) 
 
 
Figure B35: 1 mM D-BOC-Tyr on the OMNiMIP (50 x 4.1 mm column) synthesized with L-
NALA (9.) 
 
 
Figure B36: 1 mM racemic-BOC-Tyr on the OMNiMIP (50 x 4.1 mm column) synthesized with 
L-NALA (9.) 
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APPENDIX C: CHROMATOGRAMS FOR CHAPTER FOUR 
Select chromatograms reprinted with permission from Organic Letters 2014 16 (5), 1402-1405.  
Copyright 2014 American Chemical Society. 
Acetone on the 20% R-BOC-Tyr imprinted column (Dv = 3.61.) 
 
Acetone on the 20% S-BOC-Tyr imprinted column (Dv = 3.23.) 
 
Figure C1: Void volume (Dv) determined by acetone. 
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Chromatograms.  The following figures compare the chromatograms of selected analytes from 
the list in Table 1 on the DuoMIPs.  In some cases, the chromatograms were analyzed at 
different chart speeds making them appear to be different sizes; however, all chromatograms 
were normalized in size with respect to time and calibrated to the red line. 
2.5 mM S-BOC-Tyr (7a) on the 20% R-BOC-Tyr imprinted column (Dv = 3.61) 
 
 
 
 
 
 
 
 
 
 
 
2.5 mM S-BOC-Tyr (7a) on the 20% S-BOC-Tyr imprinted column (Dv = 3.23) 
 
 
 
 
 
 
 
 
 
Figure C2:  S-BOC-Tyr (7a) on the DuoMIPs. 
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2.5 mM R-BOC-Tyr (7b) on the 20% R-BOC-Tyr imprinted column (Dv = 3.61) 
 
 
 
 
 
 
 
 
2.5 mM R-BOC-Tyr (7b) on the 20% S-BOC-Tyr imprinted column (Dv = 3.23) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C3:  R-BOC-Tyr (7b) on the DuoMIPs. 
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Important Note:  Although the retention time on the R-MIP is higher, the k’ of the analyte on the 
S-MIP is higher, as shown in Table 1.  This is due to the difference in dead volume values.  Thus, 
AC is still accurately accounted for. 
1 mM S-Z-Phe (75a) on the 20% R-BOC-Tyr imprinted column (Dv = 3.61) 
 
 
 
 
 
 
 
1 mM S-Z-Phe (75a) on the 20% S-BOC-Tyr imprinted column (Dv = 3.23) 
 
 
 
 
 
 
 
 
 
 
Figure C4:  S-Z-Phe (75a) on the DuoMIPs. 
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1 mM R-Z-Phe (75b) on the 20% R-BOC-Tyr imprinted column (Dv = 3.61) 
 
 
1 mM R-Z-Phe (75b) on the 20% S-BOC-Tyr imprinted column (Dv = 3.23) 
 
 
 
 
 
Figure C5:  R-Z-Phe (75b) on the DuoMIPs. 
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0.2 mM S-Z-Trp (76a) on the 20% R-BOC-Tyr imprinted column (Dv = 3.61) 
 
 
 
 
 
 
 
 
 
 
0.2 mM S-Z-Trp (76a) on the 20% S-BOC-Tyr imprinted column (Dv = 3.23) 
 
 
 
 
Figure C6:  S-Z-Trp (76a) on the DuoMIPs. 
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Important Note:  Although the retention time on the R-MIP is higher, the k’ values of the analyte 
on both DuoMIPs are the same, as shown in Table 1.  This is due to the difference in dead 
volume values.  Thus, AC cannot be determined for this analyte. 
1 mM S-Z-Ser (77a) on the 20% R-BOC-Tyr imprinted column (Dv = 3.61)  
 
 
 
 
 
 
 
 
 
1 mM S-Z-Ser (77a) on the 20% S-BOC-Tyr imprinted column (Dv = 3.23) 
 
 
 
 
 
 
 
 
Figure C7:  S-Z-Ser (77a) on the DuoMIPs. 
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Important Note:  Although the retention time on the R-MIP is higher, the k’ values of the analyte 
on both DuoMIPs are the same, as shown in Table 1.  This is due to the difference in dead 
volume values.  Thus, AC cannot be determined for this analyte. 
 
1 mM R-Z-Ser (77b) on the 20% R-BOC-Tyr imprinted column (Dv = 3.61) 
 
1  mM R-Z-Ser (77b) on the 20% S-BOC-Tyr imprinted column (Dv = 3.23) 
 
 
 
 
 
 
 
 
 
Figure C8:  R-Z-Ser (77b) on the DuoMIPs. 
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1.0 mM S-phenyl-glycinol (78) on the 20% R-BOC-Tyr imprinted column (Dv = 3.61) 
 
 
 
 
 
 
 
 
1.0 mM S-phenyl-glycinol (78) on the 20% S-BOC-Tyr imprinted column (Dv = 3.23) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C9:  S-phenyl glycinol (78) on the DuoMIPs. 
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Important Note:  Although the retention time on the R-MIP is higher, the k’ of the analyte on the 
S-MIP is higher, as shown in Table 1.  This is due to the difference in dead volume values.  Thus, 
AC is still accurately accounted for. 
 
1 mM S-phenyl lactic acid (79) on the 20% R-BOC-Tyr imprinted column (Dv = 3.61) 
 
 
 
 
 
 
1 mM S-phenyl lactic acid (79) on the 20% S-BOC-Tyr imprinted column (Dv = 3.23) 
 
 
 
 
 
 
 
 
 
 
Figure C10:  S-phenyl lactic acid (79) on the DuoMIPs. 
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Important Note:  Although the retention time on the R-MIP is higher, the k’ values for R 
mandelic acid on both DuoMIPs are the same, as shown in Table 1.  This is due to the difference 
in dead volume values.  Thus, AC cannot be determined for this analyte. 
 
1 mM R-acetyl mandelic acid (86) on the 20% R-BOC-Tyr imprinted column (Dv = 3.61) 
 
 
 
1 mM R-acetyl mandelic acid (86) on the 20% S-BOC-Tyr imprinted column (Dv = 3.23) 
 
 
 
 
 
 
 
 
 
Figure C11:  R-acetyl mandelic acid (86) on the DuoMIPs. 
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Important Note:  Although the retention time on the R-MIP is higher, the k’ values of the analyte 
on both DuoMIPs are the same, as shown in Table 1.  This is due to the difference in dead 
volume values.  Thus, AC cannot be determined for this analyte. 
2 mM S-phenyl butyric acid (81a) on the 20% R-BOC-Tyr imprinted column (Dv = 3.61) 
 
2 mM S-phenyl butyric acid (81a) on the 20% S-BOC-Tyr imprinted column (Dv = 3.23) 
 
 
Figure C12:  S-phenyl butyric acid (81a) on the DuoMIPs. 
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Important Note:  Although the retention time on the R-MIP is higher, the k’ values of the analyte 
on both DuoMIPs are the same, as shown in Table 1.  This is due to the difference in dead 
volume values.  Thus, AC cannot be determined for this analyte. 
2 mM R-phenyl butyric acid (81b) on the 20% R-BOC-Tyr imprinted column (Dv = 3.61) 
 
 
 
 
 
 
 
2 mM R-phenyl butyric acid (81b) on the 20% S-BOC-Tyr imprinted column (Dv = 3.23) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C13:  R-phenyl butyric acid (81b) on the DuoMIPs. 
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APPENDIX D: SPECTRA FOR CHAPTER FIVE 
 
 
 
 
 
 
 
 
 
 
 
Figure D1: (S)-methyl 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylate (109) 
1
H NMR. 
 
 
 
 
 
 
 
 
 
 
Figure D2: (S)-methyl 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylate (109) 
13
C NMR. 
(S)-methyl 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylate
NAME       vecar step 1
EXPNO                 6
PROCNO                1
Date_          20110210
Time              10.44
INSTRUM           spect
PROBHD   5 mm QNP 1H/15
PULPROG            zgpg
TD               262144
SOLVENT           CDCl3
NS                  250
DS                    0
SWH           25125.629 Hz
FIDRES         0.095847 Hz
AQ            5.2167158 sec
RG              18390.4
DW               19.900 usec
DE                 6.50 usec
TE                296.7 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                 9.75 usec
PL1                3.50 dB
SFO1        100.6208180 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             90.00 usec
PL12              17.50 dB
PL13              17.50 dB
PL2               -1.00 dB
SFO2        400.1320007 MHz
SI               131072
SF          100.6127690 MHz
WDW                  EM
SSB                   0
LB                 2.00 Hz
GB                    0
PC                 1.40
-20200 180 160 140 120 100 80 60 40 20 0 ppm
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NAME       vecar step 1
EXPNO                 5
PROCNO                1
Date_          20110210
Time              10.10
INSTRUM           spect
PROBHD   5 mm QNP 1H/15
PULPROG              zg
TD                32768
SOLVENT           CDCl3
NS                    8
DS                    1
SWH           11574.074 Hz
FIDRES         0.353213 Hz
AQ            1.4156276 sec
RG                228.1
DW               43.200 usec
DE                 6.50 usec
TE                295.9 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.00 usec
PL1                0.00 dB
SFO1        400.1309204 MHz
SI                65536
SF          400.1300072 MHz
WDW                  EM
SSB                   0
LB                 0.10 Hz
GB                    0
PC                 1.00
(S)-methyl 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylate
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Figure D3: (S)-methyl 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylate (109) IR. 
 
 
 
 
 
 
 
 
 
 
Figure D4: (S)-methyl 6-(tert-butyldimethylsilyloxy)-2,5,7,8-tetramethylchroman-2-carboxylate 
(110) 
1
H NMR. 
 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
6
.1
5
9
.5
1
3
.0
5
1
.1
1
9
.2
6
3
.1
9
3
.0
0
NAME       vecar step 2
EXPNO                 1
PROCNO                1
Date_          20100517
Time              12.38
INSTRUM           spect
PROBHD   5 mm QNP 1H/15
PULPROG              zg
TD                32768
SOLVENT           CDCl3
NS                    8
DS                    0
SWH            6410.256 Hz
FIDRES         0.195625 Hz
AQ            2.5559540 sec
RG                228.1
DW               78.000 usec
DE                 6.50 usec
TE                294.0 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.00 usec
PL1                0.00 dB
SFO1        400.1309204 MHz
SI                65536
SF          400.1300072 MHz
WDW                  EM
SSB                   0
LB                 0.10 Hz
GB                    0
PC                 1.00
(S)-methyl 6-((tert-butyldimethylsilyl)oxy)-2,5,7,8-tetramethylchroman-2-carboxylate
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Figure D5: (S)-methyl 6-(tert-butyldimethylsilyloxy)-2,5,7,8-tetramethylchroman-2-carboxylate 
(110) 
13
C NMR. 
 
 
 
 
 
 
 
 
 
 
 
Figure D6: (S)-methyl 6-(tert-butyldimethylsilyloxy)-2,5,7,8-tetramethylchroman-2-carboxylate 
(110) IR. 
 
(S)-methyl 6-((tert-butyldimethylsilyl)oxy)-2,5,7,8-tetramethylchroman-2-carboxylate
NAME       vecar step 2
EXPNO                 4
PROCNO                1
Date_          20110215
Time              10.42
INSTRUM           spect
PROBHD   5 mm QNP 1H/15
PULPROG            zgpg
TD               262144
SOLVENT           CDCl3
NS                  400
DS                    0
SWH           25125.629 Hz
FIDRES         0.095847 Hz
AQ            5.2167158 sec
RG              18390.4
DW               19.900 usec
DE                 6.50 usec
TE                296.8 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                 9.75 usec
PL1                3.50 dB
SFO1        100.6208180 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             90.00 usec
PL12              17.50 dB
PL13              17.50 dB
PL2               -1.00 dB
SFO2        400.1320007 MHz
SI               131072
SF          100.6127690 MHz
WDW                  EM
SSB                   0
LB                 2.00 Hz
GB                    0
PC                 1.40
-20200 180 160 140 120 100 80 60 40 20 0 ppm
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Figure D7: (S)-6-(tert-butyldimethylsilyloxy)-2,5,7,8-tetramethylchroman-2-carbaldehyde (111) 
1
H NMR. 
 
 
 
 
 
 
 
 
 
 
Figure D8: (S)-6-(tert-butyldimethylsilyloxy)-2,5,7,8-tetramethylchroman-2-carbaldehyde (111) 
13
C NMR. 
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NAME             Step 3
EXPNO                41
PROCNO                1
Date_          20091124
Time              12.15
INSTRUM           spect
PROBHD   5 mm QNP 1H/15
PULPROG              zg
TD                32768
SOLVENT           CDCl3
NS                    8
DS                    0
SWH            6410.256 Hz
FIDRES         0.195625 Hz
AQ            2.5559540 sec
RG                 90.5
DW               78.000 usec
DE                 6.50 usec
TE                296.1 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.00 usec
PL1                0.00 dB
SFO1        400.1309204 MHz
SI                65536
SF          400.1300072 MHz
WDW                  EM
SSB                   0
LB                 0.10 Hz
GB                    0
PC                 1.00
(S)-6-((tert-butyldimethylsilyl)oxy)-2,5,7,8-tetramethylchroman-2-carbaldehyde
(S)-6-((tert-butyldimethylsilyl)oxy)-2,5,7,8-tetramethylchroman-2-carbaldehyde
NAME       vecar step 3
EXPNO                 4
PROCNO                1
Date_          20100603
Time              12.54
INSTRUM           spect
PROBHD   5 mm QNP 1H/15
PULPROG            zgpg
TD               262144
SOLVENT           CDCl3
NS                  200
DS                    0
SWH           44444.445 Hz
FIDRES         0.169542 Hz
AQ            2.9491701 sec
RG              18390.4
DW               11.250 usec
DE                 6.50 usec
TE                295.0 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                 9.75 usec
PL1                3.50 dB
SFO1        100.6208180 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             90.00 usec
PL12              17.50 dB
PL13              17.50 dB
PL2               -1.00 dB
SFO2        400.1320007 MHz
SI               131072
SF          100.6127690 MHz
WDW                  EM
SSB                   0
LB                 2.00 Hz
GB                    0
PC                 1.40
-100-50250 200 150 100 50 0 ppm
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Figure D9: (S)-6-(tert-butyldimethylsilyloxy)-2,5,7,8-tetramethylchroman-2-carbaldehyde (111) 
IR. 
 
 
 
 
 
 
 
 
 
 
 
Figure D10: 11-(carboxyundecyl)triphosphonium bromide (114) 
1
H NMR. 
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NAME       vecar step 4
EXPNO                11
PROCNO                1
Date_          20110129
Time               8.39
INSTRUM           spect
PROBHD   5 mm QNP 1H/15
PULPROG              zg
TD                32768
SOLVENT           CDCl3
NS                   15
DS                    2
SWH           11574.074 Hz
FIDRES         0.353213 Hz
AQ            1.4156276 sec
RG                 71.8
DW               43.200 usec
DE                 6.50 usec
TE                296.4 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.00 usec
PL1                0.00 dB
SFO1        400.1309204 MHz
SI                65536
SF          400.1300072 MHz
WDW                  EM
SSB                   0
LB                 0.10 Hz
GB                    0
PC                 1.00
(11-carboxyundecyl)triphenylphosphonium bromide
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Figure D11: 11-(carboxyundecyl)triphosphonium bromide (114) 
13
C NMR. 
 
Figure D12: 11-(carboxyundecyl)triphosphonium bromide (114) IR. 
(11-carboxyundecyl)triphenylphosphonium bromide
NAME       vecar step 4
EXPNO                12
PROCNO                1
Date_          20110129
Time              10.45
INSTRUM           spect
PROBHD   5 mm QNP 1H/15
PULPROG            zgpg
TD               262144
SOLVENT           CDCl3
NS                 1000
DS                    0
SWH           25125.629 Hz
FIDRES         0.095847 Hz
AQ            5.2167158 sec
RG              18390.4
DW               19.900 usec
DE                 6.50 usec
TE                297.4 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                 9.75 usec
PL1                3.50 dB
SFO1        100.6208180 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             90.00 usec
PL12              17.50 dB
PL13              17.50 dB
PL2               -1.00 dB
SFO2        400.1320007 MHz
SI               131072
SF          100.6127690 MHz
WDW                  EM
SSB                   0
LB                 2.00 Hz
GB                    0
PC                 1.40
-20200 180 160 140 120 100 80 60 40 20 0 ppm
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Figure D13: (S,E)-13-(6-(tert-butyldimethylsilyloxy)-2,5,7,8-tetramethylchroman-2-yl)tridec-12-
enoic acid (116) 
1
H NMR. 
 
 
Figure D14: (S,E)-13-(6-(tert-butyldimethylsilyloxy)-2,5,7,8-tetramethylchroman-2-yl)tridec-12-
enoic acid (116) 
13
C NMR. 
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NAME              P5-1H
EXPNO                 1
PROCNO                1
Date_          20110125
Time              10.36
INSTRUM           spect
PROBHD   5 mm QNP 1H/15
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                    8
DS                    0
SWH            4789.272 Hz
FIDRES         0.146157 Hz
AQ            3.4210291 sec
RG                 90.5
DW              104.400 usec
DE                 6.50 usec
TE                296.2 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.00 usec
PL1                0.00 dB
SFO1        400.1320007 MHz
SI                65536
SF          400.1300102 MHz
WDW                  EM
SSB                   0
LB                 0.10 Hz
GB                    0
PC                 1.00
(S,E)-13-(6-((tert-butyldimethylsilyl)oxy)-2,5,7,8-tetramethylchroman-2-yl)tridec-12-enoic acid
(S,E)-13-(6-((tert-butyldimethylsilyl)oxy)-2,5,7,8-tetramethylchroman-2-yl)tridec-12-enoic acid
NAME             P5-13C
EXPNO                 1
PROCNO                1
Date_          20110125
Time              10.44
INSTRUM           spect
PROBHD   5 mm QNP 1H/15
PULPROG            zgpg
TD               262144
SOLVENT           CDCl3
NS                  128
DS                    0
SWH           25125.629 Hz
FIDRES         0.095847 Hz
AQ            5.2167158 sec
RG              18390.4
DW               19.900 usec
DE                 6.50 usec
TE                296.6 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                 9.75 usec
PL1                3.50 dB
SFO1        100.6208180 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             90.00 usec
PL12              17.50 dB
PL13              17.50 dB
PL2               -1.00 dB
SFO2        400.1320007 MHz
SI               131072
SF          100.6127727 MHz
WDW                  EM
SSB                   0
LB                 2.00 Hz
GB                    0
PC                 1.40
-20200 180 160 140 120 100 80 60 40 20 0 ppm
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Figure D15: (S,E)-13-(6-(tert-butyldimethylsilyloxy)-2,5,7,8-tetramethylchroman-2-yl)tridec-12-
enoic acid (116) IR. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure D16: (R)-13-(6-(tert-butyldimethylsilyloxy)-2,5,7,8-tetramethylchroman-2-yl)tridecanoic 
acid (119) 
1
H NMR.  
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NAME       vecar step 6
EXPNO                 4
PROCNO                1
Date_          20110331
Time              10.37
INSTRUM           spect
PROBHD   5 mm QNP 1H/15
PULPROG              zg
TD                32768
SOLVENT           CDCl3
NS                    8
DS                    1
SWH           11574.074 Hz
FIDRES         0.353213 Hz
AQ            1.4156276 sec
RG                    2
DW               43.200 usec
DE                 6.50 usec
TE                297.2 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.00 usec
PL1                0.00 dB
SFO1        400.1309204 MHz
SI                65536
SF          400.1300072 MHz
WDW                  EM
SSB                   0
LB                 0.10 Hz
GB                    0
PC                 1.00
(R)-13-(6-((tert-butyldimethylsilyl)oxy)-2,5,7,8-tetramethylchroman-2-yl)tridecanoic acid
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Figure D17: (R)-13-(6-(tert-butyldimethylsilyloxy)-2,5,7,8-tetramethylchroman-2-yl)tridecanoic 
acid (119) 
13
C NMR. 
 
 
Figure D18: (R)-13-(6-(tert-butyldimethylsilyloxy)-2,5,7,8-tetramethylchroman-2-yl)tridecanoic 
acid (119) IR. 
(R)-13-(6-((tert-butyldimethylsilyl)oxy)-2,5,7,8-tetramethylchroman-2-yl)tridecanoic acid
NAME       vecar step 6
EXPNO                 5
PROCNO                1
Date_          20110331
Time              11.08
INSTRUM           spect
PROBHD   5 mm QNP 1H/15
PULPROG            zgpg
TD               262144
SOLVENT           CDCl3
NS                  225
DS                    0
SWH           25125.629 Hz
FIDRES         0.095847 Hz
AQ            5.2167158 sec
RG              18390.4
DW               19.900 usec
DE                 6.50 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                 9.75 usec
PL1                3.50 dB
SFO1        100.6208180 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             90.00 usec
PL12              17.50 dB
PL13              17.50 dB
PL2               -1.00 dB
SFO2        400.1320007 MHz
SI               131072
SF          100.6127690 MHz
WDW                  EM
SSB                   0
LB                 2.00 Hz
GB                    0
PC                 1.40
-20200 180 160 140 120 100 80 60 40 20 0 ppm
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Figure D19: Carnosine Methyl Ester Dihydrochloride (115) 
1
H NMR.  
 
Figure D20: Carnosine Methyl Ester Dihydrochloride (115) 
13
C NMR.  
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NAME      vecar step 6E
EXPNO                 1
PROCNO                1
Date_          20110317
Time              13.04
INSTRUM           spect
PROBHD   5 mm QNP 1H/15
PULPROG              zg
TD                32768
SOLVENT            DMSO
NS                   16
DS                    0
SWH           11990.407 Hz
FIDRES         0.365918 Hz
AQ            1.3664756 sec
RG                    2
DW               41.700 usec
DE                 6.50 usec
TE                297.2 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.00 usec
PL1                0.00 dB
SFO1        400.1309204 MHz
SI                65536
SF          400.1299987 MHz
WDW                  EM
SSB                   0
LB                 0.10 Hz
GB                    0
PC                 1.00
(R)-methyl 2-(3-aminopropanamido)-3-(1H-imidazol-4-yl)propanoate
(R)-methyl 2-(3-aminopropanamido)-3-(1H-imidazol-4-yl)propanoate
NAME      vecar step 6E
EXPNO                 3
PROCNO                1
Date_          20110408
Time              10.42
INSTRUM           spect
PROBHD   5 mm QNP 1H/15
PULPROG            zgpg
TD               262144
SOLVENT            DMSO
NS                  275
DS                    0
SWH           25125.629 Hz
FIDRES         0.095847 Hz
AQ            5.2167158 sec
RG              18390.4
DW               19.900 usec
DE                 6.50 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                 9.75 usec
PL1                3.50 dB
SFO1        100.6208180 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             90.00 usec
PL12              17.50 dB
PL13              17.50 dB
PL2               -1.00 dB
SFO2        400.1320007 MHz
SI               131072
SF          100.6127690 MHz
WDW                  EM
SSB                   0
LB                 2.00 Hz
GB                    0
PC                 1.40
-20200 180 160 140 120 100 80 60 40 20 0 ppm
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Figure D21: Carnosine Methyl Ester Dihydrochloride (115) IR. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure D22: (R)-methyl 2-(3-(13-((R)-6-((tert-butyldimethylsilyl)oxy)-2,5,7,8-
tetramethylchroman-2-yl)tridecanamido)propanamido)-3-(1H-imidazol-4-yl)propanoate (119) 
1
H 
NMR. 
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NAME       vecar step 7
EXPNO                 4
PROCNO                1
Date_          20110428
Time              10.34
INSTRUM           spect
PROBHD   5 mm QNP 1H/15
PULPROG              zg
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH           11574.074 Hz
FIDRES         0.353213 Hz
AQ            1.4156276 sec
RG                    2
DW               43.200 usec
DE                 6.50 usec
TE                297.5 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.00 usec
PL1                0.00 dB
SFO1        400.1309204 MHz
SI                65536
SF          400.1300072 MHz
WDW                  EM
SSB                   0
LB                 0.10 Hz
GB                    0
PC                 1.00
(R)-methyl 2-(3-(13-((R)-6-((tert-butyldimethylsilyl)oxy)-2,5,7,8-tetramethylchroman-2-yl)tridecanamido)propanamido)-3-(1H-imidazol-4-yl)propanoate
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Figure D23: (R)-methyl 2-(3-(13-((R)-6-((tert-butyldimethylsilyl)oxy)-2,5,7,8-
tetramethylchroman-2-yl)tridecanamido)propanamido)-3-(1H-imidazol-4-yl)propanoate (119) 
13
C NMR. 
 
 
 
 
 
 
 
 
 
 
Figure D24: (R)-methyl 2-(3-(13-((R)-6-((tert-butyldimethylsilyl)oxy)-2,5,7,8-
tetramethylchroman-2-yl)tridecanamido)propanamido)-3-(1H-imidazol-4-yl)propanoate (119) 
IR. 
(R)-methyl 2-(3-(13-((R)-6-((tert-butyldimethylsilyl)oxy)-2,5,7,8-tetramethylchroman-2-yl)tridecanamido)propanamido)-3-(1H-imidazol-4-yl)propanoate
NAME       vecar step 7
EXPNO                 5
PROCNO                1
Date_          20110428
Time              10.55
INSTRUM           spect
PROBHD   5 mm QNP 1H/15
PULPROG            zgpg
TD               262144
SOLVENT            MeOD
NS                  125
DS                    0
SWH           25125.629 Hz
FIDRES         0.095847 Hz
AQ            5.2167158 sec
RG              18390.4
DW               19.900 usec
DE                 6.50 usec
TE                298.6 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                 9.75 usec
PL1                3.50 dB
SFO1        100.6208180 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             90.00 usec
PL12              17.50 dB
PL13              17.50 dB
PL2               -1.00 dB
SFO2        400.1320007 MHz
SI               131072
SF          100.6127690 MHz
WDW                  EM
SSB                   0
LB                 2.00 Hz
GB                    0
PC                 1.40
-20200 180 160 140 120 100 80 60 40 20 0 ppm
 193 
 
 
Figure D25: (R)-methyl 2-(3-(13-((R)-6-hydroxy-2,5,7,8-tetramethylchroman-2-
yl)tridecanamido)propanamido)-3-(1H-imidazol-4-yl)propanoate (106) 
1
H NMR. 
 
 
 
 
 
 
 
 
 
 
 
Figure D26: (R)-methyl 2-(3-(13-((R)-6-hydroxy-2,5,7,8-tetramethylchroman-2-
yl)tridecanamido)propanamido)-3-(1H-imidazol-4-yl)propanoate (106) 
13
C NMR. 
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NAME       vecar step 8
EXPNO                31
PROCNO                1
Date_          20110615
Time              10.34
INSTRUM           spect
PROBHD   5 mm QNP 1H/15
PULPROG              zg
TD                32768
SOLVENT            MeOD
NS                   16
DS                    1
SWH           11574.074 Hz
FIDRES         0.353213 Hz
AQ            1.4156276 sec
RG                    2
DW               43.200 usec
DE                 6.50 usec
TE                295.6 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.00 usec
PL1                0.00 dB
SFO1        400.1309204 MHz
SI                65536
SF          400.1300138 MHz
WDW                  EM
SSB                   0
LB                 0.10 Hz
GB                    0
PC                 1.00
(R)-methyl 2-(3-(13-((R)-6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)tridecanamido)propanamido)-3-(1H-imidazol-4-yl)propanoate
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Figure D27: (R)-methyl 2-(3-(13-((R)-6-hydroxy-2,5,7,8-tetramethylchroman-2-
yl)tridecanamido)propanamido)-3-(1H-imidazol-4-yl)propanoate (106) IR. 
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